



Icahn School of Medicine at
Mount Sinai

Grants and Contracts Office

Funding Opportunities Monthly Edition May 2021 Due Dates

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in May 2021. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
085437	RFA-CA-19-049 -- Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-19-049	23-May-2021 [Optional][LOI/Pre-App]	750,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Laurence (Austin) Doyle, MD</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">240-276-6112</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">Doylela@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</td> </tr> </table>					Contact Name	Laurence (Austin) Doyle, MD	Contact Telephone	240-276-6112	Contact Email	Doylela@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021	Synopsis	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.
Contact Name	Laurence (Austin) Doyle, MD																		
Contact Telephone	240-276-6112																		
Contact Email	Doylela@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021																		
Synopsis	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.																		
089582	Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-116	20-May-2021	1,900,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Piotr Grodzinski, Ph.D.</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">240-781-3305</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;">grodzinp@mail.nih.gov</td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;">Link to program URL</td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">20-May-2021 , 18-Nov-2021</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected</td> </tr> </table>					Contact Name	Piotr Grodzinski, Ph.D.	Contact Telephone	240-781-3305	Contact Email	grodzinp@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	20-May-2021 , 18-Nov-2021	Synopsis	This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected
Contact Name	Piotr Grodzinski, Ph.D.																		
Contact Telephone	240-781-3305																		
Contact Email	grodzinp@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	20-May-2021 , 18-Nov-2021																		
Synopsis	This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

100992	RFA-CA-21-013 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-013	09-May-2021 [Optional][LOI/Pre-App]	275,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	301-480-5778
Contact Email	juli.klemm@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.

100999	RFA-CA-21-017 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-017	09-May-2021 [Optional][LOI/Pre-App]	200,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	301-480-5778
Contact Email	juli.klemm@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.</p>				
100995	RFA-CA-21-016 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-016	09-May-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 301-480-5778</p> <p>Contact Email juli.klemm@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

100993	RFA-CA-21-014 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-014	09-May-2021 [Optional][LOI/Pre-App]	900,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	301-480-5778
Contact Email	juli.klemm@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

100994	RFA-CA-21-015 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-015	09-May-2021 [Optional][LOI/Pre-App]	3,000,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	301-480-5778
Contact Email	juli.klemm@nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.</p>				
101003	<p>RFA-CA-21-018 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)</p>	National Cancer Institute/NIH/DHHS	RFA-CA-21-018	09-May-2021 [Optional][LOI/Pre-App]	200,000 USD
	<p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 301-480-5778</p> <p>Contact Email juli.klemm@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

101004	RFA-CA-21-019 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-019	10-May-2021 [Optional][LOI/Pre-App]	200,000 USD
--------	---	------------------------------------	---------------	--	-------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	301-480-5778
Contact Email	juli.klemm@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-May-2021 [Optional][LOI/Pre-App], 09-Jun-2021 , 19-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U24 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

098155	Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-238	17-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	------------	--	---------------

Contact Name	Shobha Srinivasan, Ph.D.
Contact Telephone	240-276-6938
Contact Email	ss688k@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 17-Apr-2021 [Optional][LOI/Pre-App], 17-May-2021 , 07-Sep-2021 , 17-Apr-2022 [Optional][LOI/Pre-App], 17-May-2022 , 07-Sep-2022 , 17-Apr-2023 [Optional][LOI/Pre-App], 17-May-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests the efficacy or effectiveness of health promotion and disease prevention interventions, 3) research that tests culturally informed treatment or recovery interventions and 4) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions.</p>				
098054	Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-284	06-May-2021	2,250,000 USD
	<p>Contact Name Piotr Grodzinski, Ph.D.</p> <p>Contact Telephone 240-781-3305</p> <p>Contact Email grodzinp@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2021 , 04-Nov-2021 , 05-May-2022 , 03-Nov-2022 , 04-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.</p>				
085444	RFA-CA-19-052 -- Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-19-052	23-May-2021 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name Laurence (Austin) Doyle, MD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6112</p> <p>Contact Email Doylela@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p>				
101323	Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Support Global Cancer Stigma Research	National Cancer Institute/NIH/DHHS	NOT-CA-21-026	15-May-2021	Not Specified
	<p>Contact Name Vidya Vedham, Ph.D.</p> <p>Contact Telephone 240-276-7272</p> <p>Contact Email vidya.vedham@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2021</p> <p>Synopsis This Notice of Special Interest informs current awardees that the National Cancer Institute (NCI) is providing an opportunity for supplemental funding to support exploratory research studies to expand the current understanding of cancer stigma (as defined below), assess its impact on cancer control and prevention, and develop stigma-reduction interventions to improve cancer outcomes in low- and middle-income countries (LMICs). The goals of these administrative supplements focused on global cancer stigma research are to: 1) elucidate the etiology and perpetuation of cancer stigma; 2) measure the impact of cancer stigma on physical and mental well-being and associated health behaviors of patients; 3) identify mechanisms and pathways by which stigma is a barrier to cancer prevention, treatment, palliation, and survivorship; and 4) develop interventions to reduce cancer stigma and improve cancer outcomes.</p>				
085268	Neural Regulation of Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-354	27-May-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Chamelli Jhappan, Ph.D.
Contact Telephone	240-276-6200
Contact Email	jhappanc@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-May-2021 , 21-Oct-2021 , 27-May-2022
Synopsis	This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

085265	Neural Regulation of Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-353	27-May-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Chamelli Jhappan, Ph.D.
Contact Telephone	240-276-6200
Contact Email	jhappanc@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-May-2021 , 21-Oct-2021 , 27-May-2022
Synopsis	This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

098154	Research to Improve Native American Health (R21 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	PAR-20-214	17-Apr-2021 [Optional][LOI/Pre-App]	275,000 USD
--------	---	------------------------------------	------------	-------------------------------------	-------------

Contact Name	Shobha Srinivasan, Ph.D.
--------------	--------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6938</p> <p>Contact Email ss688k@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Apr-2021 [Optional][LOI/Pre-App], 17-May-2021 , 07-Sep-2021 , 17-Apr-2022 [Optional][LOI/Pre-App], 17-May-2022 , 07-Sep-2022 , 17-Apr-2023 [Optional][LOI/Pre-App], 17-May-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support developmental/exploratory studies in preparation for health promotion, disease prevention, treatment, or treatment services research to improve health in Native American (NA) populations. Applications may include 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research to develop and pilot test new or adapted interventions for feasibility, acceptability, and scalability, 3) research to test the short-term efficacy of interventions, 4) where a sufficient body of knowledge on intervention efficacy exists, research on strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions.</p>				
086863	Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-043	25-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 240-276-5600</p> <p>Contact Email ncicenters-r@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.			
100809	Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-067	07-May-2021	1,500,000 USD
	Contact Name	Jeannette F. Korczak, Ph.D.			
	Contact Telephone	240-276-5630			
	Contact Email	korczakj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 05-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024			
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.			
100808	Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-066	07-May-2021	1,500,000 USD
	Contact Name	Jeannette F. Korczak, Ph.D.			
	Contact Telephone	240-276-5630			
	Contact Email	korczakj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 05-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.</p>			
100806	Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-065	07-May-2021	300,000 USD
	Contact Name	Jeannette F. Korczak, Ph.D.			
	Contact Telephone	240-276-5630			
	Contact Email	korczakj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 05-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.</p>			
088519	National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-077	07-May-2021	Not Specified
	Contact Name	Referral Officer			
	Contact Telephone	240-276-6390			
	Contact Email	ncirefof@dea.nci.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.</p>				
067401	Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-307	07-May-2021	1,025,000 USD
	<p>Contact Name Frank Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email pernafm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. This program will use the NIH R21/R33 Phased Innovation Award award mechanism.</p>				
100910	RFA-CA-21-009 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-009	27-Apr-2021 [Optional][LOI/Pre-App]	150,000 USD
	Contact Name Tony Dickherber, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

100916	RFA-CA-21-012 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-012	27-Apr-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101460	Notice of Special Interest (NOSI): New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	NOT-CA-21-025	27-May-2021	Not Specified
	<p>Contact Name Paul C. Pearlman, Ph.D.</p> <p>Contact Telephone 240-276-6429</p> <p>Contact Email paul.pearlman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-May-2021 , 29-Sep-2021</p> <p>Synopsis This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) Center for Global Health (CGH) is seeking to leverage ongoing Innovative Molecular Analysis Technologies (IMAT) program activities to stimulate exploratory research on technology platforms relevant for global oncology and appropriate for use in low-resource settings globally. NCI CGH is prepared to support highly meritorious R21 applications submitted to either RFA-CA-21-003 or RFA-CA-21-005, with the goal of helping drive innovation in this field and enrich the pool of investigators participating in the NCI-sponsored Affordable Cancer Technologies (ACTs) Program.</p>				
100914	RFA-CA-21-011 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-011	27-Apr-2021 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Tony Dickherber, Ph.D.</p> <p>Contact Telephone 301-547-9980</p> <p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

100903	RFA-CA-21-007 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-007	27-Apr-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	--	-------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

100905	RFA-CA-21-008 -- Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-008	27-Apr-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	---	------------------------------------	---------------	--	-------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
079335	<p>Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-19-149	07-May-2021	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Miguel R. Ossandon, Ph.D.</p> <p>240-276-5714</p> <p>ossandom@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</p>			
082214	<p>Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	PAR-19-274	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Gila Neta, Ph.D.</p> <p>240-276-6785</p> <p>gila.neta@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.			
085445	RFA-CA-19-053 -- Revision Applications for Mechanisms of Cancer Drug Resistance (P50 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-19-053	23-May-2021 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name	Laurence (Austin) Doyle, MD			
	Contact Telephone	240-276-6112			
	Contact Email	Doylela@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P50 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.			
100856	RFA-CA-21-005 -- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-005	27-Apr-2021 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Tony Dickherber, Ph.D., Program Director			
	Contact Telephone	301-547-9980			
	Contact Email	dickherberaj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>			
--	-----------------	--	--	--	--

100859	<p>RFA-CA-21-006 -- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	RFA-CA-21-006	27-Apr-2021 [Optional][LOI/Pre-App]	900,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Tony Dickherber, Ph.D., Program Director
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>			
100854	RFA-CA-21-003 -- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-003	27-Apr-2021 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Tony Dickherber, Ph.D., Program Director</p> <p>301-547-9980</p> <p>dickherberaj@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>			
100855	RFA-CA-21-004 -- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-004	27-Apr-2021 [Optional][LOI/Pre-App]	900,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Tony Dickherber, Ph.D., Program Director
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

100913	RFA-CA-21-010 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-010	27-Apr-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers proposing to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
086964	NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-052	07-May-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 24-Jun-2021 , 07-Sep-2021 , 20-Oct-2021 , 07-Jan-2022 , 24-Feb-2022 , 07-May-2022 , 24-Jun-2022 , 07-Sep-2022 , 20-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
067494	Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-324	07-May-2021	Not Specified
	<p>Contact Name Frank Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email pernafm@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This program will use the NIH R01 Research Project Grant award mechanism.</p>			
070540	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-530	07-May-2021	Not Specified
	Contact Name	Miguel Ossandon MS			
	Contact Telephone	240-276-5714			
	Contact Email	ossandom@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
076579	Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research	National Cancer	PA-18-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(R01 Clinical Trial Not Allowed)	Institute/NIH/DHHS	876		Specified
	<p>Contact Name Dr. Roberto Flores</p> <p>Contact Telephone 240-276-7119</p> <p>Contact Email floresr2@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
085422	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-363	07-May-2021	499,999 USD
	<p>Contact Name Anne Menkens, Ph.D.</p> <p>Contact Telephone 240-276-6510</p> <p>Contact Email menkensa@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
071800	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-629	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Anne Menkens, Ph.D.</p> <p>Contact Telephone 240-276-6510</p> <p>Contact Email menkensa@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
100707	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-033	07-May-2021	2,499,995 USD
	<p>Contact Name Lori A. Henderson, Ph.D.</p> <p>Contact Telephone 240-276-5930</p> <p>Contact Email hendersonlori@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.</p>				
101162	Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using	National Cancer	NOT-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Risk-Stratified Pathways	Institute/NIH/DHHS	CA-21-019		Specified
	<p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email michelle.mollica@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023</p> <p>Synopsis The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences' interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways. Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.</p>				
077667	Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-932	07-May-2021	Not Specified
	<p>Contact Name Erica S. Breslau, PhD, MPH</p> <p>Contact Telephone 240-276-6773</p> <p>Contact Email breslaue@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		health care providers. This FOA will use the NIH Research Project (R01) award mechanism.			
076909	Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-902	07-May-2021	Not Specified
	Contact Name	Gabriela Riscuta, MD, CNS			
	Contact Telephone	240-276-7118			
	Contact Email	gabriela.riscuta@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. The purpose of this funding opportunity announcement (FOA) is twofold: 1) to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2) to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA will use the NIH Research Project (R01) award mechanism.			
076805	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-893	07-May-2021	Not Specified
	Contact Name	Frank M. Perna, Ed.D., Ph.D.			
	Contact Telephone	240-276-6782			
	Contact Email	pernafm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R01 Research Project Grant award mechanism.</p>			
100708	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-035	07-May-2021	Not Specified
	Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.			
	Contact Telephone	240-276-7048			
	Contact Email	heckmanbm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.</p>			
092626	RFA-CA-20-031 -- Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-20-031	07-May-2021	1,250,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Sudha Sivaram, DrPH, MPH
Contact Telephone	240-276-5804
Contact Email	nciglobaltraining@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the United States (U.S.)-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

076806	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-892	07-May-2021	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Frank M. Perna, Ed.D., Ph.D.
Contact Telephone	240-276-6782
Contact Email	pernafm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021
Synopsis	National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

083680	Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-309	07-May-2021	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Tanya Agurs-Collins, Ph.D
Contact Telephone	240-276-6956
Contact Email	collinsta@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.

085441	RFA-CA-19-051 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U54 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-19-051	23-May-2021 [Optional][LOI/Pre-App]	750,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Laurence (Austin) Doyle, MD
Contact Telephone	240-276-6112

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Doylela@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U54 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p>				
082215	Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-275	07-May-2021	275,000 USD
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.</p>				
082216	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-276	07-May-2021	50,000 USD
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.</p>				
085440	RFA-CA-19-050 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-19-050	23-May-2021 [Optional][LOI/Pre-App]	750,000 USD
	<p>Contact Name Laurence (Austin) Doyle, MD</p> <p>Contact Telephone 240-276-6112</p> <p>Contact Email Doylela@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p>				
079333	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-150	07-May-2021	275,000 USD
	<p>Contact Name Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</p>				
101459	Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities	National Cancer Institute/NIH/DHHS	NOT-CA-21-020	07-May-2021	Not Specified
	<p>Contact Name Kathy Cronin, Ph.D.</p> <p>Contact Telephone 240-276-6836</p> <p>Contact Email cronink@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that efficiently use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely collected by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic status, income, insurance status, age, education level, or geographic area. The Surveillance, Epidemiology, and End Results (SEER) Program and the National Program of Cancer Registries (NPCR) are uniquely positioned to support research to assess health disparities in the United States (US) population because they contain information on all cases diagnosed within geographically defined areas. The goal of these hypothesis-driven studies should be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.</p>				
090500	Center of Excellence for Research on Complementary and Integrative Health (P01 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-138	25-May-2021	6,250,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	Craig Hopp, Ph.D.D			
	Contact Telephone	301-496-5825			
	Contact Email	hoppdc@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages the submission of applications requiring multi-project, synergistic collaborations blending multiple research approaches from outstanding multidisciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and "synergy" that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH and high research priority based on the current Strategic Plan. Applications in response to this FOA may propose to involve human participants in mechanistic studies, but this FOA will not support clinical trials of efficacy or effectiveness.</p>			

067449	Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18-322	07-May-2021	275,000 USD
--------	--	---	-----------	-------------	-------------

	Contact Name	Wen G. Chen, PhD			
	Contact Telephone	301-451-3989			
	Contact Email	chenw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	<p>National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101958	Limited Competition for the Continuation or Revision of Multisite Clinical Trial Clinical Coordinating Center (Collaborative UH3 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-117	15-Mar-2021	Not Specified
	<p>Contact Name Wendy Weber, N.D., Ph.D., M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email weberwj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021 , 28-May-2021 , 28-Sep-2021 , 28-Jan-2022 , 27-May-2022 , 28-Sep-2022 , 27-Jan-2023 , 29-May-2023 , 27-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) accepts applications for competing renewal of a Clinical Coordinating Center (CCC) for ongoing clinical trials supported by NCCIH or competitive revisions to support ancillary studies to ongoing NCCIH-supported clinical trials. Extension of an ongoing clinical trial will be supported when there is a need for additional time to complete the trial or when an extended period of follow-up is well justified to assess longer term outcomes. Competitive revisions will be supported when there is compelling justification for the addition of an ancillary study to an ongoing clinical trial. The objective of the CCC is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The CCC is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Both a Data Coordinating Center (DCC) application and a corresponding CCC application should be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing clinical trial. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application or competitive revision prior to submitting to this FOA.</p>				
067448	Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18-323	07-May-2021	Not Specified
	<p>Contact Name Wen G. Chen, PhD</p> <p>Contact Telephone 301-451-3989</p> <p>Contact Email chenw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
101953	Limited Competition for the Continuation of Multisite Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-116	15-Mar-2021	Not Specified
	<p>Contact Name Wendy Weber, N.D., Ph.D., M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email weberwj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Mar-2021 , 28-May-2021 , 28-Sep-2021 , 28-Jan-2022 , 27-May-2022 , 28-Sep-2022 , 27-Jan-2023 , 29-May-2023 , 27-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, accepts applications for competing renewal of Data Coordinating Center (DCC) for ongoing clinical trials supported by NCCIH. Extension of an ongoing clinical trial will be allowed when there is a compelling need for additional time to complete the trial or when an extended period of follow-up is well justified to assess longer term outcomes. The DCC competing renewal application must propose a comprehensive plan for completion of the clinical trial data collection that provides overall project coordination and administrative, data management, and biostatistical support for the ongoing clinical trial. Both a DCC application and a corresponding Clinical Coordinating Center (CCC) application can be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing trial. If clinical trial data collection and follow-up can be completed centrally by the DCC and no study visits at clinical sites are needed, a single application for competing renewal for the DCC can be submitted. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application prior to submitting to this FOA.</p>				
094934	Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-219	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.
Contact Telephone	301-402-1272
Contact Email	weberwj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023
Synopsis	This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-20-215 The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

091405	Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-154	07-May-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Lanay Mudd, Ph.D
Contact Telephone	301-594-9346
Contact Email	lanay.mudd@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications must have sufficient preliminary data that includes: demonstration of feasibility of remote recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety of the intervention; and evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>				
094929	Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-215	07-May-2021	Not Specified
	Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.			
	Contact Telephone	301-402-1272			
	Contact Email	weberwj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven, cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-20-219, proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.</p>			
094930	NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01)	National Center for	PAR-	07-May-2021	1,750,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Clinical Trial Required		Complementary and Integrative Health/NIH/DHHS 20-216		USD
	<p>Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email weberwj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product's mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>				
100802	NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)		National Eye Institute/NIH/DHHS	PAR-21-042 07-May-2021	Not Specified
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair's Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations.</p>			
100803	<p>NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required)</p>	National Eye Institute/NIH/DHHS	PAR-21-043	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Donald Everett, MA</p> <p>301-451-2020</p> <p>everettd@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair's Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial</p>			
100798	<p>NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial)</p>	National Eye	PAR-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Required		Institute/NIH/DHHS	21-041	Specified
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair's Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for the Chair's grant, which includes the scientific rationale, study aims and significance of the research project.</p>				
076351	NEI Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed)		National Eye Institute/NIH/DHHS	PAR- 18-864 07-May-2021	Not Specified
	<p>Contact Name Sangeeta Bhargava, PhD,</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email bhargavas@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021</p> <p>Synopsis National Eye Institute (NEI) invites applications for investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research. This FOA will use the NIH UG1 Clinical Research Cooperative Agreements - Single Project award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
081744	NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-19-260	07-May-2021	275,000 USD
	<p>Contact Name: Donald Everett, M.A.</p> <p>Contact Telephone: 301-451-2020</p> <p>Contact Email: everettd@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis: This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.</p>				
101324	Notice of Special Interest (NOSI): NEI Anterior Segment Initiative (ASI): Identification and Development of New Biomarkers and Effective Methods to Diagnose Dry Eye Disease.	National Eye Institute/NIH/DHHS	NOT-EY-21-007	05-Apr-2021	Not Specified
	<p>Contact Name:</p> <p>Contact Telephone:</p> <p>Contact Email:</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Apr-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 05-Sep-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response.			
081084	NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-19-231	07-May-2021	300,000 USD
	Contact Name	Donald Everett, MA			
	Contact Telephone	301-451-2020			
	Contact Email	everettd@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.			
100058	Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-027	07-May-2021	1,920,000 USD
	Contact Name	Shimian Zou, Ph.D.			
	Contact Telephone	301-827-8301			
	Contact Email	zous@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 07-Jan-2022 , 07-May-2022 , 07-Jan-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcement (FOA) seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.			
100990	NHLBI Program Project Applications (P01 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-088	25-May-2021	Not Specified
	Contact Name	Denis Buxton, Ph.D.			
	Contact Telephone	301-435-0515			
	Contact Email	denis.buxton@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023			
	Synopsis	This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also include implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which includes an Early Stage Investigator as Project Leader.			
100447	Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-815	07-May-2021	Not Specified
	Contact Name	Rebecca A. Roper, MS, MPH			
	Contact Telephone	301-496-1051			
	Contact Email	Rebecca.Roper@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.</p>			
074657	The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-18-784	07-May-2021	Not Specified
	Contact Name	Lis Caler, Ph.D.			
	Contact Telephone	301-435-0222			
	Contact Email	lis.caler@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	<p>National Heart, Lung, and Blood Institute (NHLBI) invites applications for functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
079552	Implementation of Shared Decision Making for HLBS Diseases and Conditions (R01 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-19-166	07-May-2021	2,499,995 USD
	Contact Name	Susan T. Shero, BSN, MS			
	Contact Telephone	301-496-1051			
	Contact Email	sheros@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this initiative is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lung, blood, and sleep (HLBS) diseases and conditions; and to address barriers and facilitators related to SDM strategies used to improve quality of care, adherence, and informed consent; reduce health disparities; and deliver treatments best suited for individual patients. Investigators and multidisciplinary research teams with expertise in clinical implementation research, health information technology, behavioral science, behavioral economics, workflow design, and organizational engineering are encouraged to apply.			
099803	Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-737	07-May-2021	Not Specified
	Contact Name	Lora Reineck, MD, MS			
	Contact Telephone	301-435-0222			
	Contact Email	lora.reineck@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023			
	Synopsis	Providing care that is consistent with a patient's values, preferences, and goals is a cornerstone of palliative care, an interdisciplinary patient-centered approach that aims to improve quality of life for persons with advanced illness and their families. Palliative care focuses on several objectives including relief of symptoms and suffering, communication of prognosis and treatment options in the context of patients' goals, and coordination of care within and across healthcare settings. Palliative care is not synonymous with hospice or end-of-life care. Rather, palliative care addresses the spectrum of care for serious illness from diagnosis through terminal stages of diseases. Moreover, palliative care does not necessarily entail withholding or curbing treatment. Relief of symptoms, enhancing quality of life, and many other specific aspects of goal-concordant care may, in fact, involve optimal medical or surgical treatment of diseases. The expected outcome of integrating palliative care into the management of the patient's disease is a better quality of life, a realistic understanding of risks and benefits of treatment and interventions, and medical treatment decisions that align with the patient's goals, preferences, and			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

values. Many heart, lung, blood, and sleep (HLBS) diseases, including heart failure, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary hypertension, cystic fibrosis, myelodysplastic syndromes, and aplastic anemia are life-limiting, non-curable illnesses. These and other HLBS diseases may benefit from care focused on improvement of symptoms and quality of life, in addition to care focused on slowing or halting progression of diseases. Integration of palliative care into cardiology, pulmonary, hematology, and critical care practice is recommended by multiple professional societies. Additionally, symptoms of HLBS diseases such as cough, shortness of breath, and fatigue may be especially burdensome, even in diseases that are not life-limiting. Research to improve burdensome symptoms has the potential to greatly improve the quality of life for all patients with HLBS diseases, not just those with life-limiting disease.

100825	Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-823	07-May-2021	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Weiniu Gan, Ph.D.
Contact Telephone	301-435-0202
Contact Email	ganw2@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	<p>The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other “omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.

086465	RFA-HL-20-029 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23 Recipients (R03 - Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-029	10-May-2021	100,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name	Roya Kalantari, PhD
Contact Telephone	301-480-1989
Contact Email	roya.kalantari@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-May-2021 , 08-Jun-2021 , 08-Sep-2021 , 08-Oct-2021 , 10-Jan-2022
Synopsis	The purpose of this FOA is to solicit current or recently completed NHLBI K01, K08, and K23 awardees for grant support to expand their current research objectives or to branch out to a study that resulted from the research conducted under the K award. Active NHLBI K01, K08, and K23 awardees may apply for R03 support to run concurrently with the final two years of their K award. Recently completed NHLBI K01, K08, and K23 awardees are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. Thus, this FOA is intended to enhance the capability of NHLBI K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application.

100811	NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-079	07-May-2021	450,000 USD
--------	--	--	------------	-------------	-------------

Contact Name	Patrice Desvigne-Nickens, MD
Contact Telephone	301-435-0504
Contact Email	gweinmann@nih.gov
Sponsor Website	Link to sponsor website

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.</p>			

076311	RFA-HL-19-026 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-026	06-May-2021	750,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Jane D. Scott, ScD, MSN, FAHA
Contact Telephone	301-435-0535
Contact Email	scottj2@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	06-May-2021
Synopsis	<p>National Heart, Lung, and Blood Institute (NHLBI) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

076292	RFA-HL-19-025 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-025	06-May-2021	750,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name | Jane D. Scott, ScD, MSN, FAHA
 Contact Telephone | 301-435-0535
 Contact Email | scottj2@nhlbi.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 06-May-2021

Synopsis | National Heart, Lung, and Blood Institute (NHLBI) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

074423	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18-772	07-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Herbert M. Geller, Ph.D.
 Contact Telephone | 301-451-9440

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email direducation@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Heart, Lung, and Blood Institute (NHLBI) provides highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of Intramural Research the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K22 Career Transition Award mechanism.</p>				
074422	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18-771	07-May-2021	Not Specified
	<p>Contact Name Herbert M. Geller, Ph.D.</p> <p>Contact Telephone 301-451-9440</p> <p>Contact Email direducation@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Heart, Lung, and Blood Institute (NHLBI) provides highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of Intramural Research the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the NIH K22 Career Transition Award mechanism.

084638	Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-329	11-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Nancy DiFronzo, PhD
Contact Telephone	301-435-0065
Contact Email	difronzon@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022
Synopsis	<p>This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015) . For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC) (PAR-19-330). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.</p>

084646	Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-330	11-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Nancy DiFronzo, PhD
Contact Telephone	301-435-0065

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email difronzon@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-19-329) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.</p>				
084637	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-328	11-May-2021	Not Specified
	<p>Contact Name Nahed El Kassar, MD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email nahed.elkassar@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.</p>			
092824	RFA-HL-22-006 -- Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH) (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-006	07-May-2021	2,060,000 USD
	<p>Contact Name Cheryl Anne Boyce, Ph.D. Contact Telephone 301-496-1051 Contact Email cheryl.boyce@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2021</p>	<p>Synopsis This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single site clinical trials to: (1) address barriers that impede population-level implementation of case finding and cascade screening (i.e., blood relatives of familial hypercholesterolemia (FH) index cases are systematically contacted based on their risk according to the pattern of inheritance); (2) explore implementation science methodologies to assess the uptake, cost-effectiveness, feasibility, and scalability of family-based cascade screening programs for FH; (3) develop or improve machine learning algorithms and data mining techniques to find high-risk individuals using Electronic Health Records (EHRs); and (4) optimize treatment strategies and health outcomes.</p>			
085485	RFA-HL-20-028 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-028	11-May-2021	500,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D. Contact Telephone 301-827-7981 Contact Email kathleen.rousche@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.			
085483	RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-027	11-May-2021	700,000 USD
	Contact Name	Kathleen Rousche, Ph.D.			
	Contact Telephone	301-827-7981			
	Contact Email	kathleen.rousche@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.			
102462	RFA-HL-22-002 -- Lung Transplant Consortium - Clinical Centers (U01 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-002	15-May-2021 [Optional][LOI/Pre-App]	1,375,000 USD
	Contact Name	Matt Craig, PhD			
	Contact Telephone	301-827-7841			
	Contact Email	matt.craig@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) seeks applications from lung transplant clinical centers (CCs) to form a cooperative multi-site Lung Transplant Consortium (LTC). The LTC will support CCs in conducting observational and complementary mechanistic clinical research studies that aim to understand the impact of site-specific lung transplant selection criteria and clinical management strategies on donor lung utilization and/or early post-transplant outcomes such as the development of primary graft dysfunction (PGD) and acute lung allograft dysfunction (ALAD) in recipients. Each CC application must consist of a multidisciplinary investigative team that includes a lung transplant surgeon and a lung transplant pulmonologist, and be comprised of primary and subsites that have a combined annual lung transplant volume of at least 100 transplants. Each CC application should propose hypothesis-driven scientific questions to assess certain donor and/or recipient clinical practices and their impact on donor lung utilization, PGD, ALAD or other relevant short-term outcomes that can be addressed through observational data and/or biospecimen collection and analysis at the sites included in their application. In addition, the CCs will be expected to enroll participants and contribute to a core set of data and biospecimens to be collected across all participating consortium sites through the implementation of a common research protocol under the auspices of a centralized Data Coordinating Center (DCC) and a Steering Committee (SC). By leveraging this shared longitudinal resource, LTC investigators will have the tools to identify and answer additional important research questions involving lung transplantation. This FOA runs in parallel with the LTC Data Coordinating Center (see RFA-HL-22-003).</p>			
102465	RFA-HL-22-002 -- Lung Transplant Consortium - Data Coordinating Center (U24 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-003	15-May-2021 [Optional][LOI/Pre-App]	3,500,000 USD
	Contact Name	Matt Craig, PhD			
	Contact Telephone	301-827-7841			
	Contact Email	matt.craig@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications to serve as the Data Coordinating Center (DCC) that will support the research activities of a cooperative multi-site Lung Transplant Consortium (LTC). The primary responsibility of the</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

DCC will be to oversee the conduct of multiple observational and complementary mechanistic clinical research studies involving lung transplantation performed under a common research protocol by awarded Clinical Centers (CCs) within the LTC. The NHLBI anticipates that the DCC will collaborate strategically with the CCs to provide support for regulatory and administrative activities, common research protocol development, statistical data analysis, data and biospecimen collection and storage, the reporting of study results through publication in a timely manner, and the dissemination of datasets and biospecimens for secondary analyses by the broader research community at the conclusion of the program. The DCC will promote collaboration and communication among LTC investigators and will coordinate outreach activities including engaging foundations, societies, and other entities with a shared interest in lung transplantation. The DCC will be responsible for integrating the efforts of 8 Clinical Center awards consisting of approximately 24 sites performing local site-specific observational research studies to identify factors that impact donor lung utilization and early post-transplant outcomes such as primary and acute lung allograft dysfunction in lung transplant recipients. In addition, the DCC, in partnership with the LTC Steering Committee, will oversee the creation and implementation of a common research protocol to enroll participants for collection of a core set of data and biospecimens across all participating consortium sites. By leveraging this shared longitudinal resource, LTC investigators will have the tools to identify and answer additional important research questions involving lung transplantation. This FOA runs in parallel with the LTC Clinical Centers (see RFA-HL-22-002).

085482	RFA-HL-20-024 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-024	11-May-2021	500,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Kathleen Rousche, Ph.D.
Contact Telephone	301-827-7981
Contact Email	kathleen.rousche@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021
Synopsis	This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085480	RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-022	11-May-2021	600,000 USD
	<p>Contact Name Margaret Ochocinska, PhD</p> <p>Contact Telephone 301-827-8285</p> <p>Contact Email ochocinm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.</p>				
085481	RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-023	11-May-2021	700,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100053	Notice of Special Interest (NOSI): Clarification of the Objectives and Program Elements in NHGRI Applications Submitted in Response to the "Ruth L. Kirschstein NRSA Institutional Research Training Grants (Parent T32)"	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-010	25-May-2021	Not Specified
	<p>Contact Name Luis A. Cubano, Ph.D.</p> <p>Contact Telephone 301-480-3435</p> <p>Contact Email luis.cubano@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis The National Human Genome Research Institute (NHGRI) is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s): Genome sciences to support training with a focus on the quantitative sciences, bioinformatics, and technology development; Genomic medicine to support training with a focus on innovation and understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care; Ethical, Legal and Social Implications (ELSI) of Genomic Research to support training with a focus on developing multi-disciplinary conceptual and methodological skills necessary to pursue independent careers as ELSI researchers.</p>				
079894	Initiative to Maximize Research Education in Genomics: Courses (R25 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	PAR-19-185	25-May-2021	Not Specified
	<p>Contact Name Bettie J. Graham, Ph.D.</p> <p>Contact Telephone 301-496-7531</p> <p>Contact Email bettie_graham@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development.</p>				
085902	Initiative to Maximize Research Education in Genomics: Diversity Action Plan	National Human Genome Research Institute/NIH/DHHS	PAR-	25-May-2021	1,500,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[\(R25\)](#)

Research Institute/NIH/DHHS 19-380

USD

Contact Name	Tina Gatlin, Ph.D.
Contact Telephone	301-480-2280
Contact Email	gatlincl@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI Diversity Action Plan (DAP) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral, social and clinical research workforce in genomics. This funding opportunity announcement seeks to expose students at the undergraduate, post-baccalaureate and graduate levels who are from diverse backgrounds, including those from underrepresented groups, to the foundational sciences relevant to genomics to enable them to pursue careers that span all areas of interest to NHGRI - genome sciences, genomic medicine and genomics and society. For the purposes of this FOA, the term “genomics” encompasses issues and activities in these three areas.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101174	Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-018	05-Apr-2021	Not Specified

Contact Name	Michael W. Smith, Ph.D.
Contact Telephone	301-480-3413
Contact Email	smithmw@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Apr-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024
Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and clinical applications in human genomics.			
101030	Notice of Special Interest (NOSI): Clone Program (Defunct)	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-004	07-May-2021	Not Specified
	Contact Name	Colin Fletcher, Ph.D.			
	Contact Telephone	301-496-7531			
	Contact Email	fletcher2@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 08-Jan-2022 , 05-Feb-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.			
080381	Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-209	06-May-2021	Not Specified
	Contact Name	Jim A. Turpin, Ph.D.			
	Contact Telephone	301-451-2732			
	Contact Email	jturpin@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-May-2021			
	Synopsis	The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event -driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					interactions (DDI) studies using drug development and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.
087001	Transgender People: Immunity, Prevention, and Treatment (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-054	11-May-2021	275,000 USD
	Contact Name	Jim A. Turpin, Ph.D.			
	Contact Telephone	301-451-2732			
	Contact Email	jturpin@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-May-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).			
101626	RFA-AI-20-077 -- Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-077	05-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Mercy PrabhuDas, Ph.D., M.B.A.			
	Contact Telephone	240-627-3534			
	Contact Email	mprabhudas@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and function. This program will establish collaborations among			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.			
101637	RFA-AI-20-078 -- Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-078	05-May-2021 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Mercy PrabhuDas, Ph.D., M.B.A.			
	Contact Telephone	240-627-3534			
	Contact Email	mprabhudas@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens, and environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.			
090119	Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAS-20-121	07-May-2021	275,000 USD
	Contact Name	Chris Lambros, PhD			
	Contact Telephone	240-627-3093			
	Contact Email	clambros@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	presence of human immunodeficiency virus (HIV).																		
097705	NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-270	12-May-2021	150,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Greg Deye, M.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-627-3371</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>gregory.deye@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>12-May-2021 , 14-Sep-2021 , 12-Jan-2022 , 13-May-2022 , 14-Sep-2022 , 13-Jan-2023 , 12-May-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).</td> </tr> </table>					Contact Name	Greg Deye, M.D.	Contact Telephone	240-627-3371	Contact Email	gregory.deye@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-May-2021 , 14-Sep-2021 , 12-Jan-2022 , 13-May-2022 , 14-Sep-2022 , 13-Jan-2023 , 12-May-2023	Synopsis	This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).
Contact Name	Greg Deye, M.D.																		
Contact Telephone	240-627-3371																		
Contact Email	gregory.deye@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-May-2021 , 14-Sep-2021 , 12-Jan-2022 , 13-May-2022 , 14-Sep-2022 , 13-Jan-2023 , 12-May-2023																		
Synopsis	This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).																		
073919	Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-18-764	07-May-2021	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Rosemary McKaig, M.P.H, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-627-3214</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>rm434n@nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-May-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. This FOA will use the NIH Research Project (R01) award mechanism.</td> </tr> </table>					Contact Name	Rosemary McKaig, M.P.H, Ph.D.	Contact Telephone	240-627-3214	Contact Email	rm434n@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2021	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. This FOA will use the NIH Research Project (R01) award mechanism.
Contact Name	Rosemary McKaig, M.P.H, Ph.D.																		
Contact Telephone	240-627-3214																		
Contact Email	rm434n@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2021																		
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. This FOA will use the NIH Research Project (R01) award mechanism.																		
073662	Novel Biomarkers for the Development of HIV Incidence Assays with	National Institute of Allergy and	PA-18-753	07-May-2021	275,000														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Improved Specificity (R21 Clinical Trial Not Allowed)	Infectious Diseases/NIH/DHHS			USD
	Contact Name	Usha Sharma, Ph.D., M.P.H.			
	Contact Telephone	240-292-4809			
	Contact Email	usharma@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections. This FOA will use the NIH Research Project (R01) award mechanism.			
073660	Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-753	07-May-2021	Not Specified
	Contact Name	Usha Sharma, Ph.D., M.P.H.			
	Contact Telephone	240-292-4809			
	Contact Email	usharma@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections. This FOA will use the NIH Research Project (R01) award mechanism.			
101499	RFA-AI-21-001 -- Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-001	16-May-2021 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Lakshmi Ramachandra, MSc, PhD			
	Contact Telephone	301-669-5061			
	Contact Email	Lakshmi.ramachandra@mail.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.</p>				
099870	NIAID Research Education Program (R25 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-289	25-May-2021	1,625,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 07-Sep-2021 , 25-May-2022 , 07-Sep-2022</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities related to NIAID's mission areas with a primary focus on: The overarching goal of this NIAID R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs of NIAID mission areas Courses for Skills Development Research Experiences Mentoring Activities</p>				
087230	NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-063	07-May-2021	Not Specified
	<p>Contact Name Martin Gutierrez, Ph.D.</p> <p>Contact Telephone 240-292-4844</p> <p>Contact Email mgutierrez@niaid.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.</p>				
101691	NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-082	14-May-2021	Not Specified
	<p>Contact Name Natalia Kruchinin, Ph.D.</p> <p>Contact Telephone 240-669-2919</p> <p>Contact Email NIAIDU44@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-May-2021 , 13-Sep-2021 , 14-Jan-2022 , 13-May-2022 , 13-Sep-2022 , 13-Jan-2023 , 13-May-2023 , 14-Sep-2023 , 13-Jan-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and may be proposed under this program.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101688	NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-083	14-May-2021	Not Specified
	<p>Contact Name: Greg Deye, M.D.</p> <p>Contact Telephone: 240-627-3371</p> <p>Contact Email: gregory.deye@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 14-May-2021 , 13-Sep-2021 , 14-Jan-2022 , 13-May-2022 , 13-Sep-2022 , 13-Jan-2023 , 13-May-2023 , 14-Sep-2023 , 13-Jan-2024</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.</p>				
102077	RFA-AI-20-080 -- Human Immunology Project Consortium (HIPC) Coordinating Center (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-080	05-May-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Alison Deckhut Augustine, Ph.D.</p> <p>Contact Telephone: 240-627-3475</p> <p>Contact Email: NIAIDHPCU19@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021</p> <p>Synopsis: The goal of this FOA is to support a Coordinating Center for the Human Immunology Project Consortium (HIPC) program. The HIPC program, supported through a separate FOA, will consist of 5-8 multi-project cooperative agreement (U19) awardees that will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The HIPC Coordinating Center supported by this FOA will be responsible for: coordinating cross-HIPC data integration, analysis, and visualization; developing and maintaining a public HIPC website and knowledgebase</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		to support cross-HIPC data analysis and visualization; and fostering collaborations amongst HIPC-funded investigators by managing the HIPC subcommittees and an Infrastructure and Opportunity Fund to support collaborative studies.			
078717	Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-083	07-May-2021	275,000 USD
	<p>Contact Name: Dona Love, Ph.D.</p> <p>Contact Telephone: 301-761-7788</p> <p>Contact Email: dona.love@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis: The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.</p>				
102326	RFA-AI-21-007 -- Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-007	31-May-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Katrin Eichelberg, MSc, PhD</p> <p>Contact Telephone: 240-669-2921</p> <p>Contact Email: keichelberg@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 31-May-2021 [Optional][LOI/Pre-App], 30-Jun-2021</p> <p>Synopsis: To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| milestones.

078301	Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-050	07-May-2021	275,000 USD
--------	---	--	-----------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Adeola Adeyeye, M.D.</p> <p>240-669-5005</p> <p>adeyeyeao@niaid.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 07-Sep-2021</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care. The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.</p>
---	--

078292	Engaging Men in HIV Testing, Prevention, and Care (R01 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-042	07-May-2021	Not Specified
--------	---	--	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Adeola Adeyeye, M.D.</p> <p>240-669-5005</p> <p>adeyeyeao@niaid.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 07-Sep-2021</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care. The R01 mechanism is intended to support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094378	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-209	07-May-2021	Not Specified
	<p>Contact Name Deborah Philip, Ph.D.</p> <p>Contact Telephone 301-761-7776</p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-210).</p>				
099832	Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-291	07-May-2021	275,000 USD
	<p>Contact Name Timothy A. Gondré-Lewis, Ph.D.</p> <p>Contact Telephone 240-627-3566</p> <p>Contact Email tglewis@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>			
099831	Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-290	07-May-2021	100,000 USD
	Contact Name	Stacy E. Ferguson, Ph.D.			
	Contact Telephone	240-627-3504			
	Contact Email	fergusont@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023			
	Synopsis	<p>The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>			
094380	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-210	07-May-2021	Not Specified
	Contact Name	Shawn Drew Gaillard, Ph.D.			
	Contact Telephone	301-761-7776			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-20-209).</p>				
081206	Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-237	07-May-2021	275,000 USD
	<p>Contact Name Chao Jiang, Ph.D.</p> <p>Contact Telephone 301-761-7802</p> <p>Contact Email chao.jiang@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.</p>				
085477	NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-371	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Shawn Drew Gaillard, Ph.D.</p> <p>Contact Telephone 240-627-3857</p> <p>Contact Email Shawn.Gaillard@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Allergy and Infectious Diseases (NIAID) provides support for the NIAID Research Scholar Development Award (RSDA), which is intended to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) will utilize the NIH Career Transition Award (K22) mechanism.</p>				
102076	<p>RFA-AI-20-079 -- Human Immunology Project Consortium (HIPC) (U19 Clinical Trial Optional)</p>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-079	05-May-2021 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name Alison Deckhut Augustine, Ph.D.</p> <p>Contact Telephone 240-627-3475</p> <p>Contact Email NIAIDHPCU19@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) for the Human Immunology Project Consortium (HIPC) solicits applications from single institutions, or consortia of institutions, to participate in a network of human immunology profiling research groups in the area of infectious diseases, including HIV. The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, vaccine adjuvants or natural infections by capitalizing on recent advances in immune profiling technologies. Studies supported under this FOA will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The resulting data will be used to develop molecular signatures that define immune response profiles and identify biomarkers that correlate with the outcomes of vaccinations, vaccine adjuvants or natural infections in humans. An additional goal of this program is to promote rapid public access to HIPC-supported data and meta-data through public portals such as ImmPort. A companion FOA will support development and operation of a HIPC Coordinating Center that will be responsible for fostering collaborations amongst HIPC-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					funded investigators; facilitating public dissemination of integrated HIPC findings and knowledge; and supporting development or adoption of new, robust methods for data integration, analysis, presentation, and visualization to further research and development in this field.
102629	RFA-AI-21-005 -- Tropical Medicine Research Centers Coordinating Center (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-005	19-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Malla Rao, Ph.D.			
	Contact Telephone	240-627-3352			
	Contact Email	mrao@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-May-2021 [Optional][LOI/Pre-App], 18-Jun-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits applications for a Tropical Medicine Research Centers Coordinating Center (TMRC CC) for the Tropical Medicine Research Centers (TMRC). The TMRC CC will oversee and coordinate efforts across the TMRCs related to data management, data and specimen sharing, scientific collaboration, creation and maintenance of a virtual sample repository, organizing annual meetings, managing an Opportunity Fund to support research by junior and early-stage investigators, and liaising with United States Government (USG) counterparts and other stakeholders.			
102623	RFA-AI-21-004 -- Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-004	19-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Malla Rao, Ph.D.			
	Contact Telephone	240-627-3352			
	Contact Email	mrao@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-May-2021 [Optional][LOI/Pre-App], 18-Jun-2021			
	Synopsis	This funding opportunity announcement (FOA) solicits research applications focused on the etiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, treatment and control of select Neglected Tropical Diseases (NTDs) in endemic areas. The Tropical Medicine Research Centers (TMRCs) are intended to advance NIAID's global research			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>effort by targeting research endeavors to: develop novel diagnostic, prevention and therapeutic strategies adapted for the unique needs of low and middle-income countries (LMICs), as classified by the World Bank; create and sustain in-country research capacity; stimulate scientific collaboration and global partnerships; provide opportunities for junior and early-stage investigators to conduct research on NTDs; and facilitate sample sharing to support translational research to develop or evaluate new drugs, diagnostics, vaccines, therapeutics, and/or vector control strategies.</p>			
101127	RFA-AR-22-001 -- Centers of Research Translation (CORT) (P50 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	RFA-AR-22-001	11-Apr-2021 [Optional][LOI/Pre-App]	5,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Aron Marquitz, Ph.D.</p> <p>301-435-1240</p> <p>aron.marquitz@nih.gov</p> <p>Link to program URL</p> <p>11-Apr-2021 [Optional][LOI/Pre-App], 11-May-2021</p>			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications for Centers of Research Translation (CORT). Overall, a CORT research program should be carried out by a synergistic team of scientists who, through an interdisciplinary team science approach, will address a highly significant translational research challenge in a single or a group of highly-related disease(s) or condition(s) within the mission of the NIAMS. The focus of research could be either 1) a disease-targeted translational theme addressed by synergistic Research Projects with optional Research Cores; or 2) a disease-related critical translational research question addressed through a single collaborative Research Project enabled by a number of highly interactive Research Cores whose work is integrated during the development and implementation of the Project. A CORT must have a minimum of three highly meritorious research components consisting of one or more translational Research Projects and optional Research Cores. An Administrative Core is required in all applications. To facilitate an interdisciplinary team science approach, the lead investigators of the research components must be drawn from relevant and, as appropriate, different research disciplines, and may be based in different departments, divisions, and/or institutions. Combined, the projects and cores will generate new knowledge that will improve our understanding of human pathophysiology and lead to identification of new targets, other tangible products or deliverables, and development of more effective treatment, diagnostic, or prevention strategies for human disease.</p>			
067950	Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R21 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin	PA-18-408	07-May-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Diseases/NIH/DHHS					
	<p>Contact Name Gayle E. Lester, Ph.D.</p> <p>Contact Telephone 301-594-3511</p> <p>Contact Email lester1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
067972	Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R01 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-18-409	07-May-2021	275,000 USD
	<p>Contact Name Gayle E. Lester, Ph.D.</p> <p>Contact Telephone 301-594-3511</p> <p>Contact Email lester1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH R01 Research Project Grant award mechanism.</p>				
101494	Notice of Special Interest (NOSI): Promoting Research on COVID-19	National Institute of Arthritis and	NOT-AR-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	and Rheumatic, Musculoskeletal and Skin Diseases	Musculoskeletal and Skin Diseases/NIH/DHHS	21-012		Specified
	<p>Contact Name Marie Mancini, Ph.D.</p> <p>Contact Telephone 301-594-5032</p> <p>Contact Email mancinim2@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 15-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021</p> <p>Synopsis The purpose of this Notice is to announce to potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) an interest in research on the impact of COVID-19 as related to diseases and conditions within the NIAMS mission.</p>				
080488	Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-215	28-May-2021	200,000 USD
	<p>Contact Name Zeynep Erim, Ph.D.</p> <p>Contact Telephone 301-451-4792</p> <p>Contact Email erimz@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-May-2021</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIBIB R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA seeks to support programs that include innovative approaches to enhance biomedical engineering design education to ensure a future workforce that can meet the nation’s needs in biomedical research and healthcare technologies. Applications are encouraged from institutions that propose to establish new or to enhance existing team-based design courses or programs in undergraduate biomedical engineering departments or other degree-granting programs with biomedical engineering tracks/minors. This FOA targets the education of undergraduate biomedical engineering/bioengineering students in a team-based environment. While current best practices such as</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

multidisciplinary/interdisciplinary education, introduction to the regulatory pathway and other issues related to the commercialization of medical devices, and clinical immersion remain encouraged components of a strong BME program, this FOA also challenges institutions to propose other novel, innovative and/or ground-breaking activities that can form the basis of the next generation of biomedical engineering design education.

079361	Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-158	07-May-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Seila Selimovic, Ph.D. Program Director
Contact Telephone	301-451-4577
Contact Email	seila.selimovic@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021
Synopsis	The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

079367	Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-156	07-May-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Seila Selimovic, Ph.D. Program Director
Contact Telephone	301-451-4577
Contact Email	seila.selimovic@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022
Synopsis	This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

079366	Bioengineering Research Partnerships (U01 Clinical Trial Required)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-157	07-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Seila Selimovic, Ph.D. Program Director
 Contact Telephone | 301-451-4577
 Contact Email | seila.selimovic@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 07-May-2021

Synopsis | This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

079360	Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-159	07-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Seila Selimovic, Ph.D. Program Director
 Contact Telephone | 301-451-4577
 Contact Email | seila.selimovic@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 07-May-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>			
--	-----------------	---	--	--	--

088092	NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-20-084	07-May-2021	400,000 USD
--------	---	--	------------	-------------	-------------

	<p>Contact Name</p>	Randy King, Ph.D.			
	<p>Contact Telephone</p>	301-451-0707			
	<p>Contact Email</p>	Randy.King@nih.gov			
	<p>Sponsor Website</p>				
	<p>Program URL</p>	Link to program URL			
	<p>Deadline Dates (ALL)</p>	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	<p>Synopsis</p>	<p>This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.</p>			

081819	Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19-261	03-May-2021	Not Specified
--------	---	---	------------	-------------	---------------

	<p>Contact Name</p>	Christopher C. Lindsey, PhD		
	<p>Contact Telephone</p>	301-435-6907		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email chris.lindsey@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021 , 13-Dec-2021</p> <p>Synopsis The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing male and/or female non-hormonal contraception development with the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism, fertility studies). The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their development program for either male or female contraceptives.</p>				
097282	Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PA-20-282	19-May-2021 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Susan Taymans, PhD</p> <p>Contact Telephone 301-496-6517</p> <p>Contact Email Taymanss@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-May-2021 [Optional][LOI/Pre-App], 19-Jun-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 19-Feb-2022 , 19-Sep-2022 [Optional][LOI/Pre-App], 19-Oct-2022 , 19-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and Office of Disease Prevention (ODP) invite applications for exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
097283	Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-20-281	19-May-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Susan Taymans, PhD</p> <p>Contact Telephone: 301-496-6517</p> <p>Contact Email: Taymanss@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 19-May-2021 [Optional][LOI/Pre-App], 19-Jun-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 19-Feb-2022 , 19-Sep-2022 [Optional][LOI/Pre-App], 19-Oct-2022 , 19-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023</p> <p>Synopsis: National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and Office of Disease Prevention (ODP) invite applications for exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program.</p>				
096510	NICHD Research Education Programs (R25 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-250	25-May-2021	750,000 USD
	<p>Contact Name: Dennis A. Twombly, Ph.D.</p> <p>Contact Telephone: 01-301-451-3371</p> <p>Contact Email: dtwombly@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022</p> <p>Synopsis: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development			
090064	NICHD Resource Program Grants in Bioinformatics (P41 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-126	07-May-2021	8,750,000 USD
	Contact Name	James N. Coulombe, PhD			
	Contact Telephone	301-451-1390			
	Contact Email	CoulombeJ@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support the continued operation, enhancement, and dissemination of unique database bioinformatics resources that are of major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development, maintenance, and enhancement of the resource, user training and services, provision of community-generated data storage and archiving, wide dissemination of the tools and/or resources, and establishment of interoperability with other NIH bioinformatics resources.			
102078	RFA-RM-21-011 -- Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-RM-21-011	18-May-2021 [Optional][LOI/Pre-App]	200,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-May-2021 [Optional][LOI/Pre-App], 18-Jun-2021			
	Synopsis	The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community. Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions. This FOA is a Common Fund initiative (Common Fund) through the NIH Office of the Director, Office of Strategic Coordination (<https://dpcpsi.nih.gov/>). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by a trans-NIH team led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

072586	Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-691	07-May-2021	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name | Melissa Parisi, MD, PhD
 Contact Telephone | 301-435-6880
 Contact Email | parisima@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 07-May-2021

Synopsis | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

079181	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19-133	07-May-2021	300,000 USD
--------	--	---	------------	-------------	-------------

Contact Name | Mahua Mukhopadhyay, PhD
 Contact Telephone | 301-435-6886
 Contact Email | mukhopam@mail.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.			
072577	Innovative Therapies and Tools for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-689	07-May-2021	Not Specified
	Contact Name	Melissa Parisi, MD, PhD			
	Contact Telephone	301-435-6880			
	Contact Email	parisima@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH Research Project (R01) award mechanism.			
072588	Innovative Therapies and Tools for Screenable Disorders in Newborns (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-690	07-May-2021	100,000 USD
	Contact Name	Melissa Parisi, MD, PhD			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-435-6880				
Contact Email	parisima@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021				
Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R03 Small Grant Program award mechanism.</p>				

075836	Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-838	07-May-2021	2,499,995 USD
--------	---	---	-----------	-------------	---------------

Contact Name	Ravi Ravindranath, PhD				
Contact Telephone	301-435-6889				
Contact Email	ravindr@n@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021				
Synopsis	<p>National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH Research Project (R01) award mechanism.			
072575	Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-688	07-May-2021	Not Specified
	Contact Name	George P. Giacoia MD			
	Contact Telephone	301-496-5589			
	Contact Email	giacoia@exchange.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH Research Project (R01) award mechanism.			
074832	Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-790	07-May-2021	Not Specified
	Contact Name	Marion Koso-Thomas, M.D, MPH			
	Contact Telephone	301-435-6873			
	Contact Email	kosomari@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH Research Project (R01) award mechanism.

074138	Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-766	07-May-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name Tracy King, MD, MPH
 Contact Telephone 301-402-1822
 Contact Email tracy.king@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021

Synopsis National Institute of Child Health and Human Development (NICHD) invites applications focusing on identification and management of behavioral symptoms and mental health conditions in individuals with intellectual disabilities (ID). Specific areas of interest for this funding opportunity are (1) applications to develop and validate assessment tools that reliably identify behavioral symptoms or diagnose mental health conditions in individuals with ID, and (2) applications studying the pharmacokinetics, safety and efficacy of specific psychotropic medications for treatment of behavioral symptoms or mental health conditions in individuals with ID. This FOA will use the NIH Research Project (R01) award mechanism.

070059	NICHD Research Project Grant (R01 - Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-480	07-May-2021	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name NICHD Referral Office
 Contact Telephone
 Contact Email NICHDReferral@mail.nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 07-May-2021

Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for clinical trials that fall within the NICHD mission. This FOA will use the NIH Research Project (R01) award mechanism.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
070412	Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-506	07-May-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Ekaterini Tsilou, MD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-496-6287</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>tsiloue@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-May-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>National Institute of Child Health and Human Development (NICHD) invites applications to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations. This FOA will use the NIH Research Project (R01) award mechanism.</td> </tr> </table>					Contact Name	Ekaterini Tsilou, MD	Contact Telephone	301-496-6287	Contact Email	tsiloue@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2021	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations. This FOA will use the NIH Research Project (R01) award mechanism.
Contact Name	Ekaterini Tsilou, MD																		
Contact Telephone	301-496-6287																		
Contact Email	tsiloue@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2021																		
Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations. This FOA will use the NIH Research Project (R01) award mechanism.																		
072576	Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-687	07-May-2021	100,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>George P. Giacoia MD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-496-5589</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>giacoia@exchange.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-May-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH R03 Small Grant Program award mechanism.</td> </tr> </table>					Contact Name	George P. Giacoia MD	Contact Telephone	301-496-5589	Contact Email	giacoia@exchange.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2021	Synopsis	National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH R03 Small Grant Program award mechanism.
Contact Name	George P. Giacoia MD																		
Contact Telephone	301-496-5589																		
Contact Email	giacoia@exchange.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2021																		
Synopsis	National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH R03 Small Grant Program award mechanism.																		
100064	Notice of Special Interest (NOSI): Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-20-022	07-May-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Regina Bures, PhD</td> </tr> </table>					Contact Name	Regina Bures, PhD												
Contact Name	Regina Bures, PhD																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-9485</p> <p>Contact Email regina.bures@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages applications that propose to conduct secondary analyses using publicly available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost-effective research utilizing data and biospecimens collected with NICHD resources.</p>				
101700	Notice of Special Interest (NOSI): Biophysical and Biomechanical Aspects of Embryonic Development (R21)	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-21-004	07-May-2021	Not Specified
	<p>Contact Name Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email mukhopam@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022</p> <p>Synopsis The Notice of Scientific Interest (NOSI) is intended to encourage innovative and high risk/impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this program can explore approaches and concepts new to the area of developmental tissue mechanics, research and development of new technologies, or initial research and development of data upon which significant future research may be built. The focus of this NOSI is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders.</p>				
070064	NICHD Small Grant Program (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-481	07-May-2021	100,000 USD
	<p>Contact Name NICHD Referral Office</p> <p>Contact Telephone </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	NICHDReferral@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021
Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for small research projects that can be carried out in a short period of time with limited resources. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This FOA will use the NIH R03 Small Grant Program award mechanism.

075841	Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-839	07-May-2021	275,000 USD
--------	---	---	-----------	-------------	-------------

Contact Name	Ravi Ravindranath, PhD
Contact Telephone	301-435-6889
Contact Email	ravindr@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021
Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
074839	Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-791	07-May-2021	100,000 USD
	<p>Contact Name Marion Koso-Thomas, M.D, MPH</p> <p>Contact Telephone 301-435-6873</p> <p>Contact Email kosomari@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
087240	Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-064	07-May-2021	100,000 USD
	<p>Contact Name Regina Bures, Ph.D.</p> <p>Contact Telephone 301-496-9485</p> <p>Contact Email regina.bures@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085590	Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19-375	07-May-2021	200,000 USD
	<p>Contact Name James N. Coulombe, Ph.D.</p> <p>Contact Telephone 301-451-1390</p> <p>Contact Email CoulombeJ@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The goal of the Gabriella Miller Kids First Pediatric Data Resource is to build a collection of curated genomic and phenotypic data from childhood cancer and birth defects cohorts and provide a central portal where data and analysis tools will be readily accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.</p>				
101701	NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-108	08-Apr-2021	Not Specified
	<p>Contact Name Leslie A. Frieden, Ph.D</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: right;">Synopsis</p> <p>Jan-2024</p> <p>The purpose of the NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00) is to provide support and mentorship to outstanding students enrolled in integrated dual degree dental (DDS/DMD) and PhD programs during the transition from predoctoral student to postdoctoral scholar. This phased award program will facilitate completion of predoctoral dual degree dentist scientist training (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enhance dual degree dentist scientists' research career trajectories This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
102061	<p>NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00 Independent Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-060	08-Apr-2021	Not Specified
	<p style="text-align: right;">Synopsis</p> <p>08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-Jan-2024</p> <p>The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award for a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00) is to support outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences, over the transition from predoctoral to postdoctoral research training. This phased award program will facilitate completion of graduate PhD or dual degree clinician scientist programs (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable achievement of an independent research faculty position and subsequent NIDCR career development and research project awards. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>	<p>Contact Name Leslie A. Frieden, Ph.D.</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>			
079343	<p>NIDCR Dentist Scientist Career Transition Award for Intramural</p>	National Institute of Dental and	PAR-19-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Investigators (K22 Independent Clinical Trial Not Allowed)	Craniofacial Research/NIH/DHHS	152		Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion 'Clinical Trial Required' FOA (PAR-18-360). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants" should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19-151).</p>				
079337	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-151	07-May-2021	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research funding. This Funding Opportunity Announcement (FOA) is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should apply to the companion ‘Clinical Trial Required’ FOA (PAR-18-360). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-152).

087115	Improving Oral Health and Reducing Disparities in Adolescents (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-059	07-May-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Darien Weatherspoon, DDS, MPH
Contact Telephone	301-594-5394
Contact Email	darien.weatherspoon@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.

086963	NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-046	07-May-2021	200,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Lu Wang, Ph.D.
Contact Telephone	301-594-4846
Contact Email	wanglu@nidcr.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML).</p>			
079222	<p>NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Basic Experimental Studies with Humans Required)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-141	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Leslie A. Frieden, PhD</p> <p>301-496-4263</p> <p>leslie.frieden@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA (PAR-18-432). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-144).</p>			
079369	<p>NIDCR Mentored Career Development Award to Promote Diversity</p>	National Institute of Dental and	PAR-19-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	in the Dental, Oral and Craniofacial Workforce (K01 Independent Basic Experimental Studies with Humans Required)	Craniofacial Research/NIH/DHHS	161		Specified
	<p>Contact Name Lynn Mertens King, Ph.D.</p> <p>Contact Telephone 301-594-5006</p> <p>Contact Email lynn.king@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trial Required’ NIDCR K01 PAR-18-359). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NIDCR K01 PAR-19-160 Clinical Trial Not Allowed.</p>				
079322	NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-145	07-May-2021	200,000 USD
	<p>Contact Name Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone 301-594-5394</p> <p>Contact Email darien.weatherspoon@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.			
096097	Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-233	07-May-2021	Not Specified
	Contact Name	Orlando Lopez, PhD			
	Contact Telephone	301-402-4243			
	Contact Email	orlando.lopez@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.			
076573	Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 - Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-875	07-May-2021	Not Specified
	Contact Name	Darren Weatherspoon, DDS, MPH			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-5394</p> <p>Contact Email darien.weatherspoon@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
087123	<p>NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-060	07-May-2021	Not Specified
	<p>Contact Name Dena Fischer, DDS, MSD, MS</p> <p>Contact Telephone 301-594-4876</p> <p>Contact Email dena.fischer@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected as part of a previous NIDCR award.</p>				
087114	<p>Improving Oral Health and Reducing Disparities in Adolescents (R01 Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-058	07-May-2021	Not Specified
	<p>Contact Name Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone 301-594-5394</p> <p>Contact Email darien.weatherspoon@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</p>				
074728	Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-787	07-May-2021	Not Specified
	<p>Contact Name Chiayeng Wang, Ph.D.</p> <p>Contact Telephone 301-827-4647</p> <p>Contact Email chiayeng.wang@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
083076	Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-292	07-May-2021	Not Specified
	<p>Contact Name Kathryn Stein, Ph.D.</p> <p>Contact Telephone 301-827-4653</p> <p>Contact Email kathryn.stein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic investigation of the interplay of genes/gene networks and environmental factors in dental, oral, craniofacial (DOC), and other diseases and conditions.			
081268	Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-239	07-May-2021	Not Specified
	Contact Name	Darren Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	darien.weatherspoon@mail.nih			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.			
072035	NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-656	07-May-2021	Not Specified
	Contact Name	Melissa W. Riddle, PhD			
	Contact Telephone	301-451-3888			
	Contact Email	riddleme@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include traditional clinical trials			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to develop and test behavior change interventions for preventing and treating dental, oral, or craniofacial conditions, as well as interventions that are used as tools to understand mechanisms of behavior change. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UH3 phase of the award will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stage 0 & I) through implementation and cost-effectiveness research (Stages IV/V). This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

100184	National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-306	07-May-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Dena Fischer, DDS, MSD, MS
Contact Telephone	301-594-4876
Contact Email	dena.fischer@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 09-Feb-2022 , 07-May-2022 , 09-Jun-2022 , 07-Jul-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023
Synopsis	The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>studies to be conducted in the National Dental PBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the National Dental PBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, consideration of the dental PBRN as an appropriate venue for conduct of the research, NIDCR program priorities, and availability of funds. The main goals of the dental PBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice. This FOA encourages applications proposing research studies that align with the goals of the dental PBRN.</p>			
079225	NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-144	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Leslie A. Frieden, PhD</p> <p>301-496-4263</p> <p>leslie.frieden@nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p>			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants" should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19- 141). The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.</p>			
079378	NIDCR Mentored Career Development Award to Promote Diversity	National Institute of Dental and	PAR-19-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	in the Dental, Oral and Craniofacial Workforce (K01 Independent Clinical Trial Not Allowed)	Craniofacial Research/NIH/DHHS	160		Specified
	<p>Contact Name Lynn Mertens King, Ph.D.</p> <p>Contact Telephone 301-594-5006</p> <p>Contact Email lynn.king@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor . This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-18-359).</p>				
053538	Precision Imaging of Oral Lesions (R21-Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-788	07-May-2021	275,000 USD
	<p>Contact Name Chiayeng Wang, Ph.D.</p> <p>Contact Telephone 301-827-4647</p> <p>Contact Email chiayeng.wang@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
076575	Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 - Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-18-874	07-May-2021	275,000 USD
	<p>Contact Name: Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone: 301-594-5394</p> <p>Contact Email: darien.weatherspoon@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis: National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
083077	Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-293	07-May-2021	275,000 USD
	<p>Contact Name: Kathryn Stein, Ph.D.</p> <p>Contact Telephone: 301-827-4653</p> <p>Contact Email: kathryn.stein@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS , and NICHD solicit applications to develop novel and robust experimental systems that offer approaches complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.</p>				
086959	NIDCR Research Grants for Analyses of Existing Genomics Data (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-045	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Lu Wang, Ph.D.</p> <p>Contact Telephone 301-594-4846</p> <p>Contact Email wanglu@nidcr.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.</p>				
069107	<p>NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-359	07-May-2021	625,000 USD
	<p>Contact Name Lynn Mertens King, PhD</p> <p>Contact Telephone 301-594-5006</p> <p>Contact Email lynn.king@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K01 Research Scientist Development Award - Research & Training award mechanism.			
069114	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-360	07-May-2021	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	leslie.frieden@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program. provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K22 Career Transition Award mechanism.			
096105	Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-232	07-May-2021	Not Specified
	Contact Name	Orlando Lopez, PhD			
	Contact Telephone	301-402-4243			
	Contact Email	orlando.lopez@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.</p>			
--	----------	---	--	--	--

100931	NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-084	07-May-2021	200,000 USD
--------	--	---	------------	-------------	-------------

	Contact Name	Preethi Chander, PhD			
	Contact Telephone	301-827-4620			
	Contact Email	preethi.chander@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application.</p>			

081272	Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-240	07-May-2021	275,000 USD
--------	---	---	------------	-------------	-------------

	Contact Name	Darren Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email darien.weatherspoon@mail.nih</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines "older adults" as those individuals age 65 years and older.</p>				
081212	<p>Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-238	07-May-2021	Not Specified
	<p>Contact Name Lynn Mertens King, PhD</p> <p>Contact Telephone 301-594-5006</p> <p>Contact Email Lynn.King@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial (DOC) research with a focus on behavioral and social sciences, and on genetics, genomics, bioinformatics and computational biology research. The intent of this program is to provide mid-career and senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field, in order to enrich their existing DOC research program; and (b) established investigators in other fields who seek training with DOC research investigators in order to facilitate the introduction of DOC research into an existing research program. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100821	RFA-DK-20-025 -- Diabetes Research Centers (P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-025	20-Apr-2021 [Optional][LOI/Pre-App]	6,250,000 USD
	<p>Contact Name Corinne M. Silva, Ph.D.</p> <p>Contact Telephone 301-451-7335</p> <p>Contact Email silvacm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Apr-2021 [Optional][LOI/Pre-App], 20-May-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2018 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org.</p>				
101487	RFA-DK-20-032 -- Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-032	22-May-2021 [Optional][LOI/Pre-App]	600,000 USD
	<p>Contact Name Henry B. Burch, M.D.</p> <p>Contact Telephone 301-827-0827</p> <p>Contact Email henry.burch@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 22-May-2022 [Optional][LOI/Pre-App], 22-Jun-2022 , 22-May-2023 [Optional][LOI/Pre-App], 22-Jun-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

085817	Bioinformatics Interdisciplinary Postdoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F32)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-379	08-Apr-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Arthur L. Castle, Ph.D.
Contact Telephone	301-594-7719
Contact Email	castlea@niddk.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022
Synopsis	This Funding Opportunity Announcement (FOA) is to enable promising postdoctoral fellows to obtain interdisciplinary training from outstanding faculty sponsors in bioinformatics and scientific research relevant to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD). This training will require mentorship in both bioinformatics and metabolic disease disciplines. In order to advance bioinformatics science and encourage its application to these diseases and disorders, NIDDK invites applications from individuals with novel individual development plans (IDP). The fellowship training plan should focus on interdisciplinary approaches and mentorship among data or computer science and medicine in topics related to diabetes, endocrinology and metabolic diseases. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

085810	Bioinformatics Interdisciplinary Predoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F31)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-378	08-Apr-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Arthur L. Castle, Ph.D.
Contact Telephone	301-594-7719
Contact Email	castlea@niddk.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022</p> <p>Synopsis This funding opportunity is to enable promising predoctoral fellows to obtain interdisciplinary training during the dissertation phase of their training from outstanding faculty sponsors in bioinformatics and scientific research relevant to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD). This training will require mentorship in both bioinformatics and metabolic disease disciplines. In order to advance bioinformatics science and encourage its application to these diseases and disorders, NIDDK invites applications from individuals with novel individual development plans (IDP). The fellowship training plan should focus on interdisciplinary approaches and mentorship among data or computer science and medicine in topics related to diabetes, endocrinology and metabolic diseases. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
101621	<p>Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed)</p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-062	07-May-2021	275,000 USD
	<p>Contact Name Peter J. Perrin, Ph.D.</p> <p>Contact Telephone 301-451-3759</p> <p>Contact Email Peter.Perrin@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| CCCs or viral reservoirs within NIDDK's mission through multiple pathways.

101528	Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-21-031	07-May-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Peter J. Perrin, Ph.D.
Contact Telephone	301-451-3759
Contact Email	Peter.Perrin@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024
Synopsis	This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

087569	Limited Competition: NIDDK Program Projects (P01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20-075	07-May-2021	6,250,000 USD
--------	---	---	------------	-------------	---------------

Contact Name	Bonnie Burgess-Beusse, Ph.D.
Contact Telephone	301-594-4726
Contact Email	Bonnie.Burgess-Beusse@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 07-Jan-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at <https://www.niddk.nih.gov/about-niddk/research-areas>.

080703	Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-222	07-May-2021	375,000 USD
--------	--	---	------------	-------------	-------------

Contact Name | Lawrence Agodoa, M.D.
 Contact Telephone | 301-594-1932
 Contact Email | SmallGrant4Diversity@niddk.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators: (1) from diverse backgrounds, including from groups nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Human Genome Research Institute (NHGRI) and (2) who at the time of award under this FOA will have/have had less than \$125,000 direct cost of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

076246	Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-857	07-May-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name | Mary Evans, Ph.D.
 Contact Telephone | 301-594-4578
 Contact Email | evansmary@niddk.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
091518	Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-20-160	07-May-2021	600,000 USD
	Contact Name	Susan Mendley, M.D.			
	Contact Telephone	301- 827-1861			
	Contact Email	susan.mendley@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			
	Synopsis	This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.			
100633	Limited Competition: Lasker Clinical Research Scholars Transition Award	National Institute of Diabetes and	PAR-20-	31-May-2021	2,495,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(R00 Clinical Trial Optional)		Digestive and Kidney Diseases/NIH/DHHS	315	USD
	<p>Contact Name Charles R. Dearolf, Ph.D.</p> <p>Contact Telephone 301-402-1225</p> <p>Contact Email dearolfc@od.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-May-2021 , 30-Sep-2021 , 31-Jan-2022 , 31-May-2022 , 30-Sep-2022 , 31-Jan-2023 , 31-May-2023 , 30-Sep-2023</p> <p>Synopsis The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.</p>				
076238	Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Not Allowed)		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-856 07-May-2021	Not Specified
	<p>Contact Name Mary Evans, Ph.D.</p> <p>Contact Telephone 301-594-4578</p> <p>Contact Email evansmary@nidk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH Research Project (R01) award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101372	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-102	07-May-2021	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.</p>				
101373	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-103	07-May-2021	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email rankint@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

078518	Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-19-065	07-May-2021	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Jose Serrano, M.D., Ph.D.
Contact Telephone	301-594-8871
Contact Email	serranoj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022
Synopsis	The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop “virtual coaches” by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate).

090534	Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20-140	07-May-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Daniel Gossett, Ph.D.
Contact Telephone	301-594-7723
Contact Email	daniel.gossett@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.			
073411	Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-741	07-May-2021	275,000 USD
	Contact Name	Aynur Unalp-Arida, MD, MSc, PhD			
	Contact Telephone	301-594-8879			
	Contact Email	aynur.unalp-arida@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			
085472	Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-365	07-May-2021	150,000 USD
	Contact Name	Lisa M. Spain, Ph.D.			
	Contact Telephone	301-451-9871			
	Contact Email	SpainL@niddk.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to provide NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This program will use the NIH Small Research Grant (R03) award mechanism.</p>				
076166	<p>Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-854	09-Apr-2021	Not Specified
	<p>Contact Name Mary Evans, Ph.D.</p> <p>Contact Telephone 301-594-4578</p> <p>Contact Email evansmary@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Apr-2021 , 10-May-2021 , 11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
073342	New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-18-730	07-May-2021	600,000 USD
	<p>Contact Name Terry Rogers Bishop, Ph.D.</p> <p>Contact Telephone 301-594-7726</p> <p>Contact Email terry.bishop@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications in nonmalignant hematology research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build and promote research activities in nonmalignant hematology. Innovative research project applications that will steer the field in new directions are invited. Each project will propose proof of principle research that is tightly focused into one specific aim and is directed at validating novel concepts and approaches that promise to open up new pathways for discovery. Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
080739	Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-19-225	07-May-2021	375,000 USD
	<p>Contact Name Carol Shreffler, PhD</p> <p>Contact Telephone 984-287-3322</p> <p>Contact Email shreffl1@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion ‘Independent Clinical Trial Required’ PAR 18-261.</p>			
084593	RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	01-Apr-2021	275,000 USD
	Contact Name	Martha I. Barnes, MS			
	Contact Telephone	919-541-3335			
	Contact Email	barnes@niehs.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Apr-2021 , 03-May-2021 , 01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022			
	Synopsis	<p>This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.</p>			
100252	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-20-020	01-Apr-2021	Not Specified
	Contact Name	Anika Dzierlenga, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 984-287-3125</p> <p>Contact Email anika.dzierlenga@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Apr-2021 , 03-May-2021</p> <p>Synopsis NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.</p>				
100259	<p>Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)</p>	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-20-015	01-Apr-2021	Not Specified
	<p>Contact Name Anika Dzierlenga, Ph.D.</p> <p>Contact Telephone 984-287-3125</p> <p>Contact Email anika.dzierlenga@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Apr-2021 , 03-May-2021</p> <p>Synopsis NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.</p>				
089481	<p>Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase 3 - Transitional Centers (P30 Clinical Trial Optional)</p>	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-115	28-May-2021	3,750,000 USD
	<p>Contact Name Hongwei Gao, M.D., Ph.D.</p> <p>Contact Telephone </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email hongwei.gao@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-May-2021 , 27-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to transition the core resources and biomedical research activities of Centers of Biomedical Research Excellence (COBRE) into independence and sustainability.</p>				
088588	IDeA Networks of Biomedical Research Excellence (INBRE) (P20 Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-102	20-May-2021	13,750,000 USD
	<p>Contact Name Krishan K. Arora, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email arorak@nigms.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-May-2021 , 20-May-2022</p> <p>Synopsis The National Institute of General Medical Sciences (NIGMS) invites applications for Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) awards from investigators at biomedical research institutions within Institutional Development Award (IDeA)-eligible states that award doctoral degrees in health-related sciences or at independent biomedical research institutes with ongoing biomedical research programs funded by the NIH or other federal agencies. The purpose of the INBRE program is to augment and strengthen the biomedical research capacity of IDeA-eligible states. The INBRE program represents a collaborative effort to sponsor research between research intensive institutions and primarily undergraduate institutions (PUIs), community colleges, and Tribally Controlled Colleges and Universities (TCCUs). Only one award will be made per IDeA-eligible state. The primary goals of the INBRE program are to: 1) build on the established multi-disciplinary research network to strengthen the biomedical research expertise and infrastructure of the lead and partner institutions; 2) build and increase the research base and capacity by providing support to faculty, postdoctoral fellows, and graduate students at the participating institutions; 3) provide research opportunities for students from PUIs, community colleges, and TCCUs, and serve as a "pipeline" for these students to continue in biomedical research careers within IDeA states; and 4) enhance science and technology knowledge of the state's workforce.</p>				
095405	National Institute of General Medical Sciences Predoctoral Institutional Research Training Grant (T32 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-213	25-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Dr. Alison Gammie</p> <p>Contact Telephone 301-594-3900</p> <p>Contact Email alison.gammie@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023</p> <p>Synopsis The goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32) program is to develop a diverse pool of well-trained scientists available to address the Nation’s biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
078176	Medical Scientist Training Program (T32)	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-036	25-May-2021	Not Specified
	<p>Contact Name Joseph Gindhart, Ph.D.</p> <p>Contact Telephone 301-594-0943</p> <p>Contact Email gindhartj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021</p> <p>Synopsis The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained physician-scientist leaders available to meet the Nation’s biomedical research needs. Specifically, this funding opportunity announcement (FOA) provides support to eligible domestic institutions to develop and implement effective, evidence-based approaches to integrated dual-degree training leading to the award of both clinical degrees, e.g., M.D., D.O., D.V.M., D.D.S., and research doctorate degrees (Ph.D. or equivalent). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to the understanding, detection, treatment and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are the iterative optimization of MSTP training efficacy and efficiency, fostering the persistence of MSTP alumni in research careers, and enhancing the diversity of the physician-scientist workforce. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

088685	Biomedical Technology Development and Dissemination Center (RM1 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-104	26-May-2021	4,250,000 USD
--------	---	---	------------	-------------	---------------

Contact Name	Haluk Resat, Ph.D.
Contact Telephone	
Contact Email	haluk.resat@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-May-2021 , 26-Jan-2022 , 26-May-2022 , 26-Jan-2023
Synopsis	<p>This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Development and Dissemination (BTDD) Centers. The BTDD program supports the development of technologies once their feasibility has been established and the dissemination of these technologies to the wider biomedical research community. The program encourages investigators to propose projects that address any of the biomedical research areas within the mission of NIGMS. The Centers are required to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Center's technologies and results. Centers should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. Potential applicants are strongly encouraged to contact NIGMS staff at least 10 weeks prior to the application due date to ascertain whether the proposed project is appropriate for an NIGMS BTDD Center.</p>

088591	Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-20-103	27-May-2021	7,500,000 USD
--------	---	---	------------	-------------	---------------

Contact Name	Peter Preusch, Ph.D.
Contact Telephone	301-594-8494
Contact Email	RM1mailbox@nigms.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-May-2021 , 27-Jan-2022 , 27-May-2022 , 27-Jan-2023</p> <p>Synopsis This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PDs/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields. Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development are not appropriate for this FOA.</p>				
085464	Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-367	17-May-2021	3,750,000 USD
	<p>Contact Name Zhongzhen Nie, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email MIRA2019RESEARCH@NIGMS.NIH.GOV</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-May-2021 , 18-Jan-2022 , 17-May-2022</p> <p>Synopsis The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows both new applications from eligible NIGMS-funded investigators and renewal applications from current established and early-stage MIRA grantees.</p>				
072936	Academic Research Enhancement Award for Undergraduate-Focused	National Institute of General	PAR-18-	07-May-2021	300,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Institutions (R15 - Clinical Trial Not Allowed)		Medical Sciences/NIH/DHHS	714	USD
	<p>Contact Name Alexandra M. Ainsztein, PhD.</p> <p>Contact Telephone 301-594-0943</p> <p>Contact Email Alexandra.Ainsztein@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of General Medical Sciences (NIGMS) invites applications for the Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions. The purpose of the award is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees, and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This FOA will use the NIH R15 Academic Research Enhancement Award (AREA) mechanism.</p>				
102287	Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)	National Institute of General Medical Sciences/NIH/DHHS	PAR-21-146	26-May-2021	Not Specified
	<p>Contact Name Edgardo Falcón-Morales, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email edgardo.falcon@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-May-2021 , 26-May-2022 , 26-May-2023</p> <p>Synopsis The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields. This program is limited to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

applications from training programs at baccalaureate degree-granting research-active institutions (i.e., those with an average of NIH Research Project Grant funding less than \$7.5 million total costs over the last 3 fiscal years). This Funding Opportunity Announcement (FOA) does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

076702	RFA-MH-19-135 -- BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-19-135	27-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	--	---------------

Contact Name | Michelle Freund, Ph.D
 Contact Telephone | 301-443-1815
 Contact Email | BRAIN-info-NIMH@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021

Synopsis | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell and circuit specific tools will require extensive focused research designed to remove barriers to delivery of gene therapies. In addition to identification and removal of barriers, the need to specifically target dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cutting-edge tools have been developed for use in model organisms, primarily rodents, fish and flies. These cutting-edge tools, such as viral delivery of genetic constructs, are increasingly adaptable to larger mammalian brains and more importantly are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains or those that are more directly relevant to the human brain is the focus of this initiative. The initiative will support initial proof of principle studies aimed at demonstrating the feasibility of this approach in humans and other mammalian species (non-human primate [NHP]/sheep/pigs). This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

081342	RFA-MH-20-135 - BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-135	27-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	--	---------------

Contact Name | Fred Friedman, Ph.D.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-4058</p> <p>Contact Email ffriedma@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021</p> <p>Synopsis The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.</p>				
099787	<p>Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional)</p>	National Institute of Mental Health/NIH/DHHS	PAR-20-293	17-May-2021	7,500,000 USD
	<p>Contact Name Joel Sherrill, Ph.D.</p> <p>Contact Telephone 301-443-2477</p> <p>Contact Email jsherril@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-May-2021 , 17-May-2022 , 17-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers will support the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders within well-defined target populations; (2) organizing and delivering optimized mental health services within real world treatment settings; and (3) continuously improving the quality, impact, and durability of optimized interventions and service delivery within diverse care systems. The ALACRITY Centers program is intended to support research that maximizes synergies across various components of the mental health research ecosystem, including new discoveries in clinical research, transformative health care technologies, advances in information science, and new federal and state mechanisms for organizing mental health care. The Centers are intended for transdisciplinary projects that could not be achieved using standard research project grant mechanisms. The ALACRITY Centers program is also expected to facilitate widespread sharing of relevant data, methods, and resources that will accelerate clinical research and practice and to provide opportunities for graduate students, postdoctoral researchers, and early-career investigators to participate in transdisciplinary, T2 translational mental health research. Applicants interested in submitting applications to support transdisciplinary programs of research focused on identification, prevention, and treatment of suicide risk, specifically, are directed to PAR-20-286 ("Practice-Based Suicide Prevention Research Centers (P50)").</p>				
092121	RFA-MH-20-525 -- NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-525	21-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Eric R. Murphy, Ph.D.			
	Contact Telephone	301-443-9230 ?			
	Contact Email	eric.murphy@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-May-2021 [Optional][LOI/Pre-App], 20-Jun-2021 , 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022			
	Synopsis	<p>The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.</p>			
088297	Silvio O. Conte Centers for Basic Neuroscience or Translational Mental	National Institute of Mental	PAR-20-	26-May-2021	10,000,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Health Research (P50 Clinical Trial Optional)	Health/NIH/DHHS	093		USD
	<p>Contact Name Susan Koester, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email koesters@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-May-2021 , 24-May-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.</p>				
088290	NIMH Mentoring Networks for Mental Health Research Education (R25 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-20-080	25-May-2021	1,000,000 USD
	<p>Contact Name Nick Gaiano, Ph.D.</p> <p>Contact Telephone 301-827-3420</p> <p>Contact Email nick.gaiano@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-May-2022</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>goal, this FOA will support creative educational activities with a primary focus on: Mentoring Activities and in particular, mentoring networks. Networks may be national or regional. All proposed networks should provide significant new opportunities, and should comprise efforts substantially beyond any ongoing mentoring, networking, or research education within academic programs, institutions, or pre-existing networks; or educational collaborations among institutions. Participants in proposed mentoring networks are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty. Proposed networks are expected to enhance the participants' professional development and to foster their career trajectory towards independent mental health research. Proposed programs are thus expected to contribute to the development of a skilled cadre of investigators in requisite scientific research areas to advance the objectives of the NIMH Strategic Plan.</p>			
088348	NIMH Short Courses for Mental Health Related Research (R25 - Independent Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-20-096	25-May-2021	1,000,000 USD
	Contact Name	Nick Gaiano, Ph.D.			
	Contact Telephone	301-827-3420			
	Contact Email	nick.gaiano@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021 , 25-May-2022			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Proposed short courses are expected to facilitate the development of a sophisticated cadre of investigators with the requisite scientific research skills to advance the mission of the NIMH. Each short course is expected to include both didactics and hands-on research experiences. Participants are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career faculty.</p>			
088301	NIMH Research Education Programs for Psychiatry Residents (R25-Independent Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-20-094	25-May-2021	1,000,000 USD
	Contact Name	Mark Chavez, Ph.D.			
	Contact Telephone	301-443-8942			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email mchavez1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-May-2022</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Courses for Skills Development Specifically, this FOA will support research-oriented experiences and activities designed to develop, maintain, and expand the scientific abilities of psychiatry residents in areas relevant to the mission of NIMH.</p>				
092681	RFA-MH-20-500 -- Post-Acute Interventions for the Treatment of Anorexia Nervosa (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-500	15-May-2021 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name Mary Rooney, Ph.D., ABPP</p> <p>Contact Telephone 301-827-1325</p> <p>Contact Email mary.rooney@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>Synopsis NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of interventions targeting sustained and enhanced treatment response following acute treatment for anorexia nervosa (AN). An emphasis is placed on trials that go beyond seeking incremental gains in intervention effects, and instead take a theory-driven, empirical approach to developing and testing interventions that will have a significant impact on weight restoration and psychological symptoms associated with AN. Consistent with an effectiveness framework, studies should take a deployment-focused approach to intervention development and testing, acknowledging that many patients will receive post-acute treatment from community providers unaffiliated with specialty eating disorder centers.</p>				
090889	Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-20-145	07-May-2021	275,000 USD
	<p>Contact Name Christopher Gordon, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-627-3867</p> <p>Contact Email cgordon1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Division’s research priorities. PA-20-144 uses the R01 grant mechanism while this PA-20-145 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data and/or including longitudinal analysis may apply using the R01 mechanism.</p>				
090786	Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-20-141	07-May-2021	450,000 USD
	<p>Contact Name Christopher Gordon</p> <p>Contact Telephone 240 -627-3867</p> <p>Contact Email cgordon1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment. For the purposes of this FOA, “intervention” is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that prevent acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected, or both.</p>				
090888	Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-20-144	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Christopher Gordon, Ph.D.</p> <p>Contact Telephone 240-627-3867</p> <p>Contact Email cgordon1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023</p> <p>Synopsis This FOA seeks innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Division's research priorities. PA-20-145 uses the R21 grant mechanism while this PA-20-144 uses the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applications with preliminary data and/or including longitudinal analysis may be more appropriate for the R01 mechanism.</p>				
076836	Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-18-894	07-May-2021	Not Specified
	<p>Contact Name Christopher Sarampote, Ph.D.</p> <p>Contact Telephone 301-443-1959</p> <p>Contact Email csarampo@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from groups underrepresented in biomedical, behavioral, clinical and social sciences research. This award supports the completion of the doctoral research project. This FOA will utilize the NIH R36 Dissertation Award award mechanism.</p>				
068701	NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-18-350	07-May-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Pim Brouwers, Ph.D.</p> <p>Contact Telephone 240-627-3863</p> <p>Contact Email ebrouwer@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
083168	Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-19-297	07-May-2021	Not Specified
	<p>Contact Name Anjené Addington</p> <p>Contact Telephone 301-443-6653</p> <p>Contact Email anjene.addington@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

(PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.

077196	New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 (Collab) Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-18-907	07-May-2021	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name	Alexander Arguello, PhD
Contact Telephone	301-827-3547
Contact Email	alexander.arguello@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022
Synopsis	National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA should be used when two or more sites are needed to complete the study. For a linked set of collaborative R01s, each site must have its own Program Director/Principal Investigator and the set of linked applications provide a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA will use the NIH Research Project (R01) award mechanism.

077195	New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-18-908	07-May-2021	Not Specified
--------	--	--	-----------	-------------	---------------

Contact Name	Alexander Arguello, PhD
Contact Telephone	301-827-3547
Contact Email	alexander.arguello@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079331	Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-146	07-May-2021	275,000 USD
	<p>Contact Name Enrique Michelotti, PhD</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-19-147)</p>				
079325	Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-147	07-May-2021	Not Specified
	<p>Contact Name Enrique Michelotti, PhD</p> <p>Contact Telephone 301-443-5415</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.</p>				
080855	Institutional Translational Research Training Program (T32)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-228	26-May-2021	Not Specified
	<p>Contact Name Letitia Weigand, Ph.D.</p> <p>Contact Telephone 301-496-4188</p> <p>Contact Email letitia.weigand@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-May-2021</p> <p>Synopsis The purpose of the Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic scientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS and NIA missions, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

requirements for translating discoveries into viable therapies. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

078105	RFA-NS-19-006 -- BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-19-006	28-May-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	--	---------------

Contact Name	Stephanie Fertig
Contact Telephone	301-469-1779
Contact Email	BRAIN-FOAs@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	28-May-2021 [Optional][LOI/Pre-App], 27-Jun-2021
Synopsis	<p>This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.</p>

072851	RFA-NS-18-019 -- BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-019	04-May-2021	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Edmund Talley, PhD
Contact Telephone	301-496-1917
Contact Email	BRAIN-FOAs@nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the optimization of existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and temporal scales, in any region and throughout the entire depth of the brain. This FOA is intended for the iterative refinement of emergent technologies and approaches that have already demonstrated their transformative potential through initial proof-of-concept testing, and are appropriate for accelerated development of hardware and software while scaling manufacturing techniques towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience practice. Proposed technologies should be compatible with experiments in behaving animals, and should include advancements that enable or reduce major barriers to hypothesis-driven experiments. Technologies may engage diverse types of signaling beyond neuronal electrical activity for large-scale analysis, and may utilize any modality such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. Applications are expected to integrate appropriate domains of expertise, including where appropriate biological, chemical and physical sciences, engineering, computational modeling and statistical analysis. This program will use the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>				
072848	<p>RFA-NS-18-020 -- BRAIN Initiative: New Technologies and Novel Approaches for Large-Scale Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-020	04-May-2021	Not Specified
	<p>Contact Name Edmund Talley, PhD</p> <p>Contact Telephone 301-496-1917</p> <p>Contact Email BRAIN-FOAs@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for proof-of-concept testing and development of new technologies and novel approaches for largescale recording and manipulation of neural activity to enable transformative understanding of dynamic signaling in the nervous system. In particular, we seek exceptionally creative approaches to address major challenges associated with recording and manipulating neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, and should include advancements that enable or reduce major barriers to hypothesis-driven experiments. Technologies may engage diverse types of signaling beyond neuronal electrical activity for large-scale analysis, and may utilize any modality such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. Where appropriate, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis. This program will use the NIH R01 Research Project Grant award mechanism.</p>			
083919	Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-315	07-May-2021	Not Specified
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022</p> <p>Synopsis The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.</p>				
100817	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-057	04-May-2021	Not Specified
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.</p>				
100818	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-058	04-May-2021	Not Specified
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.</p>				
100816	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-056	04-May-2021	Not Specified
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.</p>				
065643	CREATE Bio Optimization Track for Biologics (SBIR-U44)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17-457	07-May-2021	Not Specified
	<p>Contact Name Chris Boshoff, Ph.D.</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email chris.boshoff@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites SBIR applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II, and Fast-Track award mechanism.</p>				
102396	NINDS Institutional Research Training Program (T32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-149	25-May-2021	Not Specified
	Contact Name Stephen Korn, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email korns@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-May-2022 , 25-May-2023</p> <p>Synopsis The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research. Programs should be designed to enhance the breadth and depth of training in NINDS mission areas by incorporating didactic, research and career development components in the context of a defined scientific theme. Programs may support basic, clinical and/or translational research. Critical components of programs supported by this FOA include mechanisms to ensure a thorough understanding of experimental design, strong statistics and analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences. Regardless of theme, programs should provide opportunities and activities that will foster the development of quantitative literacy and the application of quantitative approaches to the trainees' research. NINDS institutional training programs are intended to be 1-2 years in duration and support training of one or more of the following groups: dissertation stage predoctoral students in their 3rd and/or 4th year of graduate school, postdoctoral fellows and fellowship-stage clinicians. (NINDS does not support first or second year graduate students under this PAR). This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
086929	NINDS Postdoctoral Mentored Career Development Award (K01 - No Independent Clinical Trial Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-049	07-May-2021	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone</p> <p>Contact Email korns@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent small clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent small clinical trial as lead investigator, should apply to the companion FOA (PAR-20-050).</p>			
070582	CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-542	07-May-2021	7,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Hao Wang, Ph.D.</p> <p>301-496-1779</p> <p>CREATEinquiries@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021</p>			
	Synopsis	<p>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>			
069923	NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-420	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Peter R. Gilbert, Sc.M.</p> <p>Contact Telephone 301-496-0870</p> <p>Contact Email pgilbert@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). This FOA will use the NIH Research Project (R01) award mechanism.</p>				
071756	Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-622	07-May-2021	Not Specified
	<p>Contact Name Jill A. Morris, Ph.D.</p> <p>Contact Telephone 301-496-5745</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
069928	NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-422	07-May-2021	Not Specified
	<p>Contact Name Peter R. Gilbert, ScM</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-0870</p> <p>Contact Email pgilbert@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). This FOA will utilize the Cooperative Agreement (U01) grant mechanism.</p>				
070148	Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAS-18-483	07-May-2021	Not Specified
	<p>Contact Name Robert Riddle, PhD</p> <p>Contact Telephone 301-496-5745</p> <p>Contact Email rr260c@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
086932	NINDS Postdoctoral Mentored Career Development Award (K01 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-050	07-May-2021	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email korns@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049).</p>				
071757	Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (R21 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-623	07-May-2021	275,000 USD
	<p>Contact Name Jill A. Morris, Ph.D.</p> <p>Contact Telephone 301-496-5745</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications that propose to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. The primary objective of this FOA is to remove barriers to hydrocephalus research that are due to scarcity of tools to investigate both the disease mechanisms and alternative therapies (non-shunt) in a rigorous manner. Applications should aim to transform the field of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.				
079593	Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-171	07-May-2021	Not Specified
	<p>Contact Name Adam L. Hartman, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email adam.hartman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 18-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered)). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>				
073884	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-761	07-May-2021	750,000 USD
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs. This FOA will utilize the R61/R33 Phased Innovation Award mechanism.			
073885	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-762	07-May-2021	750,000 USD
	Contact Name	Mary Ann Pellemounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pellemounter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. This FOA will utilize the NIH R61/R33 Phased Innovation Award mechanism.			
070119	NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-468	07-May-2021	Not Specified
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	jonesmiche@ninds.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial that also meets the definition of a clinical trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS Scientific/Research contact prior to submitting an application with human subjects to determine the appropriate funding opportunity. This FOA will utilize the NIH K22 Career Transition Award mechanism.</p>				
070137	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-486	07-May-2021	975,000 USD

Contact Name	Michelle Jones-London, Ph.D.				
Contact Telephone	301-451-7966				
Contact Email	jonesmiche@ninds.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2021				
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

070123	NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-No Independent Clinical Trials)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-469	07-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Michelle Jones-London, Ph.D.
 Contact Telephone | 301-451-7966
 Contact Email | jonesmiche@ninds.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 07-May-2021

Synopsis | National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity is designed to enhance the participation of highly trained early career investigators from underrepresented groups in neuroscience research. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K22 Career Transition Award mechanism.

070586	CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-543	07-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Chris Boshoff, Ph.D.
 Contact Telephone | 301-496-1779

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Contact Email	chris.boshoff@nih.gov		
		Sponsor Website			
		Program URL	Link to program URL		
		Deadline Dates (ALL)	07-May-2021		
		Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-track only.		
070144	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-490	07-May-2021	975,000 USD
		Contact Name	Michelle Jones-London, Ph.D.		
		Contact Telephone	301-451-7966		
		Contact Email	jonesmiche@ninds.nih.gov		
		Sponsor Website			
		Program URL	Link to program URL		
		Deadline Dates (ALL)	07-May-2021		
		Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

100306	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-032	07-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stephen Korn, Ph.D.</p> <p>301-496-4188</p> <p>korns@ninds.nih.gov</p> <p></p> <p>Link to program URL</p> <p>07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>
---	--

086471	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-021	07-May-2021	Not Specified
--------	--	--	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p>	<p>Stephen Korn, Ph.D.</p> <p>301-496-4188</p>
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email korns@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of “mentored training” within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
065641	CREATE Bio Optimization Track for Biologics (U01)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17-456	07-May-2021	2,500,000 USD
	<p>Contact Name Chris Boshoff, Ph.D.</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email chris.boshoff@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.			
100819	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-059	15-Mar-2021	Not Specified
	Contact Name	Mary Ann Pellemounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pellemounter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Mar-2021 , 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023			
	Synopsis	The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.			
078414	Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-058	07-May-2021	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	adamsls@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.			
068622	Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-159	07-May-2021	275,000 USD
	Contact Name	Martha Matocha, PhD			
	Contact Telephone	301-594-2775			
	Contact Email	matocham@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
078636	Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-073	07-May-2021	Not Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	tullyla@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.			
077974	Addressing Caregiver Symptoms through Technological Tools (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-024	07-May-2021	275,000 USD
	Contact Name	Augie Diana, Ph.D.			
	Contact Telephone	301-402-6423			
	Contact Email	dianaa@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.			
078635	Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-074	07-May-2021	Not Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	tullyla@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.

079184	Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)	National Institute of Nursing Research/NIH/DHHS	PAR-19-135	07-May-2021	300,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Michelle R.J. Hamlet, PhD
Contact Telephone	301-496-9623
Contact Email	hamletm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Oct-2021 , 07-Jan-2022

Synopsis The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions (e.g., the university or college with a unique identifier number (such as DUNS) and a unique NIH Institutional Profile File (IPF) number)) must award NIH-relevant baccalaureate or advanced degrees in health professions and have received no more than \$6 million per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by the institution as a whole (meaning all schools and colleges within an institution). In other words, the funding for all the institution's health professional schools, graduate schools, and colleges and all the institution's non-health professional schools and colleges that are part of the institution are considered together and summed as total NIH funding when determining institutional eligibility. For institutions with multiple campuses, eligibility can be considered for each individual campus (e.g. main, satellite, etc.) only if a unique identifier number or NIH IPF number is established for each campus. For institutions that use one identifier number or NIH IPF number for all campuses, eligibility is determined for all campuses (e.g. main, satellite, etc.) together. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.			
079185	End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-136	07-May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Lynn S. Adams, Ph.D. 301-594-8911 lynn.adams@nih.gov Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.			
076049	Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-849	07-May-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Mary C. Roary, Ph.D. 301-594-2154 mary.roary@nih.gov Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH Research Project (R01) award mechanism.			
084549	Palliative Care in Home and Community Settings (R01 Clinical Trial)	National Institute of Nursing	PAR-19-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Optional		Research/NIH/DHHS	321	Specified
	<p>Contact Name Karen A. Kehl, PhD, RN, FPCN</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email karen.kehl@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.</p>				
085700	Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-377	07-May-2021	Not Specified
	<p>Contact Name Lois A. Tully, PhD</p> <p>Contact Telephone 301-594-5968</p> <p>Contact Email tullyla@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.</p>				
078345	End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-045	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Karen A. Kehl, Ph.D.</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email kehlka@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.</p>				
077411	<p>Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)</p>	National Institute of Nursing Research/NIH/DHHS	PAR-19-057	07-May-2021	Not Specified
	<p>Contact Name Lynn S. Adams, Ph.D.</p> <p>Contact Telephone 301-594-8911</p> <p>Contact Email adamsls@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.</p>				
077788	<p>Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)</p>	National Institute of Nursing Research/NIH/DHHS	PA-18-945	07-May-2021	Not Specified
	<p>Contact Name Martha Matocha, PhD</p> <p>Contact Telephone 301-594-2775</p> <p>Contact Email matocham@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.</p>					
077972	Addressing Caregiver Symptoms through Technological Tools (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-023	07-May-2021	Not Specified
<p>Contact Name Augie Diana, Ph.D.</p> <p>Contact Telephone 301-402-6423</p> <p>Contact Email dianaa@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.</p>					
074459	Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-776	07-May-2021	Not Specified
<p>Contact Name Sung Sug (Sarah) Yoon, PhD, RN</p> <p>Contact Telephone 301-402-6959</p> <p>Contact Email sungsug.yoon@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) and Office of Dietary Supplements (ODS) invite applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		subsequently fetal development and the health of the newborn. This FOA will use the NIH Research Project (R01) award mechanism.			
070260	End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-498	07-May-2021	Not Specified
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	adamsls@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH Research Project (R01) award mechanism.			
077785	Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-944	07-May-2021	Not Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	tullyla@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					illness.
078362	End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-044	07-May-2021	275,000 USD
	Contact Name	Karen A. Kehl, Ph.D.			
	Contact Telephone	301-594-8010			
	Contact Email	kehlka@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.			
077787	Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-943	07-May-2021	275,000 USD
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	tullyla@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.			
077789	Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-946	07-May-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Martha Matocha, PhD</p> <p>Contact Telephone 301-594-2775</p> <p>Contact Email matocham@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.</p>				
084550	Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-320	07-May-2021	275,000 USD
	<p>Contact Name Karen A. Kehl, PhD, RN, FPCN</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email karen.kehl@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.</p>				
079344	End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-153	07-May-2021	275,000 USD
	<p>Contact Name Lynn S. Adams, Ph.D.</p> <p>Contact Telephone 301-594-8911</p> <p>Contact Email lynn.adams@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.</p>				
070262	End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-499	07-May-2021	275,000 USD
	<p>Contact Name Lynn S. Adams, Ph.D.</p> <p>Contact Telephone 301-594-8911</p> <p>Contact Email adamsls@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
068621	Mechanisms, Models, Measurement, & Management in Pain Research (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-141	07-May-2021	Not Specified
	<p>Contact Name Martha Matocha, PhD</p> <p>Contact Telephone 301-594-2775</p> <p>Contact Email matocham@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH Research Project (R01) award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
077789	Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-946	07-May-2021	275,000 USD

Contact Name	Martha Matocha, PhD
Contact Telephone	301-594-2775
Contact Email	matocham@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.

084550	Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-320	07-May-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Karen A. Kehl, PhD, RN, FPCN
Contact Telephone	301-594-8010
Contact Email	karen.kehl@mail.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.</p>				
079344	End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-153	07-May-2021	275,000 USD
	<p>Contact Name Lynn S. Adams, Ph.D.</p> <p>Contact Telephone 301-594-8911</p> <p>Contact Email lynn.adams@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.</p>				
070262	End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-499	07-May-2021	275,000 USD
	<p>Contact Name Lynn S. Adams, Ph.D.</p> <p>Contact Telephone 301-594-8911</p> <p>Contact Email adamsls@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
068621	<p>Mechanisms, Models, Measurement, & Management in Pain Research (R01 Clinical Trial Optional)</p>	National Institute of Nursing Research/NIH/DHHS	PA-18-141	07-May-2021	Not Specified
	<p>Contact Name Martha Matocha, PhD</p> <p>Contact Telephone 301-594-2775</p> <p>Contact Email matocham@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076050	<p>Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)</p>	National Institute of Nursing Research/NIH/DHHS	PA-18-850	07-May-2021	275,000 USD
	<p>Contact Name Mary C. Roary, Ph.D.</p> <p>Contact Telephone 301-594-2154</p> <p>Contact Email mary.roary@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
085882	Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-381	07-May-2021	Not Specified
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email hussk@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 05-Jul-2021 , 07-Sep-2021 , 05-Feb-2022 , 05-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>				
102700	Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards	National Institute of Nursing Research/NIH/DHHS	NOT-NR-21-001	25-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 12-Jun-2021 , 08-Aug-2021 , 07-Sep-2021 , 25-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 25-Jan-2022 , 12-Feb-2022 , 08-Apr-2022 , 07-May-2022 , 25-May-2022 , 12-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 12-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 12-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 12-Jun-2023 , 08-Aug-2023 , 07-Sep-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute of Nursing Research (NINR) is committed to training the next generation of nurse scientists at all levels of education and encouraging training in important new areas of nursing research.			
085884	Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-382	07-May-2021	400,000 USD
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI			
	Contact Telephone	301-594-5970			
	Contact Email	hussk@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 16-Jul-2021 , 07-Sep-2021 , 16-Feb-2022 , 16-Mar-2022 , 07-May-2022 , 16-Jun-2022 , 16-Jul-2022 , 07-Sep-2022 , 16-Feb-2023 , 16-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.			
099971	Notice of Special Interest (NOSI): Administrative Supplements for NIA-VA Mentored Physician-Scientist Award in Alzheimer’s Disease and its Related Dementias (AD/ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-20-043	07-May-2021	Not Specified
	Contact Name	Lisa A. Opanashuk, Ph.D.			
	Contact Telephone	301-827-5422			
	Contact Email	Lisa.Opanashuk@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	The purpose of this initiative is to increase the number of early stage physician-scientists in Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) research and improve patient care for veterans. To accomplish this goal, NIA and the U.S. Department of Veterans Affairs (VA) have created a two-part opportunity for early career VA physician-scientists to pair with both VA- and NIA-funded mentors in the AD/ADRD field. This will also facilitate the development of a sustainable process for collaboration and address key barriers or challenges that often hinder communication, sharing of resources, and increased coordination between the VA and NIA.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
101126	RFA-AG-22-002 -- Aging Effects on Osteoimmunology (R01 Clinical Trials Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-22-002	15-May-2021 [Optional][LOI/Pre-App]	1,500,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>John P. Williams, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-496-6403</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>williamsj6@nih.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA), issued by the National Institute on Aging (NIA) of the National Institutes of Health, solicits grant applications that will examine the role of aging in the interactions between the immune systems and skeletal systems in animal models. Research projects that will determine the mechanisms involved in how both aging of the bone marrow niche and immunosenescence impact these interactions, leading to pathological conditions in bone homeostasis, are the focus of this FOA.</td> </tr> </table>					Contact Name	John P. Williams, Ph.D.	Contact Telephone	301-496-6403	Contact Email	williamsj6@nih.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021	Synopsis	This Funding Opportunity Announcement (FOA), issued by the National Institute on Aging (NIA) of the National Institutes of Health, solicits grant applications that will examine the role of aging in the interactions between the immune systems and skeletal systems in animal models. Research projects that will determine the mechanisms involved in how both aging of the bone marrow niche and immunosenescence impact these interactions, leading to pathological conditions in bone homeostasis, are the focus of this FOA.
Contact Name	John P. Williams, Ph.D.																		
Contact Telephone	301-496-6403																		
Contact Email	williamsj6@nih.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021																		
Synopsis	This Funding Opportunity Announcement (FOA), issued by the National Institute on Aging (NIA) of the National Institutes of Health, solicits grant applications that will examine the role of aging in the interactions between the immune systems and skeletal systems in animal models. Research projects that will determine the mechanisms involved in how both aging of the bone marrow niche and immunosenescence impact these interactions, leading to pathological conditions in bone homeostasis, are the focus of this FOA.																		
101456	RFA-AG-22-006 -- New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-22-006	17-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Amanda DiBattista, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-827-3342</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>amanda.dibattista@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>17-May-2021 [Optional][LOI/Pre-App], 17-Jun-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The goal of this Funding Opportunity Announcement is to support research on novel approaches and/or innovative expansion of existing approaches to identify the presence of neurogenesis and study its dynamics in brain aging and AD/ADRD.</td> </tr> </table>					Contact Name	Amanda DiBattista, Ph.D.	Contact Telephone	301-827-3342	Contact Email	amanda.dibattista@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	17-May-2021 [Optional][LOI/Pre-App], 17-Jun-2021	Synopsis	The goal of this Funding Opportunity Announcement is to support research on novel approaches and/or innovative expansion of existing approaches to identify the presence of neurogenesis and study its dynamics in brain aging and AD/ADRD.
Contact Name	Amanda DiBattista, Ph.D.																		
Contact Telephone	301-827-3342																		
Contact Email	amanda.dibattista@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	17-May-2021 [Optional][LOI/Pre-App], 17-Jun-2021																		
Synopsis	The goal of this Funding Opportunity Announcement is to support research on novel approaches and/or innovative expansion of existing approaches to identify the presence of neurogenesis and study its dynamics in brain aging and AD/ADRD.																		
088437	Harmonization of Alzheimer's Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery (U24 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-20-099	25-May-2021	13,855,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Marilyn Miller, Ph.D.</td> </tr> </table>					Contact Name	Marilyn Miller, Ph.D.												
Contact Name	Marilyn Miller, Ph.D.																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-9350</p> <p>Contact Email millerm@nia.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023</p> <p>Synopsis The National Institute on Aging (NIA) invites applications specific to infrastructure that will support, under a single cooperative agreement (U24), phenotypic data harmonization on subjects with Alzheimer's Disease Sequencing Project (ADSP) genetic and genomic data. These data will become a long-lived "legacy" data set that will be perpetually curated. The FOA will fund a single vanguard network of researchers with expertise in genetics, epidemiology, and clinical specialties who will work with the ADSP and with study cohort leads on data harmonization efforts to optimize the ability to identify well-targeted therapeutic approaches for Alzheimer's disease and related dementias (AD/ADRD).</p>				
088306	Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-20-095	25-May-2021	900,000 USD
	<p>Contact Name Basil Eldadah, MD, Ph.D.</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email basil.eldadah@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development Courses for Skills Development Research Experiences</p>				
101782	Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (T32)	National Institute on Aging/NIH/DHHS	PAR-21-112	25-May-2021	Not Specified
	<p>Contact Name Yuan Luo, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-9350</p> <p>Contact Email yuan.luo@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 27-Sep-2021 , 25-May-2022 , 26-Sep-2022 , 25-May-2023 , 25-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks to enable the development of a diverse, translational research workforce capable of participating and/or leading cross-disciplinary team science programs focused on advancing therapy development for Alzheimer's disease (AD) and AD-related dementias (ADRD). This FOA will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science and behavioral research). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD and AD-related dementias. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
088853	National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (U24 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-20-110	25-May-2021	Not Specified
	<p>Contact Name Marilyn M. Miller. Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email millerm@nia.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure that will support the storage, analysis, and sharing of primary and secondary data for the genetics and genomics of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).</p>				
082792	Limited Competition: NIA Genome Center for Alzheimer's Disease (GCAD) (U54 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-288	25-May-2021	Not Specified
	<p>Contact Name Marilyn Miller, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-496-9350
Contact Email	millerm@nia.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022
Synopsis	This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.

083966	NIA Program Project Applications (P01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-314	07-May-2021	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name	Robin A. Barr, D.Phil
Contact Telephone	301-496-9322
Contact Email	BarrR@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 21-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022
Synopsis	The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission. Each application submitted to this FOA must include at least three related research projects that share a common central theme, focus, and/overall objective and an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award.

085643	Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-374	25-May-2021	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Sanoj Suneja, PhD
--------------	-------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-7710</p> <p>Contact Email sunejas@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022</p> <p>Synopsis National Institute on Aging (NIA) invites applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. This FOA will use the NIH U19 Research Program – Cooperative Agreements award mechanism.</p>				
101820	NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 - Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-20-317	25-May-2021	1,875,000 USD
	<p>Contact Name NIA Training Office</p> <p>Contact Telephone </p> <p>Contact Email NIATraining@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-May-2022 , 25-May-2023</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Curriculum or Methods Development</p>				
101921	RFA-AG-22-008 -- The Cellular Scale Connectome in Aging and Alzheimer's Disease (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-22-008	15-May-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Mirosław 'Mack' Mackiewicz, Ph.D.</p> <p>Contact Telephone 301-594-7636</p> <p>Contact Email miroslaw.mackiewicz@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that will: (1) promote the development of a comprehensive characterization of brain circuits susceptible to Alzheimer's disease type pathology and/or neurodegeneration in mouse models of Alzheimer's disease (AD), (2) share data on the cell connectome in the aging and AD brain in a common reference brain cell atlas that integrates both molecular and anatomical annotations, and (3) complement and extend research on vulnerable cell types to include the mapping of connectivity changes between cells in aging and AD and provide a greater understanding of the mechanisms underlying resilience and vulnerability in AD.</p>				
070904	Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-18-570	07-May-2021	Not Specified
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email saliveme@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
075498	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-820	07-May-2021	5,000,000 USD
	<p>Contact Name Lorenzo M. Refolo, Ph.D.</p> <p>Contact Telephone 301-594-7576</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email refolol@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Aging's (NIA) invites applications for pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>				
070906	Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-18-571	07-May-2021	100,000 USD
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email saliveme@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) invites pilot/feasibility projects that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
070905	Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-18-572	07-May-2021	275,000 USD
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email saliveme@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
097636	Notice of Special Interest (NOSI): Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimer's Disease and Related Dementias (AD/ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-20-040	07-May-2021	Not Specified
	<p>Contact Name Janine Simmons, M.D., Ph.D.</p> <p>Contact Telephone 301-480-8959</p> <p>Contact Email janine.simmons@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Notice of Special Interest (NOSI) is intended to underscore NIA's continued commitment to psychological and neuroscientific research on affective, motivational, and social functions in midlife and aging. NIA supports research to further</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>clarify the changes in and trajectories of these processes in adults who are aging normally and/or in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). NIA also seeks to understand how changes in the structure and function of neurobiological and neuromodulatory systems mediate or moderate affective, motivational, and social behaviors and interact with other psychological functions, including cognition. NIA’s goals are three-fold: (1) to advance understanding of normative maturational changes in affective, motivational, and social processes, their role in behavior and cognition, and their underlying integrative neural-behavioral mechanisms; (2) to elucidate how dysfunction in these processes might manifest in MCI and the early stages of AD/ADRD; and/or (3) to determine how dysfunction in these processes might account for any of the Behavioral and Psychological Symptoms of Dementia (BPSD) observed in AD/ADRD. Such studies may identify novel targets for preventative or therapeutic interventions to promote social, emotional, and cognitive well-being; facilitate adaptive function in aging; normalize social or emotional dysregulation; and/or strengthen social or emotional resilience at different stages of the life course and at different disease stages in AD/ADRD.</p>				
100297	Notice of Special Interest (NOSI): Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging	National Institute on Aging/NIH/DHHS	NOT-AG-21-012	07-May-2021	Not Specified
	<p>Contact Name Luci Roberts, Ph.D. Contact Telephone Contact Email roberlu@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform applicants of NIA’s interest in research on the neural mechanisms underlying fundamental affective processes in aging. Grant applications are encouraged to 1) extend research on neural mechanisms underlying affective processes into aging models; and/or 2) seek to “reverse translate” clinical research results on affective processes in aging into model systems that support elucidation of fundamental neural mechanisms. NIA also wishes to encourage collaboration among cognitive and affective neuroscientists and/or investigators working at different levels of neurobiological and behavioral analysis.</p>				
086469	Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-394	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Shahrooz Vahedi, Ph.D.</p> <p>Contact Telephone 301-496-9322</p> <p>Contact Email shahrooz.vahedi@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA's strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.</p>				
102562	AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-21-141	25-May-2021	400,000 USD
	<p>Contact Name Laurie Ryan</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email ryanl@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-May-2022 , 25-May-2023</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development It is essential to expand and diversify the skilled AD/ADRD clinical trial workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of AD/ADRD clinical trialists in state-of-the-art clinical research skills.</p>				
102870	RFA-AG-22-012 -- High-Priority Behavioral and Social Research Networks in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R24 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG-22-012	23-May-2021 [Optional][LOI/Pre-App]	1,250,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name John W. R. Phillips, PhD</p> <p>Contact Telephone 301- 827-4137</p> <p>Contact Email John.Phillips@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure via networks for behavioral and social research on Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD); attract new researchers into behavioral and social research on AD/ADRD; infuse a focus on health disparities into AD/ADRD research; and address ongoing needs for harmonization and biomarker collection in large population panel studies to support AD/ADRD research as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: decision neuroscience and aging; measurement for dementia care in home and community-based services (HCBS); the dementia care workforce; and education and AD/ADRD.</p>				
102872	<p>RFA-AG-22-013 -- High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional)</p>	National Institute on Aging/NIH/DHHS	RFA-AG-22-013	23-May-2021 [Optional][LOI/Pre-App]	1,250,000 USD
	<p>Contact Name John W. R. Phillips, Ph.D.</p> <p>Contact Telephone 301- 827-4137</p> <p>Contact Email John.Phillips@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

limited to the following priority areas: midlife reversibility of biobehavioral risk associated with early life adversity; harmonization of Health and Retirement Study (HRS) international aging studies; biomarker collection in population studies; and innovation in longitudinal aging studies.

100265	RFA-AA-20-011 -- Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource Core (U24) (Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-20-011	26-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	---	---------------	-------------------------------------	---------------

Contact Name	Mark Egli, Ph.D.
Contact Telephone	301-594-6382
Contact Email	megli@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Apr-2021 [Optional][LOI/Pre-App], 26-May-2021
Synopsis	This Funding Opportunity Announcement (FOA) solicits cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits submission of administrative resource cores (U24) applications. Please see companion FOAs for submission of resource-related and support cores (U24) applications, RFA-AA-20-012, and for submission of collaborative research projects (U01) applications, RFA-AA-20-013 .

100267	RFA-AA-20-013 -- Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-20-013	26-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Mark Egli, Ph.D.
Contact Telephone	301-594-6382
Contact Email	megli@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Apr-2021 [Optional][LOI/Pre-App], 26-May-2021
Synopsis	This Funding Opportunity Announcement (FOA) solicits cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits research projects (U01) applications. Please see the companion FOA, RFA-AA-20-011 for submission of administrative resource cores applications, and companion FOA, RFA-AA-20-012 for submission of resource-related and support cores applications.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100266	RFA-AA-20-012 -- Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24) (Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-20-012	26-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Mark Egli, Ph.D.</p> <p>Contact Telephone 301-594-6382</p> <p>Contact Email megli@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Apr-2021 [Optional][LOI/Pre-App], 26-May-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits research cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits submission of Research Resource core applications (U24) to support the consortium. Please see companion RFA-AA-20-011 for submission of an Administrative Resource core (U24) application, and companion RFA-AA-20-013 for submission of Research Project applications (U01).</p>				
100731	NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-072	25-May-2021	Not Specified
	<p>Contact Name Gary J Murray, Ph.D.</p> <p>Contact Telephone 301-443-9940</p> <p>Contact Email gary.murray@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023</p> <p>Synopsis The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. The resource should be available to any qualified investigator, and should be highly quality controlled, and not duplicate resources available commercially or through other sources. Resources should be designed to provide services to the broad alcohol research community and should not be limited by any specific regional focus.</p>				
071738	Understanding Processes of Recovery in the Treatment of Alcohol Use	National Institute on Alcohol Abuse	PA-18-619	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Disorder (R01 Clinical Trial Optional)		and Alcoholism/NIH/DHHS		Specified
	<p>Contact Name Brett T. Hagman</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email brett.hagman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076319	Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R01 - Clinical Trial Optional)		National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-863 07-May-2021	Not Specified
	<p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email rfreeman@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL </p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
101405	RFA-AA-21-001 -- Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional)		National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-001 07-May-2021	2,500,000 USD
	Contact Name	Laura E. Kwako, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-451-8507</p> <p>Contact Email laura.kwako@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications on health disparities and health services-related research focusing on: 1.) access to treatment; 2.) making treatment more appealing; 3.) costs; 4.) dissemination and implementation. All Applications are expected to emphasize health disparities in addition to the other four areas of focus mentioned above.</p>				
072233	Genetics of Alcohol Sensitivity and Tolerance (R01 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-660	07-May-2021	Not Specified
	<p>Contact Name Hemin R. Chin, Ph.D.</p> <p>Contact Telephone 301-443-1282</p> <p>Contact Email chinh@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel genetic mechanisms underlying the development of tolerance and the progression to alcohol use disorder. Alcohol use disorders is complex, multifactorial, and influenced both by genetic and environmental factors. The purpose of this FOA is to stimulate and support efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076324	Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R21 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-862	07-May-2021	275,000 USD
	<p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email rfreeman@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.			
076327	Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-861	07-May-2021	100,000 USD
	Contact Name	Robert Freeman, Ph.D.			
	Contact Telephone	301-443-8820			
	Contact Email	rfreeman@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R03 Small Grant Program award mechanism.			
083915	Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-311	07-May-2021	1,775,000 USD
	Contact Name	Elizabeth M Powell, PhD			
	Contact Telephone	301-443-0786			
	Contact Email	elizabeth.powell3@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660).

072235	Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	/PAR-18-659	07-May-2021	Not Specified
--------	--	---	-------------	-------------	---------------

Contact Name | Elizabeth M Powell, PhD
 Contact Telephone | Elizabeth M Powell, PhD
 Contact Email | elizabeth.powell3@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 07-May-2021

Synopsis | National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications on sensitivity and tolerance mechanisms underlying the development of alcohol use disorders. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol dependence. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. This FOA will use the NIH R21/R33 Phased Innovation Award mechanism.

097916	Notice of Special Interest (NOSI): Secondary Analyses of Existing Alcohol Research Data	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-018	07-May-2021	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name | Wenxing Zha, Ph.D.
 Contact Telephone | 301-443-0633
 Contact Email | zhaw@mail.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research.</p>				
098270	Notice of Special Interest (NOSI): Alcohol and Aging	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-019	07-May-2021	Not Specified
	<p>Contact Name Andras Orosz, Ph.D.</p> <p>Contact Telephone 301-443-2193</p> <p>Contact Email orosza@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. The following broad research areas will be encouraged: 1) Basic and clinical research defining the effects of alcohol consumption on lifespan, health span, and age-related diseases depending on level of alcohol consumption, drinking pattern, and duration of drinking; 2) Research to inform evidence-based guidance for identifying risk for alcohol use disorder (AUD) among older adults as well as prevention, diagnosis, and treatment of AUD in this population; and 3) Research to extend the health span of older adults who drink and decrease the health care burden of age-related diseases associated with alcohol use.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100945	Notice of Special Interest (NOSI): Advances in Research for the Treatment, Services, and Recovery of Alcohol Use Disorder	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-022	07-May-2021	Not Specified
	<p>Contact Name Brett T. Hagman, Ph.D.</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email brett.hagman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to advance research on various topics that fall within NIAAA's Division of Treatment and Recovery Research (DTRR). DTRR's research interests are wide-ranging and encompass broad categories such as health services, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for alcohol use disorder (AUD) treatment and sustaining recovery. Other areas of interest include topics focusing on special-emphasis and underserved populations, including NIH-designated U.S. health disparity populations, as well as those with co-occurring disorders; and fetal alcohol spectrum disorders (FASD). In all studies, at all levels from FASD to elderly, efforts will be made to include participants that reflect the diversity of the population at large.</p>				
101458	Notice of Special Interest (NOSI): Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-024	07-May-2021	Not Specified
	<p>Contact Name Li Lin</p> <p>Contact Telephone 301-827-7749</p> <p>Contact Email linli@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Synopsis The purpose of this Notice is to inform potential applicants of the NIAAA's special interest in research project applications studying the harmful effects of alcohol on the body's tissues, organs, and systems in diverse populations across the lifespan.			
080217	Summer Research Education Experience Program (R25 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-197	07-May-2021	500,000 USD
	Contact Name L Lynn Morin Contact Telephone 301-402-0176 Contact Email Lynn.Morin@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2021 Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.				
101187	NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-093	08-Apr-2021	Not Specified
	Contact Name Alberto L. Rivera-Rentas, Ph.D. Contact Telephone 301-496-1804 Contact Email riverara@nidcd.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-Jan-2024 Synopsis The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| by a sponsor or co-sponsor.

090099	Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-20-127	07-May-2021	2,499,995 USD
--------	---	---	------------	-------------	---------------

Contact Name	Trinh T. Ly, MD
Contact Telephone	301-435-4085
Contact Email	trinh.ly@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications with a clinical trial, only low risk clinical trials will be supported.

090106	Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-20-123	07-May-2021	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Trinh T. Ly, MD
Contact Telephone	301-435-4085
Contact Email	trinh.ly@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications with

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| a clinical trial, only low risk clinical trials will be supported.

078368	Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-046	07-May-2021	275,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Lana Shekim, Ph.D.
Contact Telephone	301-496-5061
Contact Email	shekiml@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	This funding opportunity announcement (FOA) solicits Research Project Grants (R21) applications on augmentative and alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.

078310	Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-047	07-May-2021	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Lana Shekim, Ph.D.
Contact Telephone	301-496-5061
Contact Email	shekiml@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022
Synopsis	This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| translational.

101155	NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-063	07-May-2021	2,499,995 USD
--------	---	---	------------	-------------	---------------

Contact Name	Trinh T. Ly, M.D.
Contact Telephone	301-435-4085
Contact Email	trinh.ly@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-064, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

101736	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-096	07-May-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 08-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under PAR-21-094 "NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)" Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA PAR-21-095 "NIDCD Research Career Enhancement Award for Established Investigators (K18Independent Clinical Trial Not Allowed)" .</p>				
101734	NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-095	07-May-2021	Not Specified
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email riverara@nidcd.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 08-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study or an ancillary study to a clinical trial. proposing to serve as the lead</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

investigator of an independent clinical trial, as part of their research and career development. Those planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-094 or for PAR-21-096 for Independent Basic Experimental Studies with Humans Required.

101733	NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-094	07-May-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 08-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-095). Applicants not planning an independent clinical trial, but planning a basic experimental study with humans, must apply to companion FOA PAR-21-096 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)

101085	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-087	07-May-2021	315,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Independent Clinical Trial Required' (PAR-21-085). Applicants not planning an independent clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion 'Independent Clinical Trial Not Allowed' (PAR-21-086) FOA.</p>			
101080	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-086	07-May-2021	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	riverara@nidcd.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical,</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..

101078	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-085	07-May-2021	315,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-086). Observational Studies involving humans should submit under PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required).

077346	HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAS-18-915	07-May-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Richard A. Jenkins, Ph.D.
--------------	---------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA invites applications for high priority research relevant to drug misuse and HIV/AIDS. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
077319	AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-916	07-May-2021	200,000 USD
	<p>Contact Name Richard A. Jenkins, Ph.D.</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) provides support to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug misuse and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating drug misuse and/or use disorder and HIV/AIDS across all areas of research supported by NIDA. This program will use the NIH Small Research Grant (R03) award mechanism.</p>				
084960	NIDA Program Project Grant Applications (P01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-345	07-May-2021	Not Specified
	<p>Contact Name Kevin Walton, Ph.D.</p> <p>Contact Telephone 301-827-5980</p> <p>Contact Email waltonkm@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.</p>				
094123	Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-20-208	07-May-2021	100,000 USD
	<p>Contact Name Aria Crump, Sc.D.</p> <p>Contact Telephone 301-435-0881</p> <p>Contact Email acrump@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).</p>				
100294	Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-20-046	07-May-2021	Not Specified
	<p>Contact Name Roger G Sorensen, Ph.D., MPA</p> <p>Contact Telephone 301-443-3205</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rsorense@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 25-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 01-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this notice is to encourage research project submissions examining the role of neuroimmune signaling in the CNS in relation to: the trajectory (i.e. initiation, escalation, and maintenance) of drug misuse; consequences of chronic exposure to misused drugs; abstinence and withdrawal from prolonged use; and relapse or reinstatement of drug taking at molecular, cellular, circuit, or behavioral levels.</p>				
084606	Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-327	01-May-2021	15,000,000 USD
	<p>Contact Name Ivan D. Montoya, M.D., M.P.H.</p> <p>Contact Telephone 301-827-5936</p> <p>Contact Email imontoya@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 01-Sep-2021 , 01-Jan-2022 , 01-May-2022 , 01-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to \$5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.</p>				
071556	Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-603	07-May-2021	Not Specified
	<p>Contact Name Cora Lee Wetherington, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-1319</p> <p>Contact Email cwetheri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
085474	Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-368	07-May-2021	2,499,995 USD
	<p>Contact Name Marsha F. Lopez, Ph.D., M.H.S.</p> <p>Contact Telephone 301-443-6504</p> <p>Contact Email marsha.lopez@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.</p>				
101989	Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-018	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Raul Mandler, MD</p> <p>Contact Telephone 301-480-2541</p> <p>Contact Email mandlerr@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.</p>				
074442	International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-773	07-May-2021	Not Specified
	<p>Contact Name Steven Gust, Ph.D., Director</p> <p>Contact Telephone 301-443-6480</p> <p>Contact Email ipdirector@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) solicits collaborative research applications on drug abuse and addiction that: Take advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery; Describe how the research will significantly advance U.S. health sciences; Demonstrate specific relevance to the NIDA mission and objectives. To determine whether your research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Where feasible, applications should address NIDA's international scientific priority areas (https://www.drugabuse.gov/international/research-priorities); and Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079379	Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-162	07-May-2021	1,250,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Trial Not Allowed](#)

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Karen Sirocco 301-451-8661 siroccok@nida.nih.gov Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).
--	--

077321	Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-917	07-May-2021	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	David Thomas, PhD 301-435-1313 dthomas1@nida.nih.gov Link to program URL 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. This FOA will use the NIH Research Project (R01) award mechanism.
--	---

102016	Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-017	07-May-2021	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name Contact Telephone	Raul Mandler, MD 301-480-2541
-----------------------------------	----------------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email mandlerr@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.</p>				
090993	NIDA Small Research Grant Program (R03 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PA-20-146	07-May-2021	100,000 USD
	<p>Contact Name Katrina L Foster, PhD</p> <p>Contact Telephone 301-827-5815</p> <p>Contact Email fosterkl@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.</p>				
102120	Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-019	07-May-2021	Not Specified
	<p>Contact Name Raul Mandler, MD</p> <p>Contact Telephone 301-480-2541</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email mandlerr@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) inviting research applications to explore and develop telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and Substance Use Disorder (SUD).</p>				
077343	Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-918	07-May-2021	150,000 USD
	<p>Contact Name Steven Grant, Ph.D.</p> <p>Contact Telephone 301-443-4877</p> <p>Contact Email sgrant@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources. This program will use the NIH Small Research Grant (R03) award mechanism.</p>				
083682	Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-310	07-May-2021	75,000 USD
	<p>Contact Name Holly Moore, Ph.D.</p> <p>Contact Telephone 301-827-7376</p> <p>Contact Email holly.moore@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	<p>This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.</p>			
071560	Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-602	07-May-2021	275,000 USD
	Contact Name	Cora Lee Wetherington, Ph.D.			
	Contact Telephone	301-435-1319			
	Contact Email	cwetheri@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	<p>National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>			
071562	Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-601	07-May-2021	100,000 USD
	Contact Name	Cora Lee Wetherington, Ph.D.			
	Contact Telephone	301-435-1319			
	Contact Email	cwetheri@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
079380	<p>Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)</p>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-163	07-May-2021	275,000 USD
	<p>Contact Name Karen Sirocco</p> <p>Contact Telephone 301-451-8661</p> <p>Contact Email siroccok@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).</p>				
101618	<p>Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)</p>	National Institute on Drug Abuse/NIH/DHHS	PA-21-110	07-May-2021	450,000 USD
	<p>Contact Name Amy B. Goldstein, PhD</p> <p>Contact Telephone 301-827-4124</p> <p>Contact Email amy.goldstein@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this FOA include a reduction in negative sequelae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.</p>				
074542	Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34-Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-780	07-May-2021	450,000 USD
	<p>Contact Name Richard A. Jenkins, PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) invites applications for formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected. This FOA will use the NIH R34 Planning Grant award mechanism.</p>				
074449	Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-774	07-May-2021	450,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Sarah Q. Duffy, Ph.D.</p> <p>Contact Telephone 301-451- 4998</p> <p>Contact Email duffys@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities. This FOA will use the NIH R34 Planning Grant grant mechanism.</p>				
082413	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-282	07-May-2021	Not Specified
	<p>Contact Name Vani Pariyadath, Ph.D.</p> <p>Contact Telephone 301-443-3209</p> <p>Contact Email vani.pariyadath@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 13-Oct-2021 , 07-Jan-2022 , 11-Jul-2022 , 07-Sep-2022 , 10-Mar-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding mechanism (e.g., Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional)).</p>				
102446	Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-007	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Richard A. Jenkins PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to increase the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions, as well as other publicly available data including those provided by government bodies, data warehouses and commercial data sources. Existing data may include data from completed projects as well as those that are ongoing. Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public policy. NIDA is particularly interested in research that integrates substance use considerations into program planning and policy to increase the quality of HIV services and their responsiveness to substance using populations.</p>				
091070	Extracellular RNA Carrier Subclasses in Processes Relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-148	07-May-2021	275,000 USD

	<p>Contact Name John Satterlee, Ph.D</p> <p>Contact Telephone 301-435-1020</p> <p>Contact Email satterleej@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 13-Oct-2021 , 07-Jan-2022 , 15-Mar-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 15-Mar-2023 , 07-May-2023</p> <p>Synopsis The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.			
091068	Extracellular RNA Carrier Subclasses in Processes Relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-20-147	07-May-2021	Not Specified
	Contact Name	John Satterlee, Ph.D			
	Contact Telephone	301-435-1020			
	Contact Email	satterleej@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 13-Oct-2021 , 07-Jan-2022 , 15-Mar-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 15-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.			
097934	Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations	National Institute on Minority Health and Health Disparities/NIH/DHHS	NOT-MD-20-026	07-May-2021	Not Specified
	Contact Name	Larissa Aviles-Santa, MD, MPH			
	Contact Telephone	301-827-6924			
	Contact Email	avilessantal@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.			
091370	NIMHD Exploratory/Developmental Research Grant Program (R21 -	National Institute on Minority Health	PAR-20-	07-May-2021	275,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Clinical Trial Optional	and Health Disparities/NIH/DHHS	150		USD
	<p>Contact Name</p> <p>Contact Telephone 301-402-1366</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.</p>				
102732	RFA-MD-21-005 -- Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	RFA-MD-21-005	05-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Rick Berzon, DrPH</p> <p>Contact Telephone 301-594-8949</p> <p>Contact Email rick.berzon@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Apr-2021 [Optional][LOI/Pre-App], 03-May-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined health disparity population groups. Appropriate technologies should be effective, affordable, and culturally acceptable.</p>				
102734	RFA-MD-21-006 -- Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	RFA-MD-21-006	05-Apr-2021 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Rick Berzon, DrPH 301-594-8949 rick.berzon@nih.gov Link to program URL 05-Apr-2021 [Optional][LOI/Pre-App], 03-May-2021 This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined population groups who experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.
--	---

088439	Genomic Expert Curation Panels (U24 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-101	27-May-2021	660,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Melissa A. Parisi, MD, PhD 301-435-6880 parisima@mail.nih.gov Link to program URL 27-May-2021 , 27-May-2022 The purpose of this FOA is to establish expert panels that will select genes and genomic variants associated with diseases or conditions of high priority to participating NIH Institutes and Centers (ICs) and systematically determine their clinical significance for diagnosis and treatment of these diseases or conditions. The Genomic Expert Curation Panels funded through this FOA are required to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar procedures, interfaces, tools and informatics infrastructure to determine the strength of evidence supporting the clinical significance of the selected genes and variants that will support development of clinical practice guidelines.
--	--

080328	Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-19-204	20-May-2021	8,750,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Adam Felsenfeld, Ph.D.
--------------	------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-480-2269</p> <p>Contact Email adam_felsenfeld@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-May-2021</p> <p>Synopsis The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research. Each CEGS award supports a multi-investigator, interdisciplinary team to develop transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics at its institution by facilitating the interaction of investigators from several disciplines. By training new and experienced investigators it will expand the pool of genomics scientists and engineers.</p>				
100256	<p>Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities</p>	National Institutes of Health/DHHS	NOT-MD-20-019	01-May-2021	Not Specified
	<p>Contact Name Rada K Dagher, Ph.D., M.P.H.</p> <p>Contact Telephone 301-451-2187</p> <p>Contact Email rada.dagher@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021</p> <p>Synopsis The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.</p>				
100877	<p>Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial</p>	National Institutes of Health/DHHS	PAR-21-	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Optional		068		Specified
	<p>Contact Name Basil A. Eldadah, MD, PhD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email eldadahb@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024</p> <p>Synopsis This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.</p>				
100879	Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-069	07-May-2021	275,000 USD
	<p>Contact Name Basil A. Eldadah, MD, PhD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email eldadahb@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024</p> <p>Synopsis This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Studies that move the science of HIV and aging into new directions with little or no preliminary data are appropriate for this activity code. Applications appropriate for this FOA should be consistent with the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.					
101106	Mentored Research Experiences for Genetic Counselors (R25)	National Institutes of Health/DHHS	PAR-21-074	25-May-2021	1,250,000 USD
	Contact Name	Ebony B. Madden, Ph.D.			
	Contact Telephone	301-503-5620			
	Contact Email	ebony.madden@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021 , 25-May-2022 , 25-May-2023			
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-arching goal, this funding opportunity announcement (FOA) will support innovative educational activities with a primary focus on Research Experiences.			
101111	Research Experience in Genomic Research for Data Scientists (R25)	National Institutes of Health/DHHS	PAR-21-075	25-May-2021	1,250,000 USD
	Contact Name	Ebony B. Madden, Ph.D.			
	Contact Telephone	301-503-5620			
	Contact Email	ebony.madden@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021 , 25-May-2022 , 25-May-2023			
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this funding opportunity announcement (FOA) will support creative educational activities with a primary focus on Research Experiences.			
100302	Notice of Special Interest (NOSI): NIA Availability of Administrative	National Institutes of Health/DHHS	NOT-AG-	01-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Supplements and Revision Supplements on Coronavirus Disease 2019 \(COVID-19\)](#)

20-022

Specified

Contact Name	Rebecca Fuldner, Ph.D.
Contact Telephone	301-402-7748
Contact Email	fuldnerr@nia.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-May-2021
Synopsis	NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.

[Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences \(T32 Clinical Trial Not Allowed\)](#)

087570 National Institutes of Health/DHHS

PAR-20-076

25-May-2021

Not Specified

Contact Name	Nick Gaiano, Ph. D.
Contact Telephone	301-827-3420
Contact Email	nick.gaiano@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-May-2021 , 25-May-2022
Synopsis	The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094281	HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-149	07-May-2021	Not Specified
	<p>Contact Name Jeymohan Joseph, Ph.D.</p> <p>Contact Telephone 240-627-3869</p> <p>Contact Email jjeymoha@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023</p> <p>Synopsis The goals of this Funding Opportunity Announcement (FOA) are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS disease in the setting of chronic viral suppression and ART. In addition, FOA also encourages research studies to aid in the identification/ validation of biomarkers and pre-clinical targets with quantifiable readouts in domestic and international settings. Multidisciplinary research teams and collaborative alliances are encouraged but not required.</p>				
094284	Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-151	07-May-2021	Not Specified
	<p>Contact Name Jeymohan Joseph, Ph.D.</p> <p>Contact Telephone 240-627-3869</p> <p>Contact Email jjeymoha@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Applications focused on HIV-associated CNS comorbidities and treatment should apply to the companion FOA PA-20-149.</p>				
096506	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)	National Institutes of Health/DHHS	PA-20-245	08-Apr-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p> GrantsInfo@nih.gov Link to program URL 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NOT-DA-20-037 NIDA announces a special interest in the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements, and Staff Contacts website (https://grants.nih.gov/grants/guide/contacts/parent_F30b.html) ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged. </p>
--	--

096508	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) (Defunct)	National Institutes of Health/DHHS	PA-20-246	08-Apr-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name Contact Telephone Contact Email	<p> GrantsInfo@nih.gov </p>
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023			
	Synopsis	<p>The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate's dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NOT-DA-20-037 NIDA announces a special interest in the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements, and Staff Contacts website (https://grants.nih.gov/grants/guide/contacts/parent_F30b.html) ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>			
096596	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33) (Defunct)	National Institutes of Health/DHHS	PA-20-247	08-Apr-2021	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	GrantsInfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023			
	Synopsis	The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

100374	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)	National Institutes of Health/DHHS	PA-21-051	08-Apr-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis</p>	<p>The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate’s dissertation research project and is expected to clearly enhance the individual’s potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NOT-DA-20-037 NIDA announces a special interest in the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements, and Staff Contacts website (https://grants.nih.gov/grants/guide/contacts/parent_F30b.html) ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100542	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)	National Institutes of Health/DHHS	PA-21-052	08-Apr-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow candidates to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
100399	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)	National Institutes of Health/DHHS	PA-21-047	08-Apr-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

100436	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)	National Institutes of Health/DHHS	PA-21-049	08-Apr-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	GrantsInfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>

100434	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)	National Institutes of Health/DHHS	PA-21-048	08-Apr-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-945-7573

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
090436	Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-139	13-May-2021	Not Specified
	<p>Contact Name Sergei Romashkan, M.D., Ph.D.</p> <p>Contact Telephone 301-435-3047</p> <p>Contact Email romashks@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-May-2021 , 13-Sep-2021 , 13-Jan-2022 , 13-May-2022 , 13-Sep-2022 , 13-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.</p>				
100438	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)	National Institutes of Health/DHHS	PA-21-050	08-Apr-2021	Not Specified
	Contact Name				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
086663	<p>Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)</p>	National Institutes of Health/DHHS	PAR-20-036	07-May-2021	Not Specified
	<p>Contact Name Robin E. Huebner, Ph.D., M.P.H.</p> <p>Contact Telephone 240-627-3216</p> <p>Contact Email rhuebner@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
086667	Support of Competitive Research (SCORE) Pilot Project Award (SC2 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-040	07-May-2021	300,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Irina N. Krasnova, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>irina.krasnova@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-May-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.</td> </tr> </table>					Contact Name	Irina N. Krasnova, Ph.D.	Contact Telephone		Contact Email	irina.krasnova@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2021	Synopsis	The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.
Contact Name	Irina N. Krasnova, Ph.D.																		
Contact Telephone																			
Contact Email	irina.krasnova@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2021																		
Synopsis	The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.																		
086672	Support of Competitive Research (SCORE) Research Continuance Award (SC3 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-041	07-May-2021	300,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Irina N. Krasnova, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>irina.krasnova@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>07-May-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.</td> </tr> </table>					Contact Name	Irina N. Krasnova, Ph.D.	Contact Telephone		Contact Email	irina.krasnova@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	07-May-2021	Synopsis	The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.
Contact Name	Irina N. Krasnova, Ph.D.																		
Contact Telephone																			
Contact Email	irina.krasnova@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	07-May-2021																		
Synopsis	The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.																		
088347	Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-097	07-May-2021	Not Specified														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Veerasamy Ravichandran, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email veerasamy.ravichandra@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 24-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 06-May-2022 , 26-Sep-2022 , 06-Jan-2023 , 25-Jan-2023 , 08-May-2023</p> <p>Synopsis This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of the community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase. Applications that have a significant focus on software or tool development are not appropriate for this activity.</p>				

088346	Biomedical Data Repository (U24 - Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-089	07-May-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

	<p>Contact Name Veerasamy Ravichandran, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email veerasamy.ravichandra@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 24-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 06-May-2022 , 26-Sep-2022 , 06-Jan-2023 , 25-Jan-2023 , 08-May-2023</p> <p>Synopsis This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

development are not appropriate for this activity.

100652	Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PAR-21-039	26-Apr-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Apr-2021 , 26-May-2021 , 26-Aug-2021 , 28-Sep-2021 , 28-Dec-2021 , 26-Jan-2022 , 26-Apr-2022 , 26-May-2022 , 26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023</p> <p>Synopsis</p>	<p>The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies that are NOT conducted with specific applications toward processes or products in mind and which also do not meet the clinical trial definition should submit under the appropriate ‘Clinical Trial Not Allowed’ FOA .</p>
---	---

100648	Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-038	26-Apr-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p>	
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Apr-2021 , 26-May-2021 , 26-Aug-2021 , 28-Sep-2021 , 28-Dec-2021 , 26-Jan-2022 , 26-Apr-2022 , 26-May-2022 , 26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023</p> <p>Synopsis The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials.</p>				
091820	Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35)	National Institutes of Health/DHHS	PA-20-162	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Jan-2023 , 07-Jan-2023 , 07-May-2023</p> <p>Synopsis The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers in biomedical, behavioral, or clinical research. Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the physical or quantitative sciences to pursue research careers by short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure to the principles underlying the conduct of biomedical research. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
092624	National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical	National Institutes	PAR-20-169	07-May-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Trials Optional)		of Health/DHHS		Specified
	Contact Name	Behrouz Shabestari, PhD			
	Contact Telephone	301-451-6771			
	Contact Email	shabestb@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages grant applications for National Centers for Biomedical Imaging and Bioengineering (NCBIB). NCBIB are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. NCBIB also make their technologies available to other investigators, train members of the research community in the use of the technologies and disseminate the technologies broadly.			
101706	RFA-EY-21-001 -- BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-EY-21-001	03-May-2021	400,000 USD
	Contact Name	Martha Flanders, PhD			
	Contact Telephone	301-451-2020			
	Contact Email	BRAIN-FOAs@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-May-2021 , 29-Oct-2021 , 02-May-2022 , 28-Oct-2022 , 01-May-2023 , 27-Oct-2023			
	Synopsis	This FOA seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range of modalities are appropriate including acoustic, chemical, electrical, magnetic, optical and chemical, as well as the use of genetic tools. Invasive or non-invasive approaches are sought that will enable large-scale recording and/or precise manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving animals.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Applications are encouraged from any qualified individuals, including physicists, engineers, theoreticians, and scientists, especially those not typically involved with neuroscience research.

101780	Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease	National Institutes of Health/DHHS	NOT-AT-21-002	07-May-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Wen G. Chen, M.MSc, Ph.D.
Contact Telephone	301-451-3989
Contact Email	chenw@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024
Synopsis	The purpose of this NOSI is to promote innovative and rigorous research on interoception and its impact on health and disease. This initiative is broadly supported by many participating NIH institutes, centers, and offices (ICOs). For this NOSI, interoception includes the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself and represents its internal states. This NOSI encourages basic and clinical research projects that 1) combine diverse expertise; 2) develop and use innovative technologies and approaches to delineate interoceptive mechanisms at the molecular, cellular, circuit, functional, and/or behavioral levels; 3) assess pathophysiological processes of interoception in the context of diseases and disorders; 4) determine the impact of interventions and therapies to manipulate interoceptive processes on health and/or disease; and 5) develop and validate predictive biomarkers, computational models, or artificial intelligence models relevant to interoception and its impact on health and disease.

090787	Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)	National Institutes of Health/DHHS	PA-20-142	07-May-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	GrantsInfo@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 25-May-2021 , 07-Sep-2021 , 25-Sep-2021 , 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda. Research training programs are expected to incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term predoctoral research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
088438	Genomic Community Resources (U24 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-100	25-May-2021	Not Specified
	<p>Contact Name Christopher Wellington</p> <p>Contact Telephone 301-480-3496</p> <p>Contact Email wellingtonc@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023</p> <p>Synopsis To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that use cost-effective approaches and will be valuable for the broad research community. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples).</p>				
100037	Specialized Programs of Research Excellence (SPORes) in Human Cancers for Years 2021, 2022, 2023 (P50 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-305	25-May-2021	7,000,000 USD
	Contact Name Toby T. Hecht, Ph.D, Associate Director				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-5683</p> <p>Contact Email hechtt@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) and National Institute of Dental and Craniofacial Research (NIDCR) invite applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.</p>				
086664	<p>Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-20-039	07-May-2021	1,000,000 USD
	<p>Contact Name Irina N. Krasnova, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email irina.krasnova@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

094033	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-195	07-May-2021	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

094050	NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-200	07-May-2021	100,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>			
094032	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-194	07-May-2021	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis</p>	<p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. See Related Notices section below. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Mental Health (NIMH) Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>			
094920	Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PA-18-723	07-May-2021	272,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Wendy Nilsen, PhD
Contact Telephone	240-276-6971
Contact Email	nelsonw@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021
Synopsis	<p>This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes and Centers. This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients.</p> <p>Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s).</p>

094034	NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-196	07-May-2021	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	301-496-4000
Contact Email	grantsinfo@od.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	<p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212as “prospective basic</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

095691	Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (PI2 CARBON) (R03 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-228	07-May-2021	100,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this funding opportunity announcement (FOA) is to support collaborative pilot research projects focused on potential effects relevant to human health of chemically complex natural products and/or the causal, molecular mechanisms underlying such effects. A critical element of each proposed project must be collaboration with one or more of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (CARBON). More specifically, letters of support describing collaboration with one or more of the U19 Botanical Dietary Supplements Research Centers awarded pursuant to RFA OD-19-001 by July, 2020, must be included at the time of submission. Each proposed pilot project must, with agreement of its collaborating Center(s), leverage products used in those Centers to extend understanding of their biological effects, or of their causal, molecular mechanisms of action, or increase understanding of other chemically complex natural products through use of methods developed and used in the Centers. Research approaches may range from bench through in vitro and non-human animal models to, where feasible and appropriate, obtaining additional feasibility or outcome

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

information from the clinical trials being performed by the CARBON awardees, either through inclusion of additional measures or through secondary analysis of data or specimens

088011	Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-055	07-May-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	David M. Panchision, Ph.D.
Contact Telephone	301-443-5288
Contact Email	panchisiond@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
Synopsis	This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA(PAR-20-082).

078546	Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-19-066	07-May-2021	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	Timothy A. Gondré-Lewis, Ph.D.
Contact Telephone	240-627-3566
Contact Email	tglewis@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

088090	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-037	07-May-2021	825,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Enrique Michelotti, Ph.D.
Contact Telephone	301-443-5415
Contact Email	michelottiel@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
Synopsis	This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR-20-038 .

102333	Notice of Special Interest (NOSI): National Research Service Award (NRSA) F32 Postdoctoral Fellowship Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities	National Institutes of Health/DHHS	NOT-EY-21-001	08-Apr-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023
Synopsis	The institutes participating in the Notice seek to promote diversity in all of our training and research programs and to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	increase the participation of underrepresented groups. As the US population becomes increasingly diverse, reflection of that diversity among the biomedical research workforce is vital to our science enterprise and the NIH research mission (See NOT-OD-20-031). Evidence from several reports demonstrates that an intervention designed to facilitate successful transitions along this pathway would benefit the research community (Expanding Underrepresented Minority Participation: America's Science and Technology Talent at the Crossroads, National Academy of Sciences, National Academy of Engineering, and Institute of Medicine 2011;and Advancing the Nation's Health Needs: NIH Research Training Programs).				
102332	RFA-DK-21-005 -- Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-DK-21-005	22-May-2021 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Olivier Blondel, Ph.D.			
	Contact Telephone	301-451-7334			
	Contact Email	blondelol@niddk.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021			
	Synopsis	This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.			
087977	RFA-NS-20-006 -- BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)	National Institutes of Health/DHHS	RFA-NS-20-006	02-May-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Sahana N. Kukke, PhD			
	Contact Telephone	301-496-1447			
	Contact Email	BRAIN-FOAs@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-May-2021 [Optional][LOI/Pre-App], 01-Jun-2021 , 01-Sep-2021 [Optional][LOI/Pre-App], 01-Oct-2021 , 02-Jan-2022 [Optional][LOI/Pre-App], 01-Feb-2022 , 02-May-2022 [Optional][LOI/Pre-App], 01-Jun-2022 , 03-Sep-2022 [Optional][LOI/Pre-App], 03-Oct-2022			
	Synopsis	A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102379	National Institute of Allergy and Infectious Diseases (NIAID) Clinical Site Monitoring Center (CSMC)	National Institutes of Health/DHHS	75N93020R00021	24-May-2021	Not Specified

controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system. This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.

Contact Name	Deborah Blyveis
Contact Telephone	2406695143
Contact Email	blyveisd@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	24-May-2021
Synopsis	<p>Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of Allergy, Immunology, and Transplantation has a requirement for a clinical site monitoring center. Description Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to better understand, treat, and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, pre-clinical, and clinical research focusing on protective immune responses and immune-mediated diseases through a variety of research grants and contracts. This includes support for clinical research programs and individual research projects to 1) evaluate the safety and efficacy of therapeutic and preventive approaches and agents, and 2) elucidate the underlying mechanisms of such approaches and agents. A critical component of DAIT's awarded grants and contracts involves the design and conduct of clinical research studies, including Phase 1 through 4 clinical trials of investigational approaches, intended to lead to a functional state of immune tolerance in three main clinical areas: autoimmune diseases; asthma and allergic diseases; and immune-mediated rejection of transplanted solid organs, tissues, and cells. Purpose and Objectives The purpose of this</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

acquisition is to: Provide an expanded, wide range of clinical site monitoring services for NIAID-funded clinical research/trials of immune-mediated diseases, including as examples the delivery of monitoring services for: the Immune Tolerance Network (ITN) Asthma and Allergic Diseases Clinical Research Programs: Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) Atopic Dermatitis Research Network (ADRN) Consortium for Food Allergy Research (CoFAR) Inner City Asthma Consortium (ICAC), which is to be replaced in 2021 by the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE CRN) Autoimmunity Centers of Excellence (ACE) Transplantation Clinical Research Programs: Clinical Trials in Organ Transplantation (CTOT) and in Children (CTOT-C), both of which will be replaced in Fiscal Year (FY) 2021 by the Clinical Trials in Organ Transplantation-Children and Adults (CTOT-CA) Non-network clinical research/trials on a limited, as-needed basis, and Unanticipated NIAID clinical research studies/trials that may be required in response to public health emergencies and/or emerging needs. 2. Advance the field of risk-based monitoring through innovation using novel and effective approaches, with the goal of ensuring participant safety, quality data, and greater site/study compliance. Project requirements The Contractor shall provide comprehensive clinical site and study monitoring services for a broad range of NIAID-sponsored and/or -funded clinical research (including but not limited to clinical trials) for both domestic and international research. The contractor will be responsible for: Clinical Site Monitoring System: Maintain a system to monitor domestic and international clinical research sites with respect to ensuring their adherence to regulatory requirements governing human subjects research, ICH E6(R2) Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), country- and state-specific requirements governing human subjects research, protocol-specific requirements, and NIAID policies and procedures; Training: Develop and implement training programs for clinical site personnel and site monitors; CSMC Data Management and Reporting System: Manage, maintain and update, as necessary, a centralized 21 CFR Part 11 compliant CSMC Data Management and Reporting System, using commercially available software, for the storage, quality control and retrieval of contract-generated data, reports and other materials, and for reporting on contract activities and the findings of the clinical site assessment and monitoring functions performed; Coordination and Collaboration with other NIAID Clinical Research Support Contractors and Grantees: At the direction of NIAID, the Contractor shall collaborate and coordinate with NIAID contractors, grantees, and partners on an as needed basis, in order to carry out clinical site and study monitoring and reporting responsibilities; Risk-Based Monitoring Innovation: At the direction of the COR, engage in the conduct of risk-based monitoring research that applies technological and effective solutions, with the goal of advancing strategic approaches that improve efficiencies in process and outcomes, with the outcome of increased participant safety, quality data and greater site/study compliance; Quality Assurance and Quality Control: Develop and implement a Quality Assurance/Quality Control (QA/QC) Plan designed to: (i) standardize contract processes; (ii) ensure that the conduct of all contract activities complies with domestic and country-specific regulations governing human subjects research, ICH GCP guidelines, and NIAID policies and procedures; and (iii) provide for the assessment of Contractor performance and the quality of clinical site monitoring activities conducted; Clinical, Scientific and Technical Personnel: The Contractor shall provide a Principal Investigator (PI)/Project Director with responsibility for overall project management and communications, tracking performance and cost,

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and monitoring and reporting on project status and progress. The PI/Project Director will ensure that the clinical, scientific, and technical personnel have the relevant individual education, training, expertise, experience, and qualifications required for the successful completion of contract requirements; Facilities, Equipment and Other Resources: The Contractor shall provide all facilities, equipment and other resources necessary to carry out the requirements of the contract.

069085	NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)	National Institutes of Health/DHHS	PA-18-358	07-May-2021	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	Timothy LaVaute, PHD
Contact Telephone	301-496-1447
Contact Email	lavautetm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

088012	Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-082	07-May-2021	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	David M. Panchision, Ph.D.
Contact Telephone	301-443-5288
Contact Email	panchisiond@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-20-NNN).</p>				
080162	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)	National Institutes of Health/DHHS	PA-19-192	08-Apr-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email GrantsInfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g., DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Applicants must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NOT-DA-20-037 NIDA announces a special interest in the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science.</p>				
080180	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)	National Institutes of Health/DHHS	PA-19-195	08-Apr-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	GrantsInfo@nih.gov Link to program URL 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicant's dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
--	--

080156	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)	National Institutes of Health/DHHS	PA-19-191	08-Apr-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	GrantsInfo@nih.gov Link to program URL 08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022 This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g., DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Applicants must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

080145	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)	National Institutes of Health/DHHS	PA-19-187	08-Apr-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	GrantsInfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Apr-2021 , 07-May-2021 , 08-Aug-2021 , 07-Sep-2021 , 08-Dec-2021 , 07-Jan-2022
Synopsis	The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

093908	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-185	07-May-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantsinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Feb-2023
Synopsis	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
097189	Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01)	National Institutes of Health/DHHS	PAR-20-271	05-May-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Suzanne Forry, Ph.D.			
	Contact Telephone	240-276-5922			
	Contact Email	forryscs@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021 [Optional][LOI/Pre-App], 07-May-2021 , 05-Jun-2021 , 05-Sep-2021 [Optional][LOI/Pre-App], 07-Sep-2021 , 05-Oct-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 07-Jan-2022 , 05-Feb-2022 , 05-May-2022 [Optional][LOI/Pre-App], 07-May-2022 , 05-Jun-2022 , 05-Sep-2022 [Optional][LOI/Pre-App], 05-Oct-2022 , 07-Jan-2023			
	Synopsis	<p>Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.</p>			
097158	Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations	National Institutes of Health/DHHS	NOT-HL-20-788	07-May-2021	Not Specified
	Contact Name	Lawrence J. Fine, MD, DrPH			
	Contact Telephone	301-435-0305			
	Contact Email	Lawrence.Fine@NIH.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Environmental Health Sciences (NIEHS) have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in air pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes. This notice specifically encourages intervention studies or clinical trials that examine the efficacy of personal air pollution interventions to reduce the adverse cardiopulmonary effects of Particulate Matter (PM) <2.5 µm in diameter (PM2.5) in high risk or vulnerable participants.</p>				
097215	<p>Notice of Special Interest (NOSI): Fundamental and Translational Research on Decision Making in Aging and/or Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD)</p>	National Institutes of Health/DHHS	NOT-AG-20-039	07-May-2021	Not Specified
	<p>Contact Name Luke Stoeckel, Ph.D.</p> <p>Contact Telephone 202-570-9388</p> <p>Contact Email luke.stoeckel@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest. This NOSI also encourages preclinical and applied research on decision making that may facilitate the design of decision-supportive interventions for midlife and older adults with and without MCI and AD/ADRD. Specific opportunities include the development of decision-support interventions to leverage cognitive, emotional, social, and motivational strengths of these populations; tools to assess decisional capacities; strategies for simplifying choices and offering better defaults; and the promotion of timely</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). The use of animal models to explore the neural basis of affective, cognitive, social, and motivational parameters as they relate to age-related changes in decision making is also invited.			
078543	Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-19-067	07-May-2021	Not Specified
	Contact Name	Timothy A. Gondré-Lewis, Ph.D.			
	Contact Telephone	240-627-3566			
	Contact Email	tglewis@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.			
093638	Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-180	07-May-2021	Not Specified
	Contact Name	David L. Tilley, MPH, MS, CPH			
	Contact Telephone	301-827-6014			
	Contact Email	david.tilley@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs)			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs. Prospective applicants whose research interests relate to developing improved measures and methods for understanding multimorbidity, including but not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways and identification and initial evaluation of MCC shared signatures, should see PAR-20-179.

093636	Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-179	07-May-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	David L. Tilley, MPH, MS, CPH
Contact Telephone	301-827-6014
Contact Email	david.tilley@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023
Synopsis	This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs. Prospective applicants whose research interests relate to studies that identify shared mechanisms or development of innovative interventions to address MCCs should see PAR-20-180.				
093035	Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)	National Institutes of Health/DHHS	PA-20-172	07-May-2021	Not Specified
	<p>Contact Name Larissa Avilés-Santa, MD, MPH</p> <p>Contact Telephone 301-827-6924</p> <p>Contact Email avilessantal@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.</p>				
097755	RFA-OD-20-016 -- Emergency Awards: RADx-RAD Multimodal COVID-19 Surveillance Methods for High Risk Clustered Populations (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-OD-20-016	07-May-2021	Not Specified
	<p>Contact Name Elena Koustova, PhD, MBA</p> <p>Contact Telephone 301-496-8768</p> <p>Contact Email elena.koustova@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis	<p>NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.</p>
----------	---

097838	R01 - Clone (Defunct)	National Institutes of Health/DHHS		07-May-2021	Not Specified
--------	---------------------------------------	------------------------------------	--	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p>07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024</p>
--	--

100289	Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-029	07-May-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL	<p>Enrique L. Michelotti, Ph.D. 301-443 5415 michelottiel@mail.nih.gov Link to program URL</p>
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).</p>				
099859	<p>Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)</p>	National Institutes of Health/DHHS	NOT-HL-20-814	07-May-2021	Not Specified
	<p>Contact Name Guofei Zhou, PhD</p> <p>Contact Telephone 301-827-7825</p> <p>Contact Email guofei.zhou@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).</p>				
101245	<p>Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities</p>	National Institutes of Health/DHHS	NOT-MD-21-008	07-May-2021	Not Specified
	<p>Contact Name Deborah E. Linares, Ph.D., M.A.</p> <p>Contact Telephone 301-402-2516</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email deborah.linares@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights the need for research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US.* Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.</p>				
088091	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-038	07-May-2021	Not Specified
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion FOA PAR-20-037 .</p>				
096860	Countermeasures Against Chemical Threats (CounterACT)	National Institutes	PAR-20-253	26-May-2021	275,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)	of Health/DHHS			USD
	Contact Name	Shardell Spriggs, Ph.D.			
	Contact Telephone	301-443-8189			
	Contact Email	shardell.spriggs@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	26-May-2021 , 31-May-2022 , 30-May-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.</p>			
094932	NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-218	07-May-2021	1,750,000 USD
	Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.			
	Contact Telephone	301-402-1272			
	Contact Email	weberwj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product's effect (i.e., measure of mechanism of action) when used by humans</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094931	NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-217	07-May-2021	1,050,000 USD

on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of the R61/R33 award. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.
Contact Telephone	301-402-1272
Contact Email	weberwj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product.</p> <p>This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.

100769	Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-080	07-May-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Deborah Linares, Ph.D.
Contact Telephone	301-402-2516
Contact Email	deborah.linares@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations.

100780	Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-081	07-May-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Deborah Linares, Ph.D.
Contact Telephone	301-402-2516
Contact Email	deborah.linares@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this initiative is to support research to design and implement effective interventions to enhance health advantages and reduce the health disparities among US immigrant populations.			
100758	Notice of Special Interest (NOSI): Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program	National Institutes of Health/DHHS	NOT-OD-21-021	07-May-2021	Not Specified
	Contact Name	Sarah Scharf, MPA			
	Contact Telephone	301-496-4784			
	Contact Email	sarah.scharf@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to alert the community about this opportunity and disseminate knowledge and information on a program designed to foster the expansion of U.S.-Finland biomedical and behavioral research collaboration.			
102106	NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-21-151	12-Apr-2021	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Apr-2021 , 07-May-2021 , 12-Aug-2021 , 07-Sep-2021 , 12-Dec-2021 , 07-Jan-2022 , 12-Apr-2022 , 07-May-2022 , 12-Aug-2022 , 07-Sep-2022 , 12-Dec-2022 , 07-Jan-2023 , 12-Apr-2023 , 07-May-2023 , 12-Aug-2023 , 07-Sep-2023 , 12-Dec-2023 , 07-Jan-2024			
	Synopsis	The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.			
094250	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-206	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email grantinfo@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.
---	--

094234	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-202	07-May-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name Contact Telephone 301-496-8580 Contact Email grantinfo@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 Synopsis	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094248	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-205	07-May-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094040	Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-198	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094233	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-201	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023			
	Synopsis	<p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>			

094235	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-203	07-May-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-8580

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094244	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-204	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094044	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-199	07-May-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-20-197). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

097728	Notice of Special Interest (NOSI): Discovery of Analgesic Natural Products through the NINDS IGNITE Program	National Institutes of Health/DHHS	NOT-AT-20-016	07-May-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	D. Craig Hopp, Ph.D.
Contact Telephone	301-496-5825
Contact Email	hoppdc@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to announce NCCIH participation in the NINDS IGNITE program. For this NOSI, NCCIH is interested in supporting research geared toward development of robust, validated analgesic assays suitable for medium- to high-throughput screening of natural product libraries. For the purposes of this NOSI, natural products are defined as extracts, chromatographic fractions, or isolated constituents derived from herbal, botanical, marine, microbial, or animal sources. For this NOSI, NCCIH is prioritizing analgesic targets relevant to musculoskeletal, neuropathic, and inflammatory pain conditions.

093931	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-187	07-May-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
093214	Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-173	07-May-2021	Not Specified

independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
093210	Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-171	07-May-2021	Not Specified

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.</p>				
--	---	--	--	--	--

093225	Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-174	07-May-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA.</p>			
099505	Notice of Special Interest (NOSI): Advancing the Science of Geriatric Palliative Care	National Institutes of Health/DHHS	NOT-AG-20-041	07-May-2021	Not Specified
	Contact Name	Basil Eldadah, M.D., Ph.D.			
	Contact Telephone	301-496-6761			
	Contact Email	eldadahb@nia.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023			
	Synopsis	<p>This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in geriatric populations. This NOSI covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, long-term care facilities, hospices, and other healthcare or community settings. This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure is encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.</p>			
099392	Notice of Special Interest (NOSI): Optimizing Precision Treatment of Gynecologic, Reproductive and Obstetrical Outcomes in Adolescents and Adults with PCOS and Associated Comorbid Conditions (Clinical Trial Optional)	National Institutes of Health/DHHS	NOT-HD-20-026	07-May-2021	Not Specified
	Contact Name	Esther Eisenberg, MD MPH			
	Contact Telephone	301-496-6516			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email esther.eisenberg@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) to announce the opportunity for investigators to apply for funding to optimize treatments of comorbid conditions in adolescents and reproductive age women with a diagnosis of Polycystic Ovary Syndrome (PCOS). The goals of this initiative are to stimulate interdisciplinary scientific collaboration between gynecologists/reproductive endocrinologists/obstetricians and subspecialists in diverse medical fields, including cardiologists, endocrinologists, gastroenterologists, psychiatrists, mental health professionals, pulmonologists, among others, to: 1) advance individualized treatments consistent with gynecologic, reproductive and obstetrical needs and desires; 2) promote translational and clinical research to increase knowledge and understanding of interaction of various therapies on gynecologic, reproductive and obstetric outcomes; and 3) discover and develop novel safe and more effective therapies for adolescents and women with PCOS with underlying comorbid conditions. Ultimately, this research would advance precision therapeutics for adolescents and adults with PCOS who have concomitant medical conditions.</p>				
100292	Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-028	07-May-2021	275,000 USD
	<p>Contact Name Enrique L. Michelotti, Ph.D.</p> <p>Contact Telephone 301-443 5415</p> <p>Contact Email michelottiel@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI and/or NIA; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism, (PAR-21-029).

099801	Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design Notice Number:	National Institutes of Health/DHHS	NOT-AI-20-071	07-May-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Que Dang, PhD
Contact Telephone	240-292-6181
Contact Email	que.dang@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.

100050	Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19	National Institutes of Health/DHHS	NOT-HD-20-031	07-May-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Theresa Cruz, PhD.
Contact Telephone	301-496-9233

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email cruzth@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of survivors of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the National Center for Medical Rehabilitation Research (NCMRR) at NICHD.</p>				
101300	Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis	National Institutes of Health/DHHS	NOT-MH-21-075	07-May-2021	Not Specified
	<p>Contact Name Yvonne Bennett, Ph.D.</p> <p>Contact Telephone 301-222-7094</p> <p>Contact Email yvonne.bennett@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: https://www.humanconnectome.org/ and at the NIMH Data Archive (NDA) www.nda.nih.gov .			
101367	Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis	National Institutes of Health/DHHS	NOT-MH-21-175	07-May-2021	Not Specified
	<p>Contact Name Yvonne Bennett, Ph.D.</p> <p>Contact Telephone 301-222-7094</p> <p>Contact Email yvonne.bennett@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: https://www.humanconnectome.org/ and at the NIMH Data Archive (NDA) www.nda.nih.gov.</p>				
098640	Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-20-258	07-May-2021	Not Specified
	<p>Contact Name Deborah Philp, Ph.D.</p> <p>Contact Telephone 301-761-7766</p> <p>Contact Email deborah.philp@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>			
100331	Notice of Special Interest (NOSI): Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)	National Institutes of Health/DHHS		15-May-2021	Not Specified

	Contact Name	Eric M. Hudak, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	eric.hudak@nih.gov			
	Sponsor Website				
	Program URL				
	Deadline Dates (ALL)	15-May-2021 , 15-Nov-2021 , 15-Feb-2022 , 15-May-2022 , 15-Nov-2022 , 15-Feb-2023 , 15-May-2023 , 15-Nov-2023 , 15-Feb-2024 , 15-May-2024			
	Synopsis	<p>The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH's Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: <https://heal.nih.gov/>.

093932	NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-188	07-May-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	grantinfo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

093935	NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-189	07-May-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094015	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-176	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-20-190). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094038	Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-197	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094020	Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-190	07-May-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantsinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis</p>	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
093955	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-193	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grantinfo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094026	Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-191	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Synopsis	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
093953	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-20-186	07-May-2021	Not Specified	
	Contact Name					
	Contact Telephone					
	Contact Email	grantinfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023				
	Synopsis	<p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

093954	Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-192	07-May-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>					
102271	RFA-OD-21-002 -- Tobacco Regulatory Science (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-OD-21-002	15-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Rachel Grana Mayne, PhD Contact Telephone 240-276-5899 Contact Email granar@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 15-May-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 17-Dec-2021 [Optional][LOI/Pre-App], 15-Feb-2022 , 15-May-2022 [Optional][LOI/Pre-App], 14-Jul-2022 , 17-Dec-2022 [Optional][LOI/Pre-App], 14-Feb-2023 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.</p>				
102735	RFA-NS-21-015 -- HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-21-015	28-Mar-2021 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name Michael L. Oshinsky, PhD Contact Telephone 301-496-9964 Contact Email michael.oshinsky@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 28-Mar-2021 [Optional][LOI/Pre-App], 27-Apr-2021 , 28-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 13-Sep-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Optional][LOI/Pre-App], 13-Oct-2021 , 10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 10-Sep-2023 [Optional][LOI/Pre-App], 10-Oct-2023

Synopsis This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is encouraged. The goal of each 5-year U19 application should be to identify candidate therapeutic(s) that will be ready to be submitted to RFA-NS-21-010 for further optimization.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

102738	RFA-NS-21-016 -- HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-21-016	28-Mar-2021 [Optional][LOI/Pre-App]	1,000,000 USD
--------	---	------------------------------------	---------------	--	------------------

Contact Name	Michael L. Oshinsky, PhD
Contact Telephone	301-496-9964
Contact Email	michael.oshinsky@nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Mar-2021 [Optional][LOI/Pre-App], 27-Apr-2021 , 28-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 13-Sep-2021 [Optional][LOI/Pre-App], 13-Oct-2021 , 10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 10-Sep-2023 [Optional][LOI/Pre-App], 10-Oct-2023</p> <p>Synopsis The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.</p>				
084924	<p>Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-19-343	07-May-2021	Not Specified
	<p>Contact Name Kenneth D. Gibbs, Jr., Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email kenneth.gibbs@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022</p> <p>Synopsis The purpose of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions at research-intensive institutions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

102741	Notice of Special Interest (NOSI): Understanding and Addressing the Impact of Structural Racism and Discrimination on Biomedical Career Progression and the Biomedical Research Enterprise	National Institutes of Health/DHHS	NOT-GM-21-033	17-May-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-May-2021 , 04-Oct-2021 , 13-Oct-2021 , 18-Jan-2022 , 17-May-2022 , 03-Oct-2022
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform applicants of topic areas of interest to the National Institute of General Medical Sciences (NIGMS) to study and/or address the impacts of structural racism and discrimination on biomedical career progression and the biomedical research enterprise.

102020	Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation	National Institutes of Health/DHHS	NOT-MD-21-012	03-May-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Deborah E. Linares, Ph.D., M.A.
Contact Telephone	301-402-2516
Contact Email	deborah.linares@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	03-May-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis This Notice of Special Interest (NOSI) highlights the urgent need for research strategies and interventions to address SARS-CoV-2 vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the United States (U.S.). Research is urgently needed to understand and address misinformation, distrust, and hesitancy regarding the SARS-CoV-2 (COVID-19) vaccine among adults in the U.S. and its territories, especially among populations who are at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. This NOSI solicits community-engaged research to: 1) evaluate innovative interventions to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations. Applications for this NOSI are limited to NIH Research Centers in Minority Institution's (RCMI) currently active U54 awards, which are not in an extension at the time of application submission.</p>				
102531	RFA-AG-22-020 -- Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-AG-22-020	23-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Melissa S. Gerald, Ph.D. Contact Telephone 301-496-3136 Contact Email melissa.gerald@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications focused on triadic interactions and interpersonal processes between individuals with Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD), clinicians, and care partners. NIA seeks to increase our understanding of the impact of such interactions on patient health and well-being outcomes. The goal of this initiative is to identify targets for the development of behavioral interventions to optimize interactions in clinical settings and help build and preserve strong and supportive caregiving relationships throughout all stages of AD/ADRD and across the continuum of care. To these ends, this FOA solicits basic research and Stage I behavioral intervention development clinical trials in two high-priority areas: (1) triadic communication and interpersonal relationships between patients, clinicians, and care partners; and (2) the clinical significance of dyadic processes in caregiving relationships between patients and care partners in the context of patient-caregiver-clinician encounters.</p>				
093907	Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PA-20-184	07-May-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name				
	Contact Telephone	301-496-4000			
	Contact Email	grantsinfo@od.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			
	Synopsis	<p>The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>			

093897	Research Project Grant (Parent R01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-20-183	07-May-2021	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

	Contact Name				
	Contact Telephone				
	Contact Email	grantsinfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. NOTE: The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. National Heart, Lung, and Blood Institute (NHLBI) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) National Center for Complementary and Integrative Health (NCCIH) National Institute of Mental Health (NIMH)</p>			
102906	<p>Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-21-169	26-May-2021	400,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Irina N. Krasnova, Ph.D.</p> <p></p> <p>irina.krasnova@nih.gov</p> <p></p> <p>Link to program URL</p> <p>26-May-2021 , 07-Sep-2021 , 26-May-2022 , 07-Sep-2022 , 26-May-2023 , 07-Sep-2023</p> <p>SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research NOT-OD-20-031 with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions. The purpose of SuRE awards is to provide research grant support for faculty investigators who have prior experience in leading externally-funded, independent research but are not currently funded by any NIH Research Project Grants with the exception of SuRE or SuRE-First awards.</p>			
102794	<p>RFA-OD-21-005 -- Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 - Independent Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-OD-21-005	04-May-2021 [Optional][LOI/Pre-App]	800,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Erica L. Spotts, Ph.D.</p> <p>301-594-2105</p> <p>spottse@od.nih.gov</p> <p></p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021 , 07-Sep-2021</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development</p>				
102922	<p>Notice of Special Interest (NOSI): Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project</p>	National Institutes of Health/DHHS	NOT-OD-20-024	12-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-May-2021 , 23-Jul-2021 , 23-Nov-2021 , 23-Mar-2022 , 23-Jul-2022</p> <p>Synopsis The Office of the Director of the National Institutes of Health (NIH) announces the opportunity for investigators with relevant active NIH-supported grants from the participating Institutes listed above to submit administrative supplement applications for funded projects to meet new NIH Down syndrome research objectives related to the NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project. This Notice is soliciting administrative supplements for the following mechanisms ONLY: R01,R03,R21,R24,P01,P20, P30,P40,P50,P51,U01,U10,U19,U24,U42,U54,UG1,UG3,UL1,U2C,K12, and T32.</p>				
102357	<p>RFA-HL-22-007 -- Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Clinical Centers (Collaborative UG3/UH3 Clinical Trial Required)</p>	National Institutes of Health/DHHS	RFA-HL-22-007	11-May-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Charlotte A. Pratt, MS, PhD</p> <p>Contact Telephone 301-435-0382</p> <p>Contact Email charlotte.pratt@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2021 [Optional][LOI/Pre-App], 11-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for clinical or community sites to be part of a multi-center group- or cluster-randomized trial under the Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program. ENRICH will aim to test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 years old) who are of low socio-economic status (SES), live in low-resource rural or urban communities, or who are in diverse geographic regions of the U.S. with high burden of cardiovascular disease (CVD) risk factors. Specifically, this initiative will support multi-site interventions designed to determine if a CVH module delivered within the context of a home visiting program can enhance maternal and early childhood CVH. This FOA uses the bi-phasic, milestone-driven cooperative agreement mechanism (UG3/UH3) and runs in parallel with a companion FOA (RFA-HL-22-008) that encourages applications for a collaborating Resource Coordinating Center (RCC). Awards made under this FOA will support a milestone driven planning phase including feasibility studies and pilot activities for up to 2 years (UG3), with possible transition to an implementation phase (UH3) for up to five additional years. Only UG3 trials that meet the scientific milestones and award requirements of the UG3 may transition to the UH3 phase. Applications submitted to this FOA must address both the UG3 and UH3 phases. Applications must also include plans for project management, subject recruitment and retention, scientific conduct of the trial including study design, intervention, measurement and data analysis, and performance milestones for each phase.</p>				
102358	<p>RFA-HL-22-008 -- Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Resource and Coordinating Center (U24 Clinical Trial Required)</p>	National Institutes of Health/DHHS	RFA-HL-22-008	11-May-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Charlotte A. Pratt, MS, PhD</p> <p>Contact Telephone 301-435-0382</p> <p>Contact Email charlotte.pratt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-May-2021 [Optional][LOI/Pre-App], 11-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for a Resource and Coordinating Center (RCC) for the Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program, a new NIH multi-center group- or cluster- randomized trial with clinical or community sites to be supported under the companion RFA-HL-22-007. The RCC will coordinate and provide support for the clinical or community sites that propose to test the effectiveness of an</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH disparities in both mothers and children (0-5 years of age) who are of low socio-economic status (SES), live in low-resource rural or urban communities, or are in diverse geographic regions of the U.S. with a high burden of cardiovascular disease (CVD) risk factors. Applicants should propose activities that include the following: Plan and support study coordinating structure and functions, including efforts to promote communication and collaborations among study investigators, training of staff on study protocols, convening of meetings, evaluating the data collected from the ENRICH clinical/community sites , and coordinating ancillary studies that leverage the ENRICH research platform Facilitate the development of a common intervention protocol for the UH3 phase, including the study design, analytic plan, sample size, and use of common elements and measures across studies, to be reviewed by the NHLBI-appointed DSMB and approved by the NHLBI prior to UH3 phase for the clinical or community sites Develop and implement data collection procedures, facilitate the collection of biomedical data, establish a central database, provide additional biostatistical expertise, conduct data analysis of data across study sites, and facilitate reporting of trial results, including process, impact, and outcomes measures. Involve and develop the skills of Early Stage Investigators (ESIs) and home-visiting staff professionals in early CVH promotion and implementation strategies to foster the next generation of researchers in promoting maternal and child CVH. Coordinate the development of public access data files to be made available in a data repository as designated by the NHLBI. This U24 cooperative agreement initiative is administered by the NHLBI but includes extensive participation and funding contributions from a coalition of Institutes, Centers, and Offices (ICOs) at the National Institutes of Health (NIH) as well as the Health Resources and Services Administration (HRSA) and the Administration for Children and Families (ACF). HRSA and ACF will provide the infrastructure and in-kind support to awardee investigators to gain access to evidence-based home visiting programs already being supported by HHS. HRSA and ACF staff, along with NIH staff will provide staff-level scientific and technical input for ENRICH. HRSA and ACF staff along with NIH staff may serve as project scientists on the Steering Committee and various subcommittees (e.g., intervention, measurement, publications, ancillary studies subcommittees).

102840	RFA-DK-21-004 -- The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DK-21-004	22-May-2021 [Optional][LOI/Pre-App]	2,500,000 USD
--------	---	------------------------------------	---------------	--	------------------

Contact Name	Salvatore Sechi, Ph.D.
Contact Telephone	301-594-8814
Contact Email	sechi@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 09-Feb-2022 [Optional][LOI/Pre-App], 09-Mar-2022

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Applications that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should propose a plan for integrating these discoveries with the present knowledge on established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8). In the long-term the goals of this initiative are to facilitate the development of better tools to monitor disease progression and treatment, and potentially to facilitate the development of personalized therapeutics.</p>			
102925	<p>Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project</p>	National Institutes of Health/DHHS	NOT-OD-20-024	07-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Link to program URL</p> <p>07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science).</p>			
102380	<p>AMENDMENT -- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases</p>	National Institutes of Health/DHHS	HHS-NIH-NIAID-BAA2021-1	24-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Alexandra Buck</p> <p>2406695174</p> <p>alexandra.buck@nih.gov</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Program URL	Link to program URL			
	Deadline Dates (ALL)	24-May-2021			
	Synopsis	<p>2021 NIAID DMID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2021-1 Introduction: The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH. The Research Areas included in this NIAID DMID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2021-1, as well as the projected amounts of available funding, are discussed below. Description: DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID), NIAID, NIH Research Area 001: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases. The objective of Research Area 001 is to advance vaccine technologies and platforms that have sufficient proof of concept data and/or clinical data to support vaccine development through manufacturing, toxicology testing, and testing in phase 1 or 2 clinical trials. The goal of Research Area 001 is to advance vaccine technologies and platforms which could be deployed against agents important for biodefense and/or emerging pathogens to protect human health and well-being. The development of these platforms and technologies to rapidly progress into Phase 1 clinical trials will provide critical data to reduce the risk for future development of these technologies into approved therapies and vaccines. Solicited products are anticipated to include: Vaccines for Anti-Microbial Resistant (AMR) Organisms and Vaccines for Pandemic Preparedness and Emerging Infectious Diseases. NIAID estimates that three (3) or more awards may be issued across this Research Area and the next Research Area entitled "Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases" for a total cost of up to \$11 million for the non-severable base work (direct and indirect costs combined) across all contracts. The total duration of a proposed contract should be consistent with the nature and complexity of the offeror's proposed research. The total performance period comprised of the base and any options proposed by an Offeror shall not exceed five (5) years. Research Area 002 Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases. The objective of Research Area 002 is the development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in the 2019 CDC Antibiotic Resistance Threats Report https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. For the purposes of this solicitation, therapeutic activity is defined as the cure or mitigation of disease, preferably, once signs and symptoms of infection are evident. For the purposes of this solicitation, a therapeutic candidate refers to an advanced lead series, optimized leads, or product candidate, and is either a small molecule (synthetic or natural product) or a biological product (e.g. monoclonal antibodies, recombinant proteins). Solicited products are anticipated to include: Antimicrobial Therapeutics; Antiviral</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Therapeutics; and Anti-toxin Therapeutics. NIAID estimates that three (3) or more awards may be issued across this Research Area and the preceding Research Area entitled “Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases” for a total cost of up to \$11 million for the non-severable base work (direct and indirect costs combined) across all contracts. The total duration of a proposed contract should be consistent with the nature and complexity of the offeror’s proposed research. The total performance period comprised of the base and any options proposed by an Offeror shall not exceed five (5) years

Research Area 003: Advanced Development of Sequencing-Based Diagnostics for Biothreats and Emerging Infectious Diseases The objective of Research Area 003 is to advance the research and development of nucleic acid and protein sequencing solutions on established commercial platforms for the targeted and agnostic detection of bio-threat and naturally emerging infectious pathogens. Solicited products are anticipated to include: Early through late-stage development for a sequencing-based diagnostic test that supports biodefense and naturally emerging and re-emerging infectious pathogen preparedness. Diagnostic must detect one of the following agents: Bacillus anthracis, including genotypic resistance markers Yersinia pestis, including genotypic resistance markers Francisella tularemia, including genotypic resistance markers Burkholderia sp., including genotypic resistance markers Botulinum toxin , including identifying and distinguishing relevant serotypes ESKAPE pathogens (Enterococcus faecium, Staph. aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species), including genotypic resistance markers Lassa virus Nipah virus Rift Valley Fever virus Enterovirus D68 virus Candida auris Coccidioides sp. Novel coronaviruses NIAID estimates that one (1) or more awards may be issued across this Research Area for a total cost of up to \$4 million for the non-severable base work (direct and indirect costs combined) across all contracts. The total duration of a proposed contract should be consistent with the nature and complexity of the offeror’s proposed research. The total performance period comprised of the base and any options proposed by an Offeror shall not exceed five (5) years

The Omnibus BAA is governed by Federal Acquisition Regulation (FAR) 6.102(d)(2) and FAR 35.016, as well as the NIH Policy Manual, Manual Chapter 6035, Broad Agency Announcements. A BAA may be used as a solicitation mechanism for basic and applied research directed toward advancing the state-of-the-art or increasing knowledge or understanding and that part of development not related to the development of a specific system or hardware procurement. BAAs are general in nature, identifying areas of research interest, and shall only be used when meaningful proposals with varying technical/scientific approaches can be reasonably anticipated. Offers submitted in response to this BAA will be required to present separate detailed technical and business proposals designed to meet the Technical Objectives described for each Research Area proposed. The Statement of Work (SOW), including the specific technical requirements and performance specifications, shall be developed and proposed by the Offeror, not the Government. Proposals received in response to this BAA are NOT evaluated against each other since they are not submitted in accordance with a common SOW issued by the Government. Instead, Research and Technical Objectives will be provided in the BAA that describe individual Research Areas in which the Government is interested. Proposals received in response to the BAA will be evaluated in accordance with the Evaluation Factors for Award specified in the announcement. The Government reserves the right to conduct discussions with all, some,

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

one, or none of the proposals received in response to this BAA. If discussions are conducted, the Government reserves the right to suggest modifying, adding or deleting milestones, decision points, research plans, processes, schedules, budget or product. The Government also reserves the right to make awards without discussions. Additionally, the Government reserves the right to accept proposals in their entirety or to select only portions of proposals for award. Multiple awards are anticipated. Selection for award under this BAA will be based upon the evaluation factors, importance to the agency programs, and the availability of funds. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on or about February 23, 2021 and may be accessed through Beta Sam: <https://beta.sam.gov/>. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website: <https://ecps.nih.gov> and then click on "How to Submit."

099844	Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)	National Library of Medicine/NIH/DHHS	PAR-20-304	07-May-2021	1,000,000 USD
--------	---	---------------------------------------	------------	-------------	---------------

Contact Name	Alan VanBiervliet, PhD
Contact Telephone	301-594-4882
Contact Email	vanbiervlietaq@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	National Library of Medicine (NLM) wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.

076848	NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)	National Library of Medicine/NIH/DHHS	PAR-18-896	07-May-2021	1,000,000 USD
--------	--	---------------------------------------	------------	-------------	---------------

Contact Name	Dr. Hua-Chuan Sim
Contact Telephone	301-594-4882
Contact Email	simh@mail.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Library of Medicine (NLM) offers support for innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. Biomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology. NIH defines data science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
073256	Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PA-18-722	07-May-2021	Not Specified
	<p>Contact Name Wendy Nilsen, PhD</p> <p>Contact Telephone 240-276-6971</p> <p>Contact Email nelsonw@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). This FOA will use the NIH Research Project (R01) award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
073264	Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)	Office of Behavioral and Social Sciences Research/NIH/DHHS	PA-18-723	07-May-2021	275,000 USD
	<p>Contact Name Wendy Nilsen, PhD</p> <p>Contact Telephone 240-276-6971</p> <p>Contact Email nelsonw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
101526	Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-089	07-May-2021	Not Specified
	<p>Contact Name Sheri Hild, Ph.D.</p> <p>Contact Telephone 301-594-8937</p> <p>Contact Email sheri.hild@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 07-Sep-2021 , 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-18-669 and PAR-14-066. Breeding colonies are essential to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>sustain appropriate macaques for research related to Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS). Pedigree SPF macaques are free of certain viruses, which may confound the results of HIV/AIDS-related investigations or present a risk to the personnel who care for the animals. The SPF macaques are genetically characterized for major histocompatibility complex (MHC) class I types, because MHC class I genotypes have large effects on macaque immune responses to Simian Immunodeficiency Virus (SIV, which can induce AIDS in nonhuman primates (NHP)) and on human immune responses to HIV.</p>				
095227	Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-20-181	25-May-2021	Not Specified
	<p>Contact Name Sheri Ann Hild, PhD Contact Telephone 301-594-8937 Contact Email hildsa@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 25-May-2021 , 25-Sep-2021 , 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 Synopsis This FOA encourages grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers.</p>				
088104	Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	RFA-OD-20-002	07-May-2021	Not Specified
	<p>Contact Name Oleg Mirochnitchenko, Ph.D. Contact Telephone 301-435-0748 Contact Email oleg.mirochnitchenko@mail.nih.gov Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 , 26-May-2021 , 07-Sep-2021 , 28-Sep-2021 , 07-Jan-2022 , 26-Jan-2022 , 07-May-2022 , 26-May-2022 , 07-Sep-2022 , 27-Sep-2022 , 07-Jan-2023</p> <p>Synopsis This FOA encourages grant applications for national Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The important mission of the projects described by this FOA is to provide research resources, which are facilitating the optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP's trans-NIH mission (https://orip.nih.gov/about-orip). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP's program priorities.</p>				
085529	RFA-OD-19-027--Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	RFA-OD-19-027	10-May-2021	Not Specified
	<p>Contact Name Stephanie Murphy, VMD, PhD</p> <p>Contact Telephone 301-451-7818</p> <p>Contact Email stephanie.murphy@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2021 , 26-May-2021 , 08-Sep-2021 , 28-Sep-2021 , 10-Jan-2022 , 26-Jan-2022 , 10-May-2022 , 26-May-2022 , 08-Sep-2022</p> <p>Synopsis The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing or improving animal models of human diseases; improving access to information about or generated from the use of animal models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP's trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
research will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.					
079634	Methods Development for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R21 Clinical Trial Not Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-19-176	07-May-2021	275,000 USD

Contact Name	Sige Zou, Ph.D.
Contact Telephone	301-435-0749
Contact Email	zous@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022
Synopsis	This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102421	Dear Colleague Letter: Request for Expression of Interest Regarding Provision of a Drilling Vessel to Support Future International Scientific Ocean Discovery	National Science Foundation	NSF 21-043	01-May-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name James F. Allan</p> <p>Contact Telephone 703-292-8144</p> <p>Contact Email jallan@nsf.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 [LOI/Pre-App]</p> <p>Synopsis Expressions of Interest are requested from eligible U.S. institutions to provide a multi-decadal drilling vessel, possibly through the National Science Foundation (NSF) Major Multi-User Research Facilities process as described in the NSF Major Facilities Guide, to support the science needs and enable new science discovery as defined in the recently completed Exploring Earth by Scientific Ocean Drilling 2050 Science Framework. The 2050 Science Framework is based on workshop-derived input from the American scientific community and international workshops held in Europe, Japan, China, Australia, South Korea, and India. All totaled, over 800 participants defined the need for a multi-decade program with a globally ranging scientific drillship to address critical global geoscience problems in the oceans and explore areas of the Earth otherwise inaccessible for sampling or observation.</p>				
102018	National Robotics Initiative 3.0: Innovations in Integration of Robotics (NRI-3.0)	National Science Foundation	21-559	03-May-2021	Not Specified
	<p>Contact Name David Miller</p> <p>Contact Telephone 703-292-4914</p> <p>Contact Email damiller@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021 , 22-Feb-2022</p> <p>Synopsis The National Robotics Initiative 3.0: Innovations in Integration of Robotics (NRI-3.0) program builds upon the preceding National Robotics Initiative (NRI) programs to support fundamental research in the United States that will advance the science of robot integration. The program supports research that promotes integration of robots to the benefit of humans including human safety and human independence. Collaboration between academic, industry, non-profit, and other</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>organizations is encouraged to establish better linkages between fundamental science and engineering and technology development, deployment, and use. The NRI-3.0 program is supported by multiple agencies of the federal government including the National Science Foundation (NSF), the U.S. Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Transportation (DOT), the National Institutes of Health (NIH), and the National Institute for Occupational Safety and Health (NIOSH).</p>			
102422	Dear Colleague Letter: Computer and Information Science and Engineering Graduate Fellowships (CSGrad4US)	National Science Foundation	NSF 21-044	04-May-2021	138,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-292-8950</p> <p>Contact Email csgrad4us@nsf.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021</p>	<p>Synopsis</p> <p>The computer and information science and engineering fields are experiencing booming undergraduate enrollments. Many of these undergraduate degree recipients have outstanding job opportunities in industry and at other organizations, and only a small fraction of these individuals considers pursuing related doctoral degree-granting programs. In order to increase the number of diverse, domestic graduate students in these areas and thereby bolster the U.S. population in the Nation's computer and information science and engineering research and innovation workforce, the National Science Foundation's (NSF) Directorate for Computer and Information Science and Engineering (CISE) announces its intention to support CISE Graduate Fellowships (CSGrad4US) as a pilot effort. In particular, CSGrad4US is intended for individuals who have some practical experience following their bachelor's degree and are now interested in pursuing a research-based doctoral degree. The goals of the CSGrad4US Fellowships are to: 1) select, recognize, and financially support early-career individuals with the demonstrated potential to be high-achieving CISE researchers and innovators; and 2) to broaden participation among groups underrepresented in CISE disciplines, including women, African Americans, Hispanics, American Indians, Alaska Natives, Native Hawaiians, Native Pacific Islanders, and persons with disabilities. CSGrad4US Fellowships are a part of an overall strategy by NSF's CISE directorate to develop the national workforce necessary to ensure the Nation's leadership in advancing CISE research and innovation.</p>			
092037	Civic Innovation Challenge	National Science Foundation	20-562	05-May-2021	1,000,000 USD

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name David Corman</p> <p>Contact Telephone 703-292-8754</p> <p>Contact Email dcorman@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-May-2021</p> <p>Synopsis The Civic Innovation Challenge (CIVIC) is a research and action competition in the Smart and Connected Communities (S&CC) domain designed to build a more cohesive research-to-innovation pipeline and foster a collaborative spirit. Building on the NSF S&CC program and the extensive S&CC ecosystem, CIVIC aims to accelerate the impact of S&CC research, and deepen cooperation and information sharing across sectors and regions. CIVIC will lay a foundation for a broader and more fluid exchange of research interests and civic priorities that will create new instances of collaboration and introduce new areas of technical and social scientific discovery. CIVIC will fund projects that can produce significant community impact within 12 months (following a four-month planning phase) — in contrast to many community-university partnerships that take years to provide tangible benefits to communities — and have the potential for lasting impact beyond the period of the CIVIC award.</p>				
102062	Understanding the Rules of Life: Emergent Networks (URoL:EN)	National Science Foundation	21-560	10-May-2021	3,000,000 USD
	<p>Contact Name Betsy von Holle</p> <p>Contact Telephone 703-292-4974</p> <p>Contact Email e-networks@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2021</p> <p>Synopsis The Understanding the Rules of Life: Predicting Phenotype "Big Idea" is based on developing a predictive understanding of how key properties of living systems emerge from interactions of factors such as genomes, phenotypes, and evolving environments. This activity has launched a series of new research programs designed to elucidate "minimal rules" (building a synthetic cell), "rules of complexity" (epigenetics), and "rules of interaction" (microbiome). This Understanding the Rules of Life: Emergent Networks (URoL:EN) solicitation adds to those previous foundational activities to now understand "rules of emergence" for networks of living systems and their environments. Emergent networks describe the interactions among organismal, environmental, social, and human-engineered systems that are complex and often unexpected given the</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

behaviors of these systems when observed in isolation. The behavior of emergent networks of living systems depend on, but are not wholly predicted by, chemical and physical principles and unit-level biological properties (molecule/cell/organism/population), as well as communication and information flows among nodes in the network. Networks of living systems are reciprocally coupled with natural, built, and social environments in ways that are complex and difficult to predict. The often-unanticipated outcomes of these interactions can be both wide-ranging and enormously impactful. Prediction is further hampered by accelerating perturbations within evolving environments and the associated increase in the frequency of previously rare or extreme events. Determining the emergent properties of these networks, which arise from complex and nonlinear interactions among the different systems that in isolation do not exhibit such properties, is a critical and unsolved problem. One of many examples of this could include the emerging network of interactions across scales that arose from the arrival of the nonnative pathogen, *Cryphonectria parasitica*, or Chestnut blight, introduced with nursery stock. This pathogen effectively eliminated a dominant overstory tree species, American chestnut (*Castanea dentata*), across North America and had concomitant impacts on and feedbacks between biotic, abiotic, and social networks. For example, the economic impacts of this pathogen ranged from local agricultural and social impacts to global scale impacts on the timber industry. Successful projects of the URoL:EN program are expected to use convergent approaches that explore emergent network properties of living systems across various levels of organizational scale and, ultimately, contribute to understanding the rules of life through new theories and reliable predictions about the impact of specific environmental changes on behaviors of complex living systems, or engineerable interventions and technologies based on a rule of life to address associated outcomes for societal benefit. The convergent scope of URoL:EN projects also provides unique STEM education and outreach possibilities to train the next generation of scientists in a diversity of approaches and to engage society more generally. Hence, the URoL:EN program encourages research projects that integrate training and outreach activities in their research plan, provide convergent training opportunities for researchers and students, develop novel teaching modules, and broaden participation of under-represented groups in science. The URoL:EN Program will support projects with a total budget of up to \$3,000,000 and an award duration of up to 5 years.

102254	Future Manufacturing (FM) (Defunct)	National Science Foundation	21-564	14-May-2021	Not Specified
--------	---	-----------------------------	--------	-------------	---------------

Contact Name	William Olbricht
Contact Telephone	703-292-4842
Contact Email	wolbrich@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 14-May-2021</p> <p>Synopsis</p> <p>The global manufacturing ecosystem has evolved dramatically in recent decades, driven by forces of technology and globalization and steered by the pursuit of greater efficiencies at scale. The Strategy for American Leadership in Advanced Manufacturing states that worldwide competition in manufacturing has been dominated in recent decades by the maturation, commoditization, and widespread application of computation in production equipment and logistics, effectively leveling the global technological playing field and placing a premium on low wages and incremental technical improvements [1]. The next generation of technological competition in manufacturing will be dictated by the use of computation to ensure the reliable translation of product designs to manufacturing plans; process controls that provide assurances that the execution of those plans will produce products that meet specifications; inventions of new materials, chemicals, devices, systems, processes, machines, and design and work methods; and new social structures and business practices. Fundamental research will be required in robotics, artificial intelligence, biotechnology, materials science, sustainability, education and public policy, and workforce development to lead this global competition. The research supported under this solicitation will enhance U.S. leadership in manufacturing far into the future by providing new capabilities for established companies and entrepreneurs, improving our health and quality of life, reducing the impact of manufacturing on the environment and addressing global challenges such as climate change, pandemics and smart growth. The goal of Future Manufacturing is to support fundamental research and education of a future workforce to overcome scientific, technological, educational, economic and social barriers in order to enable new manufacturing capabilities that do not exist today. Future Manufacturing will require major advances in technologies and algorithms for the synthesis and production of new materials, chemicals, devices, components and systems of assured quality with high yield at reasonable cost. It will require new advances in artificial intelligence and machine learning, new cyber infrastructure, new approaches for mathematical and computational modeling, new dynamics and control methodologies, new ways to integrate systems biology, synthetic biology and bioprocessing, and new ways to influence the economy, workforce, human behavior, and society. Future Manufacturing requires creative convergence approaches in science, technology and innovation, empirical validation, and education and workforce development to address pressing challenges for manufacturing. At the same time, Future Manufacturing can leverage highly integrated physical, digital and social frameworks that underpin society to enable manufacturing that addresses urgent social challenges such as global health disparities, economic and social divides, infrastructure deficits of marginalized populations and communities, and environmental sustainability. Cross-disciplinary partnerships among scientists, engineers, social and behavioral economists, and experts in arts and humanities may be required to provide solutions that are equitable and inclusive.</p>				
090120	Future Manufacturing (FM)	National Science Foundation	21-564	14-May-2021	Not Specified

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	William Olbricht			
	Contact Telephone	703-292-4842			
	Contact Email	wolbrich@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-May-2021			
	Synopsis	<p>The global manufacturing ecosystem has evolved dramatically in recent decades, driven by forces of technology and globalization and steered by the pursuit of greater efficiencies at scale. The Strategy for American Leadership in Advanced Manufacturing states that worldwide competition in manufacturing has been dominated in recent decades by the maturation, commoditization, and widespread application of computation in production equipment and logistics, effectively leveling the global technological playing field and placing a premium on low wages and incremental technical improvements [1]. The next generation of technological competition in manufacturing will be dictated by the use of computation to ensure the reliable translation of product designs to manufacturing plans; process controls that provide assurances that the execution of those plans will produce products that meet specifications; inventions of new materials, chemicals, devices, systems, processes, machines, and design and work methods; and new social structures and business practices. Fundamental research will be required in robotics, artificial intelligence, biotechnology, materials science, sustainability, education and public policy, and workforce development to lead this global competition. The research supported under this solicitation will enhance U.S. leadership in manufacturing far into the future by providing new capabilities for established companies and entrepreneurs, improving our health and quality of life, reducing the impact of manufacturing on the environment and addressing global challenges such as climate change, pandemics and smart growth. The goal of Future Manufacturing is to support fundamental research and education of a future workforce to overcome scientific, technological, educational, economic and social barriers in order to enable new manufacturing capabilities that do not exist today. Future Manufacturing will require major advances in technologies and algorithms for the synthesis and production of new materials, chemicals, devices, components and systems of assured quality with high yield at reasonable cost. It will require new advances in artificial intelligence and machine learning, new cyber infrastructure, new approaches for mathematical and computational modeling, new dynamics and control methodologies, new ways to integrate systems biology, synthetic biology and bioprocessing, and new ways to influence the economy, workforce, human behavior, and society. Future Manufacturing requires creative convergence approaches in science, technology and innovation, empirical validation, and education and workforce development to address pressing challenges for manufacturing. At the same time, Future Manufacturing can leverage highly integrated physical, digital and social frameworks that underpin society to enable manufacturing that addresses urgent social challenges such as global health disparities, economic and social divides, infrastructure deficits of</p>			

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

marginalized populations and communities, and environmental sustainability. Cross-disciplinary partnerships among scientists, engineers, social and behavioral economists, and experts in arts and humanities may be required to provide solutions that are equitable and inclusive.

092508	NSF Convergence Accelerator Phase I and II	National Science Foundation	20-565	17-May-2021	Not Specified
--------	--	-----------------------------	--------	-------------	---------------

Contact Name	Linda Molnar
Contact Telephone	703-292-8316
Contact Email	lmolnar@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	17-May-2021
Synopsis	<p>The goals of NSF's convergence accelerator effort are to support and accelerate use-inspired convergence research in areas of national importance within particular topics (tracks). NSF Convergence Accelerator tracks can be related to Industries of the Future (IoF), NSF's Big Ideas , or other topics, that may not relate directly to an IoF or Big Idea, however, they must have the potential for significant national impact. The 2020 NSF Convergence Accelerator is a two-phase program. Both phases are described in this solicitation. Phase I awardees receive significant resources to further develop their convergence research ideas and identify crucial partnerships and resources to accelerate their projects, leading to deliverable research prototypes in Phase II. This solicitation invites proposals for the following Tracks: Quantum Technology (Track C); AI-Driven Innovation via Data and Model Sharing (Track D).</p>

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102467	Conservation Innovation Grants--Louisiana	Natural Resources Conservation Service/Department of Agriculture	USDA-NRCS-LA-CIG-21-001-NOFO0001064	04-May-2021	150,000 USD
	Contact Name	Aziza B. Clark			
	Contact Telephone				
	Contact Email	aziza.clark@usda.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-May-2021			
	Synopsis	NRCS is announcing the availability of CIG funding to stimulate the development and adoption of innovative conservation approaches and technologies. Applications are accepted from eligible entities for projects carried out in the state of Louisiana. A total of up to \$300,000.00 is available for the Louisiana CIG competition in FY 2021. All non-federal entities (NFE) and individuals are invited to apply, with the sole exception of federal agencies. Projects may be between one and three years in duration. The maximum award amount for a single award in FY 2021 is \$150,000.00.			
057652	Large Health Services Research Demonstration and Dissemination Projects for Prevention of Healthcare-Associated Infections (R18)	Agency for Healthcare Research and Quality/DHHS	PA-17-007	25-May-2021	2,500,000 USD
	Contact Name	James I. Cleeman, M.D.			
	Contact Telephone	301-427-1330			
	Contact Email	james.cleeman@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications for funding for funding to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) that propose to address strategies and approaches for prevention and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Health Services Research Demonstration and Dissemination Projects. This FOA will utilize the AHRQ Large Health Services Research Demonstration and Dissemination Grant (R18) award mechanism.			
073607	Making Health Care Safer in Ambulatory Care Settings and	Agency for Healthcare Research and	PA-18-750	25-May-2021	1,350,000 USD

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Long Term Care Facilities (R18)	Quality/DHHS			
	Contact Name	Barbara A. Bartman, MD, MPH			
	Contact Telephone	301-427-1515			
	Contact Email	barbara.bartman@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021 , 25-Sep-2021			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications for research demonstration and implementation projects that pertain to ambulatory care settings and long term care facilities with a focus on implementing evidence-based processes to improve patient safety, especially those involving transitions in care. AHRQ is interested in studies in these two settings that develop, utilize, and evaluate strategies to implement existing measures, metrics, tools or practices that have already been validated and have been shown to be efficacious in improving patient safety sites. This FOA will use the R18 Research Demonstration and Dissemination Project award mechanism.			
057446	AHRQ Conference Grant Program (R13)	Agency for Healthcare Research and Quality/DHHS	PA-16-453	01-May-2021	150,000 USD
	Contact Name	Linda Franklin			
	Contact Telephone	301-427-1904			
	Contact Email	linda.franklin@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2021 , 01-Aug-2021 , 01-Nov-2021			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) announces its interest in supporting conferences through the AHRQ Single Year and Multiple Year Conference Grant Programs (R13). AHRQ seeks to support conferences that help to further its mission to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with HHS and other partners to make sure that the evidence is understood and used (http://www.ahrq.gov/funding/policies/foaguidance/index.html). This FOA will use the conference grant (R13) award mechanism.			
102711	Gulf War Illness Research Program--New Investigator	Department of the Army	W81XWH-21-GWIRP-NIA	07-May-2021	Not Specified

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Award			[LOI/Pre-App]	
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 [LOI/Pre-App], 19-Aug-2021</p> <p>Synopsis The FY21 GWIRP New Investigator Award supports investigators new to the field of GWI research at different stages of career development. This award enables such investigators to compete for funding separately from investigators with established programs of GWI research. The New Investigator Award aligns to the Discovery or Qualification phase as outlined in Section II.A.2. Previous experience in GWI research is allowed, but not required. However, applications naming a Principal Investigator (PI) with limited background in GWI research are strongly encouraged to include collaboration with investigators who are experienced in GWI research and/or possess other relevant expertise to strengthen the application. The application should describe how the collaboration(s) will augment the PI's ability to address the research question. PIs must meet specific eligibility criteria under one of the following categories. Transitioning Postdoctoral Fellow; Early-Career Investigator; New GWI Researcher.</p>				
102719	Gulf War Illness Research Program--Idea Award	Department of the Army	W81XWH-21-GWIRP-IA	07-May-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email help@eBRAP.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021 [LOI/Pre-App], 19-Aug-2021</p> <p>Synopsis The FY21 GWIRP Idea Award supports innovative, high-risk/high-reward research in the earliest stages of development that will contribute to markers or treatments for GWI. FY21 GWIRP Idea Award Areas of Emphasis: The FY21 GWIRP Idea Award has a special interest in the exploration of the topics listed below. Applicants are not restricted to this list and may propose studies in any other GWI research area relevant to the mission of the GWIRP and in the context of the FY21 GWIRP Overarching Challenges. • Innovative treatments for GWI • Identification of the causes of and treatment targets for</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>dysregulated biological system function. Emphasis should be placed on: Cognitive difficulties to include memory deficits, mood and behavior disturbances Non-restorative sleep or sleep disturbances Chronic wide-spread pain Chronic debilitating fatigue Gastrointestinal effects including dietary intolerances, gastroesophageal reflux disease (GERD), and functional gastrointestinal disorders (FGIDs) Sinus and respiratory effects Headaches Dermatological issues Neurological dysfunction (central, peripheral, autonomic, and/or neuromuscular) Immune system dysfunction Endocrine, exocrine, and/or excretory system dysfunction, with special attention to kidney and liver (e.g., Cytochrome P450 abnormalities) Microbiome variants The impact of stresses (e.g., exertion, immune challenge) on the severity and duration of the symptoms Disordered system crosstalk (e.g., immunological dysfunction that alters the nervous system, autonomic dysfunction that impacts functioning of the gastrointestinal tract) that contributes to malfunction in several physiological systems • Identification of molecular signatures (e.g., genomic, proteomic, metabolic, and epigenetic) underlying symptoms and the grouping of symptom sets based on common underlying pathobiology • Investigation of comorbidities, mortality, sex or ethnic differences</p>			
102437	Lung Cancer Research Program--Investigator-Initiated Translational Research Award	Department of the Army	W81XWH-21-LCRP-IITRA	05-May-2021 [LOI/Pre-App]	600,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021 [LOI/Pre-App], 28-Jul-2021			
	Synopsis	<p>The FY21 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following: · Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts. · Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission. · Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials. Preliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required.</p>			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102721	Gulf War Illness Research Program--Research Advancement Award	Department of the Army	W81XWH-21-GWIRP-RAA	07-May-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	help@eBRAP.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-May-2021 [LOI/Pre-App], 19-Aug-2021			
	Synopsis	The FY21 GWIRP Research Advancement Award supports applied research in GWI that is aimed at continued expansion and validation of markers and treatments that are supported by evidence in the GWI field.			
102416	Capacity Building for Sustainable HIV Services	Health Resources and Services Administration/DHHS	HRSA-21-064	07-May-2021	250,000,000 USD
	Contact Name	Jaclyn Perlman			
	Contact Telephone	301-945-0836			
	Contact Email	JPerlman@hrsa.gov			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	07-May-2021			
	Synopsis	This notice announces the opportunity to apply for funding under the Capacity Building for Sustainable HIV Services project. The purpose of this cooperative agreement, funded under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), is to enhance capacity building in PEPFAR countries. Capacity building encompasses quality, effectiveness, efficiency, patient-centeredness, safety, accessibility, equity, and sustainability of all HIV clinical services and related non-clinical support in identified PEPFAR countries. HRSA is committed to sustainable control of the HIV/AIDS epidemic, by working with local partners in country (such as civil society, faith-based and community-based organizations, key populations groups, etc.) and Ministries of Health to build the capacity of health care workers and health systems to produce a sustained, efficient, and responsive approach to the HIV epidemic in resource-limited countries. The program aims to build the capacity of countries to be agile and current in their response to the needs of program beneficiaries, achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets, and sustain these efforts over time.			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102390	Sickle Cell Disease Treatment Demonstration Program	Maternal and Child Health Bureau/HRSA/DHHS	HRSA-21-032	03-May-2021	5,000,000 USD
	Contact Name	Alisha S. Keehn			
	Contact Telephone	301-945-4817			
	Contact Email	akeehn@hrsa.gov			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	03-May-2021			
	Synopsis	The Health Resources and Services Administration (HRSA) is accepting applications for fiscal year (FY) 2021 for the Sickle Cell Disease Treatment Demonstration Program (TDP). The purpose of the TDP is to increase access to quality, coordinated, comprehensive care for individuals with sickle cell disease by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with sickle cell disease, and 3) improving care coordination with other providers.			
102731	Global Reach ?	Health Resources and Services Administration/DHHS	HRSA-21-066	10-May-2021	Not Specified
	Contact Name	George Tidwell			
	Contact Telephone	301-443-4688			
	Contact Email	gtidwell@hrsa.gov			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	10-May-2021			
	Synopsis	This notice announces the opportunity to apply for funding under the Global Reach I Program. The purpose of this initiative is to collaboratively formulate and deliver high quality solutions across the range of programming required to achieve durable HIV epidemic control, emphasizing new and innovative approaches pursued jointly with HRSA and other stakeholders. An additional purpose is to assist with translating new science into programming and to mitigate the impact of forces such as global pandemics in the HIV response. Programs and activities are to span health services, structural interventions, and data use and tracking systems.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
055305	Program to Accelerate Clinical Trials (PACT)	Alzheimer's Drug Discovery Foundation		16-Apr-2021	3,000,000 USD
	Contact Name				
	Contact Telephone	212-901-8019			
	Contact Email	grants@alzdiscovery.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Apr-2021 , 28-May-2021 [LOI/Pre-App], 30-Jul-2021 , 01-Oct-2021 [LOI/Pre-App], 03-Dec-2021			
	Synopsis	The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.			
055304	Drug Development Program	Alzheimer's Drug Discovery Foundation		16-Apr-2021	600,000 USD
	Contact Name	Alessio Travaglia, PhD, Scientific Program Officer			
	Contact Telephone	212-901-7998			
	Contact Email	atravaglia@alzdiscovery.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Apr-2021 , 28-May-2021 [LOI/Pre-App], 30-Jul-2021 , 01-Oct-2021 [LOI/Pre-App], 03-Dec-2021			
	Synopsis	The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer's disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application. This funding opportunity prioritizes			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.</p>				
000570	Junior Investigator Research Grant Program	American Academy of Clinical Toxicology		01-May-2021	4,500 USD
	<p>Contact Name</p> <p>Contact Telephone 703-556-9222</p> <p>Contact Email admin@clintox.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021</p> <p>Synopsis The AACT is offering a research grant program that supports clinical toxicology research and the development of new investigators' research skills.</p>				
090208	Annual Meeting and Exposition Travelships	American Association of Pharmaceutical Scientists		01-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 703-243-2800</p> <p>Contact Email abstracts@aaps.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021</p> <p>Synopsis The American Association of Pharmaceutical Scientists (AAPS) awards travelships to support the participation of student and post-doc authors who have submitted abstracts for the AAPS PharmSci 360.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
015781	Presidential Gold Medal	American College of Rheumatology		17-May-2021	5,000 USD		
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;"> Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis </td> <td style="border-left: 1px solid black; padding-left: 5px;"> 404-633-3777 ACRnominations@rheumatology.org Link to sponsor website Link to program URL 17-May-2021 The Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. Candidates will have made important contributions in multiple areas such as clinical medicine, research, education or administration. The recipient will receive a \$5,000 cash award. </td> </tr> </table>					Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	404-633-3777 ACRnominations@rheumatology.org Link to sponsor website Link to program URL 17-May-2021 The Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. Candidates will have made important contributions in multiple areas such as clinical medicine, research, education or administration. The recipient will receive a \$5,000 cash award.
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	404-633-3777 ACRnominations@rheumatology.org Link to sponsor website Link to program URL 17-May-2021 The Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. Candidates will have made important contributions in multiple areas such as clinical medicine, research, education or administration. The recipient will receive a \$5,000 cash award.						
010661	Ephraim P. Engleman Endowed Resident Research Preceptorship	American College of Rheumatology		01-May-2021	15,000 USD		
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;"> Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis </td> <td style="border-left: 1px solid black; padding-left: 5px;"> 404-365-1373 Foundation@rheumatology.org Link to sponsor website Link to program URL 01-May-2021 The Ephraim P. Engleman Endowed Resident Research Preceptorship will introduce residents to the specialty of rheumatology by supporting a full-time research experience. </td> </tr> </table>					Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	404-365-1373 Foundation@rheumatology.org Link to sponsor website Link to program URL 01-May-2021 The Ephraim P. Engleman Endowed Resident Research Preceptorship will introduce residents to the specialty of rheumatology by supporting a full-time research experience.
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	404-365-1373 Foundation@rheumatology.org Link to sponsor website Link to program URL 01-May-2021 The Ephraim P. Engleman Endowed Resident Research Preceptorship will introduce residents to the specialty of rheumatology by supporting a full-time research experience.						
049768	Investigator-Initiated Research Grant Program	American Institute for Cancer Research		14-May-2021	Not Specified		
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;"> Contact Name </td> <td style="border-left: 1px solid black; padding-left: 5px;"> </td> </tr> </table>					Contact Name	
Contact Name							

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	202-600-3004
Contact Email	research@aicr.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	14-May-2021
Synopsis	The CUP has identified significant gaps in our knowledge and understanding of the mechanisms that mediate the role of diet, nutrition, body composition and physical activity in cancer development and outcomes following a cancer diagnosis. The knowledge gaps directly inform our Investigator Initiated Research Grant Program so that we can prioritize issues of greatest scientific importance and with the highest potential for translation into effective strategies for cancer prevention and improved outcomes for people living with and beyond cancer.

005022	Investigator-Initiated Research Grants	American Institute for Cancer Research		14-May-2021	75,000 USD
--------	--	--	--	-------------	------------

Contact Name	
Contact Telephone	703-237-0159
Contact Email	research@aicr.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	14-May-2021
Synopsis	The Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet, nutrition, body composition and physical activity on cancer risk and outcomes. The CUP has identified significant gaps in our knowledge and understanding of the mechanisms that mediate the role of diet, nutrition, body composition and physical activity in cancer development and outcomes following a cancer diagnosis. The knowledge gaps directly inform the Investigator Initiated Research Grant Program so that the sponsor can prioritize issues of greatest scientific importance and with the highest potential for translation into effective strategies for cancer prevention and improved

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	outcomes for people living with and beyond cancer.																		
002145	Eight and Forty Lung and Respiratory Nursing Scholarship Fund	American Legion		15-May-2021	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 25%;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td></td> </tr> <tr> <td>Contact Email</td> <td>lasecretaire@8and40.org</td> </tr> <tr> <td>Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>15-May-2021</td> </tr> <tr> <td>Synopsis</td> <td>The 8 & 40 is rooted in supporting the medical community, specifically those professionals directly involved in respiratory illnesses in children.</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	lasecretaire@8and40.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-May-2021	Synopsis	The 8 & 40 is rooted in supporting the medical community, specifically those professionals directly involved in respiratory illnesses in children.
Contact Name																			
Contact Telephone																			
Contact Email	lasecretaire@8and40.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-May-2021																		
Synopsis	The 8 & 40 is rooted in supporting the medical community, specifically those professionals directly involved in respiratory illnesses in children.																		
058266	Overseas Assistance Grants	American Medical Women's Association		05-May-2021	1,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 25%;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td>847-517-2801</td> </tr> <tr> <td>Contact Email</td> <td>associatedirector@amwa-doc.org</td> </tr> <tr> <td>Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>05-May-2021 , 05-Sep-2021</td> </tr> <tr> <td>Synopsis</td> <td>The AWHs Overseas Assistance Grant provides assistance with transportation costs up to \$1,000 connected with pursuing medical studies in an off-campus setting where the medically neglected will benefit.</td> </tr> </table>					Contact Name		Contact Telephone	847-517-2801	Contact Email	associatedirector@amwa-doc.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	05-May-2021 , 05-Sep-2021	Synopsis	The AWHs Overseas Assistance Grant provides assistance with transportation costs up to \$1,000 connected with pursuing medical studies in an off-campus setting where the medically neglected will benefit.
Contact Name																			
Contact Telephone	847-517-2801																		
Contact Email	associatedirector@amwa-doc.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-May-2021 , 05-Sep-2021																		
Synopsis	The AWHs Overseas Assistance Grant provides assistance with transportation costs up to \$1,000 connected with pursuing medical studies in an off-campus setting where the medically neglected will benefit.																		
021267	John F. Perkins, Jr. Research Career Enhancement Award	American Physiological Society		31-May-2021	20,000 USD														

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-634-7164</p> <p>Contact Email awards@the-aps.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-May-2021</p> <p>Synopsis John F. Perkins, Jr. Research Career Enhancement Award is designed to enhance the career potential of the awardee. The award of up to \$20,000 allows an individual in the early phases of his/her career to obtain special training or an individual in the later phases of his/her career to develop new skills or retrain in areas of developing interest.</p>				
072012	David P. Rall Award for Advocacy in Public Health	American Public Health Association		14-May-2021	1,000 USD
	<p>Contact Name Deborah Dillard</p> <p>Contact Telephone 202-777-2742</p> <p>Contact Email deborah.dillard@apha.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-May-2021</p> <p>Synopsis The David P. Rall Award for Advocacy in Public Health is awarded to an individual who has made an outstanding contribution to public health through science-based advocacy.</p>				
021409	DeLano Award for Computational Biosciences	American Society for Biochemistry and Molecular Biology		05-May-2021	3,000 USD
	<p>Contact Name</p> <p>Contact Telephone 240-283-6600</p> <p>Contact Email asbmb@asbmb.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021			
	Synopsis	The DeLano Award for Computational Biosciences is given to a scientist for the most accessible and innovative development or application of computer technology to enhance research in the life sciences at the molecular level.			
039495	Bert and Natalie Vallee Award in Biomedical Science	American Society for Biochemistry and Molecular Biology		05-May-2021	10,000 USD
	Contact Name				
	Contact Telephone	240-283-6600			
	Contact Email	asbmb@asbmb.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021			
	Synopsis	The Bert and Natalie Vallee Award in Biomedical Science is awarded to an established scientist for outstanding accomplishments in basic biomedical research.			
021408	Earl and Thressa Stadtman Distinguished Scientist Award	American Society for Biochemistry and Molecular Biology		05-May-2021	10,000 USD
	Contact Name				
	Contact Telephone	240-283-6600			
	Contact Email	asbmb@asbmb.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2021			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p style="margin-left: 20px;">Synopsis</p> <p>The Earl and Thressa Stadtman Distinguished Scientist Award was established by friends and colleagues to preserve their legacies as scientists and mentors. It is awarded to an established scientist for his or her outstanding achievement in basic research in the fields encompassed by the ASBMB. The award consists of a plaque, a \$10,000 cash award and travel expenses for the ASBMB annual meeting to present a lecture.</p>					
019022	Department of Urology - Endourology Fellowship at Northwestern	American Urological Association		28-May-2021	Not Specified
<p style="margin-left: 20px;">Contact Name</p> <p style="margin-left: 20px;">Contact Telephone</p> <p style="margin-left: 20px;">Contact Email</p> <p style="margin-left: 20px;">Sponsor Website</p> <p style="margin-left: 20px;">Program URL</p> <p style="margin-left: 20px;">Deadline Dates (ALL)</p> <p style="margin-left: 20px;">Synopsis</p>		<p>Debra Caridi, Fellowship Coordinator</p> <p>516-520-1226</p> <p>debra@endourologysociety.com</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>28-May-2021 , 21-Jun-2021</p> <p>The endourology fellowship is a program with clinical, operative and research components. Previous fellows have gone on to successful careers in both academic and specialized private practice settings.</p>			
089255	General Grants - United States	Biogen, Inc.		15-May-2021	Not Specified
<p style="margin-left: 20px;">Contact Name</p> <p style="margin-left: 20px;">Contact Telephone</p> <p style="margin-left: 20px;">Contact Email</p> <p style="margin-left: 20px;">Sponsor Website</p> <p style="margin-left: 20px;">Program URL</p> <p style="margin-left: 20px;">Deadline Dates (ALL)</p> <p style="margin-left: 20px;">Synopsis</p>		<p></p> <p>617-914-1299</p> <p>grantsandgiving@biogen.com</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>15-May-2021 , 15-Aug-2021 , 01-Nov-2021 , 15-Feb-2022</p> <p>Biogen provides funding to an eligible institution or organization to support a program or project that does not fit any</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
of the other defined grant categories. Biogen is currently accepting requests in Alzheimer’s Disease.					
089253	Professional & Scientific Development Grants	Biogen, Inc.		15-May-2021	Not Specified
	Contact Name				
	Contact Telephone	617-914-1299			
	Contact Email	grantsandgiving@biogen.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2021 , 15-Aug-2021 , 01-Nov-2021			
	Synopsis	Biogen provides funding to an eligible institution or organization to support training and development for medical professionals or researchers within Biogen’s therapeutic areas of interest.			
074616	Research Grants	California Walnut Commission		17-May-2021	500,000 USD
	Contact Name	Carol Sloan RDN, FAND, Health Research Director			
	Contact Telephone	916-932-7070			
	Contact Email	csloan@walnuts.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-May-2021			
	Synopsis	The California Walnut Commission (CWC) is currently soliciting Letters of Intent (LOI) for human clinical and observational studies in the areas of human clinical trials, observational studies, narrative reviews, systematic reviews and metaanalyses examining the association between walnut consumption and health outcomes that significantly impact the quality of life or health across the lifespan. The total proposed budget must be no more than \$500,000.			
085272	Syringe Access Program Grants	Comer Foundation		01-May-2021	Not

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				Specified	
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email grants@comerfamilyfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 01-Nov-2021</p> <p>Synopsis The Comer Foundation provides support to harm reduction-centered syringe access programs (SAP) to improve the health and wellness of people affected by drug use. These programs provide free sterile syringes, education, and often community wraparound services to reduce transmission of HIV, hepatitis C and opioid overdose. Average single-year grants range from \$2,500 to \$20,000.</p>				
001440	Career Development Awards	Crohn's & Colitis Foundation of America		05-May-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 646-943-7501</p> <p>Contact Email mmbesch@crohnscolitisfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-May-2021 [LOI/Pre-App], 20-Jul-2021</p> <p>Synopsis The goal of the Career Development Award (CDA) is to encourage a career of independent basic and/or clinical investigation in the area of Crohn's disease and ulcerative colitis research.</p>				
000055	Research Fellowship Awards	Crohn's & Colitis Foundation of America		05-May-2021 [LOI/Pre-App]	174,750 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Orlando Green
Contact Telephone	646-943-7501
Contact Email	ogreen@crohnscolitisfoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	05-May-2021 [LOI/Pre-App], 20-Jul-2021
Synopsis	The Crohn's & Colitis Foundation's Research Fellowship Awards are intended to support individuals in the post-doctoral phase of their career, to develop skills related to basic and/or clinical investigation in the field of inflammatory bowel disease (IBD), or Crohn's disease and ulcerative colitis.

000628	Senior Research Awards	Crohn's & Colitis Foundation of America	05-May-2021 [LOI/Pre-App]	Not Specified
--------	--	---	---------------------------	---------------

Contact Name	Orlando Green
Contact Telephone	646-943-7501
Contact Email	ogreen@crohnscolitisfoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	05-May-2021 [LOI/Pre-App], 20-Jul-2021
Synopsis	Senior Research Awards provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources. Support will be provided for proposals relevant to Inflammatory Bowel Disease (IBD) or Crohn's disease and/or ulcerative colitis.

063869	Litwin IBD Pioneers Initiative	Crohn's & Colitis Foundation of America	05-May-2021	Not Specified
--------	--	---	-------------	---------------

Contact Name

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 646-943-7505</p> <p>Contact Email grant@crohnscolitisfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-May-2021 , 20-Jul-2021</p> <p>Synopsis The Litwin IBD Pioneers Initiative supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data.</p>				
001887	One-year Scholarship		European Association of Urology	01-May-2021	35,400 USD
	<p>Contact Name Angela Terberg</p> <p>Contact Telephone +31(0)26 389 06 80</p> <p>Contact Email eousp@uroweb.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 01-Sep-2021</p> <p>Synopsis The European Association of Urology offers support through their European Urology Scholarship Programme (EUSP). Members may apply for a one-year scholarship of up to €30,000 to be completed at a leading European research institution.</p>				
010950	General Request for Applications (RFA)		Foundation for Prader-Willi Research	21-May-2021	100,000 USD
	<p>Contact Name Jessica Bohonowych</p> <p>Contact Telephone 888-322-5487</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email jessica.bohonowych@fpwr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 21-May-2021</p> <p>Synopsis The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS.</p>				
073959	Research Grants	Gerber Foundation		15-May-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 231-924-3175</p> <p>Contact Email tgf@ncresa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2021 [LOI/Pre-App], 15-Aug-2021 , 15-Nov-2021 [LOI/Pre-App], 15-Feb-2022</p> <p>Synopsis The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age.</p>				
066449	Gene-Targeting Strategies for Neurofibromatosis Type 1	Gilbert Family Foundation		31-May-2021	1,200,000 USD
	<p>Contact Name Jim Goss</p> <p>Contact Telephone 313-782-9500</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-May-2021</p> <p>Synopsis The Gilbert Family Foundation's (GFF) Gene Therapy Initiative is pleased to announce a Request for Proposal (RFP) for high-impact research on gene therapy strategies aimed at addressing the loss of neurofibromin 1 (NF1) gene function in neurofibromatosis type 1 (NF1) patients. Proposals will be accepted for Team Science Awards defined as collaborative research amongst investigators with experience in gene-targeting strategies in or outside the NF1 field.</p>				
086725	Alpha-1 Antitrypsin Laurell's Training Award (ALTA)	Grifols		31-May-2021	59,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-May-2021</p> <p>Synopsis A primary goal of the Alpha-1 Antitrypsin Laurell's Training Award (ALTA) is to identify and engage investigators (both physicians and scientists) who are early in their careers in a longstanding commitment to investigating alpha-1 antitrypsin deficiency (AATD). In awarding 2 grants, the goal/intention is to award one grant for a clinical proposal and a second for a basic research proposal. Another objective of the ALTA award is to strengthen the network between scientists and clinicians working in the field of AATD.</p>				
022177	Young Investigators Groups	Helmholtz Association		03-May-2021	1,770,000 USD
	Contact Name	Julia Eberhardt			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone +49 30 206329-16 Contact Email julia.eberhardt@helmholtz.de Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 03-May-2021 , 31-Aug-2021 Synopsis The Helmholtz Young Investigator Groups offer early scientific independence to international top talents. The funding generally amounts to at least € 300,000 p.a. for five years with an option of a permanent position in case of a positive evaluation.				
091630	Spine and Sports Medicine Fellowship	Hospital for Special Surgery		01-May-2021	95,755 USD
	Contact Name Deja Pressley, Service Line Coordinator Contact Telephone 212-774-7351 Contact Email PressleyD@hss.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-May-2021 Synopsis The Department of Physiatry at the Hospital for Special Surgery (HSS) offers a one year Spine and Sports Medicine Fellowship focusing on a comprehensive, nonsurgical approach to conditions and diseases that affect the musculoskeletal system.				
003498	Research Internships in Science and Engineering (RISE)	Indo-US Science & Technology Forum		31-May-2021	Not Specified
	Contact Name Contact Telephone Contact Email internship@indoustf.org				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-May-2021 , 30-Nov-2021</p> <p>Synopsis Indo-US Science and Technology Forum (IUSSTF) announces the Research Internships in Science and Engineering (RISE) to create unique opportunities for science, technology, engineering and medical students from the United States to undertake internships in national laboratories, federal research centers, academic research institutes and private R & D laboratories in India.</p>				
102853	adiation Health Protection Involving Ionizing and Non-Ionizing Radiation	InfoEd Global	CDC-RFA-EH21-2103	17-May-2021	Not Specified
	<p>Contact Name Maryann Schlemmer, Project Officer</p> <p>Contact Telephone 770-488-3752</p> <p>Contact Email AAQ8@cdc.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-May-2021</p> <p>Synopsis The purpose of this solicitation is to improve the understanding of radiation science to better protect the American public, workers and emergency responders from exposure to radiation from natural, environmental, medical, and occupational sources as well as nuclear disasters. The results of this work will help improve the understanding of radiation science by the radiation protection community and will assist making public health decisions by federal, state and local public health agencies. Measurable outcomes of the program will be in alignment with one (or more) of the following performance goal(s) for the National Center for Environmental Health (NCEH): Determine human health effects associated with environmental exposures. Prevent or reduce illness, injury and death related to environmental factors. Build and enhance effective partnerships to improve environmental health capacity.</p>				
043953	Antonio M. Gotto, Jr. Prize in Atherosclerosis Research	International Atherosclerosis Society		31-May-2021	20,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 1-713-797-0401</p> <p>Contact Email GottoPrize@athero.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-May-2021</p> <p>Synopsis The International Atherosclerosis Society and Weill Cornell Medical College offers the Antonio M. Gotto, Jr. Prize in Atherosclerosis Research to encourage basic, clinical, and translational research in areas relating to the causes, prevention, and treatment of cardiovascular disease globally.</p>				
075448	Prize for Achievement	International Society for Pediatric and Adolescent Diabetes (ISPAD)		22-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone +49 (0)30 24603-210</p> <p>Contact Email secretariat@ispad.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-May-2021</p> <p>Synopsis The ISPAD Prize for Achievement is the society's highest honor. It is awarded to an ISPAD Member who has made outstanding contributions in the areas of science, education and advocacy which have had a major impact on childhood and adolescent diabetes. The prize winner will receive a free registration to the virtual meeting.</p>				
095169	Educational Grants -- Infectious Diseases (HIV/AIDS)	Janssen Biotech, Inc.		15-May-2021	Not Specified
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email jtgrantinfo@its.jnj.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2021</p> <p>Synopsis Janssen provides grants to support educational activities for healthcare providers, allied healthcare providers and patients. Priority is given for activities within Janssen’s areas of scientific interest that contribute to improved knowledge, practice and performance for healthcare providers and improved health outcomes for patients, including in the area of Infectious Diseases. Grants are available for: Continuing Medical Education (CE)/Non-Accredited Continuing Education (NCE); Fellowships; and Patient Education.</p>				
081727	Therapeutic Area Contributions - Neuroscience Program	Janssen Pharmaceuticals, Inc.		31-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 908-218-6095</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-May-2021 , 30-Sep-2021 , 15-Oct-2021</p> <p>Synopsis Janssen Pharmaceuticals, Inc. makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Neuroscience area of interest supports the following disease states: Alzheimer’s disease; major depressive disorder; schizophrenia; and schizoaffective disorder.</p>				
081724	Therapeutic Area Contributions - Infectious Diseases Program	Janssen Pharmaceuticals, Inc.		31-Mar-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 908-218-6095</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Mar-2021 , 31-May-2021 , 31-Jul-2021 , 30-Sep-2021 , 15-Nov-2021</p> <p>Synopsis Janssen Pharmaceuticals, Inc. makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; HIV / AIDS; Respiratory Infections; and Vaccines.</p>				
021422	Grant Programs - Medical Research Phase I Application	Keck (W. M.) Foundation		03-May-2021	5,000,000 USD
	<p>Contact Name Melissa Gage, Program Coordinator</p> <p>Contact Telephone 213-680-3833</p> <p>Contact Email Research_Med@wmkeck.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021 , 01-Nov-2021</p> <p>Synopsis The Medical Research Program seeks to support pioneering discoveries in medical research by funding the high-risk/high-impact work of leading researchers, laying the groundwork for new paradigms, technologies and discoveries that will save lives, provide innovative solutions, and add to our understanding of the world. Historically, grants range from \$500,000 to \$5 million and are typically \$2 million or less.</p>				
077322	Conference/Workshop Grant	Kim (D.) Foundation for the History of Science and Technology in East		01-May-2021	2,500 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Asia					
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email applications@dkimfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 01-Dec-2021</p> <p>Synopsis The D. Kim Foundation for the History of Science and Technology in East Asia awards several grants of up to \$2,500 each twice per year to scholars who are working in the history of science and technology in East Asia who plan to present papers at international conferences or workshops.</p>				
066491	Visiting Professorships	Leverhulme Trust		06-May-2021	207,000 USD
	<p>Contact Name</p> <p>Contact Telephone 020 7042 9863</p> <p>Contact Email grants@leverhulme.ac.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-May-2021</p> <p>Synopsis Visiting Professorships are for UK institutions to invite an eminent researcher from overseas to enhance the skills and knowledge of the academic staff and/or students. Applications are invited for a minimum of £10,000 and a maximum of £150,000. A Visiting Professorship may last for between 3 and 12 months, and tenures of 6 months or more can be spread over 2 or more visits.</p>				
082543	Request for Proposals: LCRF Research Grant on Disparities in Lung Cancer	Lung Cancer Research Foundation		07-May-2021	150,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 212-588-1902</p> <p>Contact Email grants@lcrf.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis LCRF will fund two research projects with a focus on overcoming disparities in lung cancer. The sponsor encourages applications from investigators of all career levels and on a wide variety of disparities-related topics.</p>				
026029	Career Development Awards for Translational Research	LUNGevity Foundation		10-May-2021	300,000 USD
	<p>Contact Name Margery Jacobson</p> <p>Contact Telephone 312-407-6109</p> <p>Contact Email mjacobson@LUNGevity.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2021</p> <p>Synopsis LUNGevity's Career Development Award in Lung Cancer Translational Research program supports future research leaders who will keep the field of lung cancer research vibrant with new ideas. Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission.</p>				
068239	Grants Program - Health & Medical Research	McGowan (William G.) Charitable Fund, Inc.		03-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 312-761-9503</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email info@williamgmcgowanfund.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021 , 15-Jul-2021 [LOI/Pre-App], 01-Sep-2021 , 15-Nov-2021 [LOI/Pre-App], 03-Jan-2022</p> <p>Synopsis The McGowan Charitable Fund partners with institutions that advance cardiac-disease research and organizations that build healthy communities through innovative heart disease prevention programs.</p>				
073452	Paul Marks Prize	Memorial Sloan-Kettering Cancer Center		07-May-2021	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-639-2000</p> <p>Contact Email marksprize@mskcc.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-May-2021</p> <p>Synopsis The Paul Marks Prize for Cancer Research recognizes outstanding young investigators who have made significant contributions to increase the understanding of cancer or improve the treatment of the disease through basic or clinical research. The winners will present their work at a scientific symposium at Memorial Sloan Kettering Cancer Center and share a cash award of \$150,000.</p>				
038045	Research Grants	Ménière's Society		15-May-2021	Not Specified
	<p>Contact Name Natasha Harrington-Benton</p> <p>Contact Telephone +44 0 1306 876883</p> <p>Contact Email research@menieres.org.uk</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p style="margin-left: 40px;">Sponsor Website Link to sponsor website</p> <p style="margin-left: 40px;">Program URL Link to program URL</p> <p style="margin-left: 40px;">Deadline Dates (ALL) 15-May-2021 , 15-Aug-2021 , 15-Nov-2021</p> <p style="margin-left: 40px;">Synopsis The Ménière's Society's Research Programme supports vital research into vestibular disorders.</p>					
061247	Merck MISP Clostridium Difficile Grant	Merck		14-May-2021	Not Specified
<p style="margin-left: 40px;">Contact Name Boski Patel</p> <p style="margin-left: 40px;">Contact Telephone 267-305-3173</p> <p style="margin-left: 40px;">Contact Email boski_patel@msd.com</p> <p style="margin-left: 40px;">Sponsor Website Link to sponsor website</p> <p style="margin-left: 40px;">Program URL Link to program URL</p> <p style="margin-left: 40px;">Deadline Dates (ALL) 14-May-2021</p> <p style="margin-left: 40px;">Synopsis The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.</p>					
058805	Investigator Studies Program (MISP) -- Surgery -- Anesthesia	Merck		01-May-2021	Not Specified
<p style="margin-left: 40px;">Contact Name Lisa Mount</p> <p style="margin-left: 40px;">Contact Telephone 267-305-1258</p> <p style="margin-left: 40px;">Contact Email lisa_mount@merck.com</p> <p style="margin-left: 40px;">Sponsor Website Link to sponsor website</p> <p style="margin-left: 40px;">Program URL Link to program URL</p>					

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-May-2021 , 18-Jun-2021 , 01-Sep-2021 , 19-Oct-2021</p> <p>Synopsis The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.</p>				
067593	Pilot Project Grants	Myositis Association		01-May-2021 [LOI/Pre-App]	100,000 USD
	<p>Contact Name Chrissy Thornton</p> <p>Contact Telephone 703-553-2631</p> <p>Contact Email chrissy@myositis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 [LOI/Pre-App], 30-Jun-2021</p> <p>Synopsis Pilot Grants are designed to fund new and innovative research projects in the hope that they will attract funding from other sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to future grant support. In addition, a competitive application will clearly distinguish itself from the investigator's existing research program. Any industry partnership must be clearly disclosed and a letter of support from the industry partner must be included. Pilot grants will be awarded for one or two years and up to a maximum of \$100,000 annually, subject to satisfactory progress.</p>				
067591	Mentored Research Fellowships	Myositis Association		01-May-2021	100,000 USD
	<p>Contact Name Chrissy Thornton</p> <p>Contact Telephone 703-553-2631</p> <p>Contact Email Chrissy@myositis.org</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 30-Jun-2021</p> <p>Synopsis Mentored Research Fellowships are designed to help promising junior investigators (MDs and PhDs) for a period of two years, subject to satisfactory progress, at the salary level approved by the participating institution, to a maximum received annually of \$50,000. Candidates should have completed residency or fellowship training or have received a PhD within the three years prior to commencing the Fellowship and be performing research under the supervision of an established mentor. Recipients must devote at least 50% of their time to research, but may include some study and clinical experience in allied fields. There should be limited supplementation of salary from outside sources.</p>				
037398	Research Associateship Program (RAP)	National Academies		01-May-2021	Not Specified
	<p>Contact Name Attn: NRC Research Associateship Programs</p> <p>Contact Telephone 202-334-2760</p> <p>Contact Email RAP@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 01-Aug-2021 , 01-Nov-2021</p> <p>Synopsis The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
078941	Research Grants - MPS II (Hunter Syndrome)	National MPS Society, Inc.		15-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 919-806-0101</p> <p>Contact Email grants@mpssociety.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-May-2021 , 15-Jul-2021 [LOI/Pre-App], 15-Sep-2021 , 15-Nov-2021 [LOI/Pre-App], 15-Jan-2022</p> <p>Synopsis The National MPS Society funds research that may lead to treatments for MPS and ML diseases and solicits applications for innovative research projects that involve clinical research, basic research and translational studies.</p>				
001639	Research Associateship Programs -- Naval Medical Research Center/Naval Health Research Center (NMRC/NHRC)	National Research Council		01-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 202-334-2760</p> <p>Contact Email rap@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058602	Research Associateship Programs -- U.S. Army Medical Research and Materiel Command	National Research Council		03-May-2021	Not Specified
	<p>Contact Name Dr. Ray Gamble, Program Administrator</p> <p>Contact Telephone 202-334-2787</p> <p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
001045	Research Associateship Programs -- Armed Forces Radiobiology Research Institute	National Research Council		01-May-2021	57,000 USD
	<p>Contact Name Dr. Ray Gamble</p> <p>Contact Telephone 202-334-2787</p> <p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 01-Aug-2021</p> <p>Synopsis The National Academies of Sciences, Engineering, and Medicine administers competitive postdoctoral and senior research awards on behalf of U.S. federal research agencies and affiliated institutions with facilities at over 100 locations throughout the U.S. and abroad. Awardees have the opportunity to: conduct independent research in an area compatible with the interests of the sponsoring laboratory devote full-time effort to research and publication access the excellent and often unique facilities of the federal research enterprise collaborate with leading scientists and engineers at the sponsoring laboratories.</p>				
058572	Research Associateship Programs -- Naval Postgraduate School	National Research Council		03-May-2021	Not Specified
	<p>Contact Name Dr. Ray Gamble, Program Administrator</p> <p>Contact Telephone 202-334-2787</p> <p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058545	Research Associateship Programs -- National Oceanic and Atmospheric Administration (NOAA)	National Research Council		03-May-2021	Not Specified
	<p>Contact Name Dr. Ray Gamble, Program Administrator</p> <p>Contact Telephone 202-334-2787</p> <p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058605	Research Associateship Programs -- U.S. Army Research Office	National Research Council		03-May-2021	Not Specified
	<p>Contact Name Dr. Eric Basques, Program Administrator</p> <p>Contact Telephone 202-334-2707</p> <p>Contact Email ebasques@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058596	Research Associateship Programs -- U.S. Army Research, Development & Engineering Command, NVESD (RDEC/NVESD)	National Research Council		03-May-2021	Not Specified
	<p>Contact Name Dr. Eric Basques, Program Administrator</p> <p>Contact Telephone 202-334-2707</p> <p>Contact Email ebasques@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058604	Research Associateship Programs -- U.S. Army Research Laboratory	National Research Council		03-May-2021	Not Specified
	<p>Contact Name Dr. Eric Basques, Program Administrator</p> <p>Contact Telephone 202-334-2707</p> <p>Contact Email ebasques@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.			
058542	Research Associateship Programs -- Air Force Research Laboratory	National Research Council		03-May-2021	80,000 USD
	Contact Name	Ms. Ellen M. Robinson			
	Contact Telephone	703-588-8527			
	Contact Email	ellen.robinson.1@us.af.mil			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-May-2021			
	Synopsis	Competitive awards are available for scientists and engineers to conduct independent research in federal laboratories and affiliated institutions. Awards include attractive stipends, health insurance, professional travel, and relocation.			
058592	Research Associateship Programs -- Army Aviation and Missile Research, Development, and Engineering Center (AMRDEC)	National Research Council		03-May-2021	Not Specified
	Contact Name	Dr. Eric Basques, Program Administrator			
	Contact Telephone	202-334-2707			
	Contact Email	ebasques@nas.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-May-2021			
	Synopsis	The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
057794	Research Associateship Programs -- National Energy Technology Laboratory	National Research Council		01-May-2021	Not Specified
	Contact Name Dr. Eric Basques Contact Telephone 202-334-2707 Contact Email ebasques@nas.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-May-2021 , 01-Aug-2021 , 01-Nov-2021 Synopsis The National Research Council provides opportunities to outstanding scientists and engineers at recent postdoctoral and experienced senior levels for tenure as guest researchers at the National Energy Technology Laboratory (NETL).				
001033	Research Associateship Programs -- Naval Research Laboratory	National Research Council		01-May-2021	Not Specified
	Contact Name Ms. Erica Deschak Contact Telephone 202-767-8323 Contact Email erica.deschak@nrl.navy.mil Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 01-May-2021 , 01-Aug-2021 , 01-Nov-2021 , 01-Feb-2022 Synopsis The Naval Research Laboratory conducts a broad based multidisciplinary program of scientific research in advanced technological development, techniques, systems, and related operational procedures				
070292	Research Associateship Programs -- Environmental Protection Agency Faculty Fellowship Program (EPA/FFP)	National Research Council		01-May-2021	Not Specified
	Contact Name Dr. Eric Basques				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 202-334-2707</p> <p>Contact Email ebasques@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-May-2021 , 01-Aug-2021 , 01-Nov-2021</p> <p>Synopsis The National Research Council provides support to promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at the Environmental Protection Agency.</p>				
088605	Research Grants	North American Spine Society		10-May-2021	100,000 USD
	<p>Contact Name Karen James, Manager of Research</p> <p>Contact Telephone 630-230-3691</p> <p>Contact Email KJames@spine.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-May-2021</p> <p>Synopsis NASS research grants provide funding for promising research projects by qualified investigators in the field of spine. Research grants should focus on basic science, clinical or translational research. Basic research may focus on projects that further our understanding of the mechanisms of disease and developing novel models for prevention and/ or treatment. Clinical research may focus on projects that investigate the epidemiology, prevention, and or treatment of spine disease. Translational research may focus on projects that move findings from the 'bench to bedside'</p>				
088607	Nontraditional Nonsurgical Treatment Grants	North American Spine Society		10-May-2021	100,000 USD
	Contact Name Karen James, Manager of Research				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	630-230-3691 KJames@spine.org Link to sponsor website Link to program URL 10-May-2021 The Nontraditional, Nonsurgical Treatment Grant is the result of a donation to research as part of a settlement of a class action lawsuit unrelated to NASS. This grant supports research of disc-related and/or neuropathic back pain by nonsurgical techniques. These funds must be used for new, nontraditional methods of nonsurgical treatment of such back and neck pain and radiculopathy. If TNF-inhibitors other than etanercept are used in research and/or treatment funded, comparison studies using perispinal etanercept in at least as many research subjects or patients should be done. Funding amount and number of grants are at the discretion of the NASS Research Project Management Committee based upon merit of applications and amount of funding available each year. It is recommended that approved grant budgets range between \$20,000-\$40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$50,000 per year.
--	---

088606	Young Investigator Grants	North American Spine Society		10-May-2021	100,000 USD
--------	---	------------------------------	--	-------------	-------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Karen James, Manager of Research 630-230-3691 KJames@spine.org Link to sponsor website Link to program URL 10-May-2021 One to two Young Investigator Grants may be awarded each year. Principal investigators may be any age. MD applicants must be within five years of completion of training at the time of application; PhD applicants must be within five years of their post-doc training. Applicants may not have received previous grant funding from the NASS Research
--	---

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Project Management Committee. It is recommended that approved grant budgets range between \$20,000-\$40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$50,000 per year.

078645	Research Traveling Fellowship	North American Spine Society		10-May-2021	7,000 USD
--------	---	------------------------------	--	-------------	-----------

Contact Name Karen James, Manager of Research
 Contact Telephone 630-230-3691
 Contact Email KJames@spine.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 10-May-2021

Synopsis The Research Traveling Fellowship spans at least five months at one medical center (other than the facility at which the applicant currently practices). The center selected by the applicant should have appropriate research facilities and agree in writing to accept the applicant if he/she receives the Fellowship. The Fellowship primarily covers the costs of travel and housing and typically ranges from \$3,000-\$7,000.

088608	Clinical Traveling Fellowship	North American Spine Society		10-May-2021	7,000 USD
--------	---	------------------------------	--	-------------	-----------

Contact Name Karen James, Manager of Research
 Contact Telephone 630-230-3691
 Contact Email KJames@spine.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 10-May-2021

Synopsis The Clinical Traveling Fellowship spans at least one month to be spent in three to five different medical centers studying spine techniques. The centers selected by the applicant should agree in writing to accept the applicant if he/she receives the Fellowship. The Fellowship primarily covers the costs of travel and housing and typically ranges

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		from \$3,000-\$7,000.			
026662	Research Grants	Ophthalmic Research Institute of Australia		25-May-2021	38,500 USD
	Contact Name				
	Contact Telephone	02 9690 1001			
	Contact Email	grants@oria.org.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-May-2021			
	Synopsis	The Ophthalmic Research Institute of Australia (ORIA) awards grants to ophthalmologists, trainee ophthalmologists or for work being done in University Departments (or equivalent) of Ophthalmology or Ophthalmic Research Institutes.			
038162	Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes	Patient-Centered Outcomes Research Institute (PCORI)		04-May-2021	10,000,000 USD
	Contact Name				
	Contact Telephone	202-827-7700			
	Contact Email	info@pcori.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	04-May-2021			
	Synopsis	The Patient-Centered Outcomes Research Institute (PCORI) seeks to fund pragmatic large pragmatic studies in patient-centered comparative effectiveness research (CER) that are designed to aid decision makers in choosing between two or more clinical care interventions through the comparison of their effectiveness, safety, and other characteristics that are important to stakeholders.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
030477	Broad PCORI Funding	Patient-Centered Outcomes Research Institute (PCORI)		04-May-2021	3,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-827-7700</p> <p>Contact Email info@pcori.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-May-2021</p> <p>Synopsis The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas outlined in PCORI's National Priorities for Research and Research Agenda: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Healthcare Systems. These broad areas encompass the patient-centered comparative CER we support.</p>				
056359	Pew Biomedical Scholars	Pew Charitable Trusts		17-May-2021 [LOI/Pre-App]	300,000 USD
	<p>Contact Name Kara Coleman</p> <p>Contact Telephone 215-575-9050</p> <p>Contact Email kcoleman@pewtrusts.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-May-2021 [LOI/Pre-App], 01-Sep-2021</p> <p>Synopsis The Pew Scholars Program in the Biomedical Sciences provides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The program makes grants to selected academic institutions</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to support the independent research of outstanding individuals who are in their first few years of their appointment at the assistant professor level.

102065	Medical Education Grants: Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Pfizer Pharmaceuticals		30-Mar-2021	20,000 USD
--------	--	------------------------	--	-------------	------------

Contact Name	Amanda Stein, Grant Officer
Contact Telephone	212-733-2323
Contact Email	amanda.j.stein@pfizer.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	30-Mar-2021 , 27-May-2021 , 29-Jul-2021 , 30-Sep-2021 , 28-Oct-2021
Synopsis	Pfizer requests applications focused on improving the care of patients on the local level with Transthyretin Cardiomyopathy (ATTR-CM).

102813	Medical Education Grant: Topical Hemostasis in Minimally Invasive Surgery	Pfizer Pharmaceuticals		12-May-2021	200,000 USD
--------	---	------------------------	--	-------------	-------------

Contact Name	Jessica Romano, Grant Officer
Contact Telephone	
Contact Email	jessica.romano@pfizer.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	12-May-2021
Synopsis	Pfizer is issuing this Request for Proposals (RFP) to support projects that will focus on educating surgeons and other healthcare professionals on topical hemostasis in minimally invasive surgical (MIS) procedures, addressing knowledge

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and practice gaps specific to perioperative bleeding during MIS including robotically-assisted procedures. Individual projects requesting up to \$200,000 will be considered.

102433	Competitive Grant Program: Pre-clinical & Translational Research in Multiple Myeloma	Pfizer Pharmaceuticals		17-May-2021	150,000 USD
--------	--	------------------------	--	-------------	-------------

Contact Name	Jacqueline Waldrop
Contact Telephone	212-733-2323
Contact Email	Jacqueline.Waldrop@pfizer.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	17-May-2021
Synopsis	Pfizer is issuing this Request for Proposals (RFP) to support pre-clinical and translational research in Multiple Myeloma. Individual projects requesting up to \$150,000 will be considered.

102627	Competitive Grant Program: NSCLC Therapy Management for Optimal Outcomes	Pfizer Pharmaceuticals		05-May-2021	150,000 USD
--------	--	------------------------	--	-------------	-------------

Contact Name	Jacqueline Waldrop
Contact Telephone	
Contact Email	Jacqueline.Waldrop@Pfizer.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	05-May-2021
Synopsis	Pfizer is issuing this Request for Proposals (RFP) for projects that focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged – Non-Small Cell Lung Cancer (NSCLC). Individual projects requesting up to a maximum of \$150,000 will be considered.

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102679	Competitive Grant Program: Quality Improvement in Pediatric Endocrinology Fields	Pfizer Pharmaceuticals		31-May-2021	0 USD
	Contact Name Akihiro Kamina, Grant Officer Contact Telephone Contact Email meg.japan@pfizer.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-May-2021 Synopsis Pfizer is issuing this Request for Proposals (RFP) for projects related to quality improvement in pediatric endocrinology fields in Japan. Individual projects requesting up to 2,500,000 JPY will be considered.				
102678	Competitive Grant Program: Improve the Care of Patients Living with Metastatic Breast Cancer	Pfizer Pharmaceuticals		13-May-2021	79,000 USD
	Contact Name Dewayne Brumlow, Grant Officer Contact Telephone Contact Email Dewayne.Brumlow@pfizer.com Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 13-May-2021 Synopsis Pfizer, through a partnership with Rethink Breast Cancer, is issuing this Request for Proposals (RFP) to encourage proposals for the implementation of strategies that will measurably improve the quality of care of metastatic breast cancer (mBC) patients. Projects should use optimal measures to improve care for patients with metastatic breast cancer, where treatment goals focus on improving quality and length of life as there is, to date, no known cure. Individual projects requesting up to \$100 000 (CAD) will be considered.				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
010211	Franco-American Medical Exchanges Grants	Philippe Foundation, Inc.		31-May-2021	Not Specified
	Contact Name	Claire Waiss			
	Contact Telephone	212-687-3290			
	Contact Email	philippefoundation@fourpointsam.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-May-2021 , 31-Aug-2021 , 30-Nov-2021			
	Synopsis	The purpose of the Philippe Foundation is to encourage, assist, aid and support scientific and medical activities and research by giving grants to doctors and scientists (post-graduates) interested in exchange programs between France and the United States, specifically in medical laboratories.			
008850	New Research Workers' Awards	Quaternary Research Foundation		15-May-2021	2,070 USD
	Contact Name	Dr Kathryn Adamson			
	Contact Telephone	+44 (0) 161 247 6251			
	Contact Email	k.adamson@mmu.ac.uk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2021 , 15-Sep-2021			
	Synopsis	The Quaternary Research Foundation provides financial support for early career research workers in Quaternary science. The New Research Workers' Awards scheme supports postgraduate research activities.			
008855	Quaternary Conference Fund	Quaternary Research Foundation		15-May-2021	1,035 USD
	Contact Name	Dr. Kathryn Adamson			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone +44 (0) 161 247 6251 Contact Email k.adamson@mmu.ac.uk Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-May-2021 , 15-Sep-2021 Synopsis The Quaternary Conference Fund is available to all members of the QRA of at least one year's standing to assist attendance at conferences and field meetings.				
008897	Quaternary Research Fund	Quaternary Research Foundation		15-May-2021	2,070 USD
	Contact Name Dr Kathryn Adamson Contact Telephone +44 (0) 161 247 6251 Contact Email k.adamson@mmu.ac.uk Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-May-2021 , 15-Sep-2021 Synopsis The Quaternary Research Fund is available to all members of the QRA of at least one year's standing, irrespective of age and status, to foster research in any area of Quaternary studies. Grants are normally for sums up to £1500 and can be used for any purpose deemed suitable by the Awards Panel (typical claims might be to fund field expenses, hire equipment to clean sections, etc.).				
093261	Amgen Fellowship Training Award	Rheumatology Research Foundation		03-May-2021	50,000 USD
	Contact Name Contact Telephone 404-365-1373 Contact Email foundation@rheumatology.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis The purpose of this award is to help ensure an adequate supply of (a) rheumatology providers meeting the needs of children and adults with rheumatic diseases in all areas of the country and (b) rheumatology educators and investigators to train future clinicians and advance research in rheumatic diseases. The Amgen Fellowship Training Awards may be used to support the salary of any fellow in an ACGME-accredited rheumatology fellowship training program.</p>				
061077	Fellowship Training Award - Workforce Expansion	Rheumatology Research Foundation		03-May-2021	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis The Fellowship Training Award for Workforce Expansion award is meant to help ensure an adequate supply of rheumatology providers meeting the needs of children and adults with rheumatic diseases in all areas of the country, particularly those currently underserved.</p>				
063215	Lawren H. Daltroy Preceptorship in Health Communciation	Rheumatology Research Foundation		03-May-2021	15,000 USD
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 03-May-2021 , 01-Nov-2021</p> <p>Synopsis The Lawren H. Daltroy Preceptorship in Health Communication was established with the aim of improving patient/clinician interactions and communications. This award provides resources to support the training, career development, and/or enhancement of research skills of researchers and clinicians. The award is up to \$15,000 per year.</p>				
061076	Paula de Merieux Fellowship Training Award	Rheumatology Research Foundation		03-May-2021	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email foundation@rheumatology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-May-2021</p> <p>Synopsis Annually, one Paula de Merieux grant is awarded to support a trainee who belongs to an underrepresented minority within rheumatology, or is a woman. For the purposes of this program, “underrepresented minority within rheumatology” shall mean Black, Hispanic, or Native American.</p>				
057304	Grants - Hansen's Disease/Leprosy	Sasakawa Memorial Health Foundation		05-May-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-May-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Through its grant program, Sasakawa Health Foundation is promoting projects to build a society where Hansen’s disease (leprosy) is not deemed an issue, discrimination and stigma do not exist, and persons affected by Hansen’s disease can receive the treatment and services they need. In FY2021, we are supporting projects in three areas: tackling disease, fighting discrimination, and preserving history.			
006463	New Investigator Grant	Scoliosis Research Society		15-May-2021	30,000 USD
	Contact Name				
	Contact Telephone	414-289-9107			
	Contact Email	info@srs.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-May-2021			
	Synopsis	New investigator research grants are meant to stimulate younger members into a career of investigation in spinal deformity. Up to \$30,000 (\$15,000 per year) may be requested.			
095418	Simons Foundation Autism Research Initiative (SFARI) - Pilot Awards	Simons Foundation		06-May-2021	300,000 USD
	Contact Name				
	Contact Telephone	646-654-0066			
	Contact Email	sfarigrants@simonsfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-May-2021			
	Synopsis	The mission of the Simons Foundation Autism Research Initiative (SFARI) is to improve the understanding, diagnosis and treatment of autism spectrum disorders (ASD) by funding innovative research of the highest quality and relevance. To this end, the Foundaiton solicits applications for SFARI Pilot Awards from individuals who will conduct			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>bold, imaginative, rigorous and relevant research. Investigators new to the field of autism are encouraged to apply for these awards. The total budget of a Pilot Award is \$300,000 or less, including 20 percent indirect costs, over a period of up to two (2) years.</p>				
048725	Gita Patel Best Practice Recognition Award	Society of Infectious Diseases Pharmacists		26-Apr-2021	Not Specified
	<p>Contact Name Kate DeSear Contact Telephone 331-248-7888 Contact Email deseak@shands.ufl.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 26-Apr-2021 , 24-May-2021 Synopsis The Society of Infectious Diseases Pharmacists (SIDP) is pleased to solicit nominations for the Gita Patel Best Practice Recognition Award. The purpose of this award is to recognize an SIDP member who has implemented and documented the impact of an innovative or collaborative “best practice” initiative to improve care in patients with infectious diseases.</p>				
091400	Early Career Awards	Thrasher Research Fund		07-May-2021	25,000 USD
	<p>Contact Name Contact Telephone 801-240-4753 Contact Email Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 07-May-2021 , 14-Sep-2021 , 05-Nov-2021 Synopsis The Fund recognizes that young investigators may find it difficult to remain in pediatric research because of a lack of</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

funding. Therefore, the purpose of this program is to encourage the development of medical research in child health by awarding small grants to new researchers, helping them gain a foothold in this important area. The goal is to fund applicants who will go on to be independent investigators. The Fund will make up to 30 awards total with two funding cycles (15 awards each).

059714	Ara Parseghian Medical Research Fund (APMRF) at Notre Dame (ND) Research Grants	University of Notre Dame		01-May-2021	Not Specified
--------	---	--------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	574-631-4689
Contact Email	skassen@nd.edu
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-May-2021
Synopsis	The mission of the APMRF is to promote research that furthers understanding of the molecular basis of Niemann Pick Type C (NPC) disease and targets development of novel strategies to treat and/or cure the disease. For more information please read the rest of the RFP including the General Information section.

062085	Innovator Awards	Wellcome Trust		24-May-2021	1,035,000 USD
--------	----------------------------------	----------------	--	-------------	---------------

Contact Name	
Contact Telephone	+44 0 20 7611 5757
Contact Email	
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	24-May-2021

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	These awards support researchers who are transforming great ideas into healthcare innovations that could have a significant impact on human health. Individuals and teams from not-for-profit and commercial organisations can apply.			
024768	Collaborative Research Grants	Zoos Victoria		21-May-2021	Not Specified
	Contact Name	Dr Michael Magrath, Senior Research Manager, Wildlife Conservation & Science			
	Contact Telephone	+61-3 9340 2752			
	Contact Email	research@zoo.org.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-May-2021 , 23-Jul-2021 , 17-Sep-2021 , 12-Nov-2021			
	Synopsis	Zoos Victoria welcomes collaborative research proposals. These could involve the use of Zoos Victoria resources, active collaboration with Zoos Victoria staff or independent research at one of Zoos Victoria's three properties: Melbourne Zoo, Werribee Open Range Zoo or Healesville Sanctuary.			